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SUMMARY 
 
There are conflicting statements in the literature on the optimum shielding for 
beta emitting radionuclides. Perspex is commonly cited as reducing 
bremsstrahlung compared to lead. Other reports indicate lead can be used.  
Newer therapies require dispensing of large activities (>1GBq) and it is vital to 
minimize high finger doses.  The shielding aspects for 90Y and 32P, two 
commonly used therapy radionuclides, have been investigated. Whole body 
doses and finger doses are examined, together with ergonomic aspects. The 
research highlights the difficulty in carrying out dose assessments and the 
disparity of the data in the literature.   
Three different assessment techniques were used: a) different types of TLDs; b) 
a variety of dose rate meters and c) spectral analysis with a germanium detector.  
The measurement and source geometries used were designed to replicate as far 
as possible those routinely encountered in the clinical environment. 
Investigations were carried out using three types of syringe shields for 10ml and 
1ml syringes; Perspex, tungsten and a hybrid shield of plastic and lead. 
In all cases the hybrid shield is the optimum choice to reduce both finger dose 
and whole body exposure. However, ergonomically it is bulky which can result in 
longer handling times.  This work identifies an improved shield design. The 
tungsten shield provides almost as much dose reduction and is preferred by 
operators. Tungsten shields are also normally routinely available in Nuclear 
Medicine departments. They are therefore considered a justifiable alternative. 
Although Perspex is still commonly recommended, both the tungsten and hybrid 
shields are superior to Perspex shields, with the exception of the 1ml shield for 
90Y where Perspex was marginally better than tungsten. 
The other critical training issue highlighted is that finger doses can exceed 
statutory annual limits within seconds if staff handle unshielded syringes or vials 
of 90Y or 32P. 
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CHAPTER 1    INTRODUCTION 
 
Beta-emitting radionuclides are used for therapeutic purposes in Nuclear 
Medicine.  The theory behind their success is that beta particles only have a 
small range (mm) in tissue.  Hence, if the radiopharmaceutical is localised to the 
organ (or area of the body) where the cells need to be destroyed, radiation dose 
will be minimal to surrounding tissues and cells.  
 
It is often assumed that the radiation protection aspects of handling such 
products are straightforward, as beta particles do not travel very far in tissue 
(maximum range: 11.9mm for 90Y and 9.0mm for 32P [1]).  However, this fact 
alone means that high finger dose (in effect skin dose) readings can be attained 
as the beta particles are often going to be stopped by the dermis of the skin [2-
19]. 
For any operator handling radioactive materials it is common practice to 
appropriately shield the source material to attenuate the amount of radiation 
he/she is exposed to.  Materials such as lead, lead glass or tungsten are used to 
shield gamma-emitting radionuclides due to greater attenuation of such high 
atomic number, high density materials. However, there has been, and still is, 
much debate as to the most effective shielding for beta-emitting radionuclides. 
Traditionally many textbooks, and much literature, advocate lower atomic number 
materials, e.g. Perspex, as shielding to reduce the finger doses to the operators 
handing beta-emitting radionuclides [2, 6, 8-10, 12, 14-17, 20-32].  Perspex is 
often recommended since its lower atomic number produces less bremsstrahlung 
than higher atomic number materials. However, use of Perspex requires a thick 
walled shield that can be cumbersome for the operator. There is a large disparity 
between authors of the thickness of Perspex or plastic required to be effective, 
ranging from: 5mm [14]; >5mm [5]; 6.3mm for 32P [27]; 7mm for 32P [32]; 8mm for 
32P [15]; 9.2mm for 90Y [27]; 10mm [6, 8-9, 16, 20, 29-31]; 12mm for 90Y [32];  
20mm [2] to unspecified/varying thickness [7, 10-12, 17, 21-26, 28]. The Society 
for Radiological Protection [33] does highlight that for beta shielding, low atomic 
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number materials yield less bremsstrahlung production but also have less 
bremsstrahlung attenuation.   A recent syringe shield design for 90Y Zevalin 
labelling uses a combination of both lead and plastic materials, Rimpler et al. [5, 
13].  This combination of materials is also suggested for some ‘in-house’ 
shielding designs [2, 29-30, 34-35], provided the lead surrounds the primary 
shielding of Perspex. This order of shielding is based on the theory that the 
Perspex will stop the betas and the higher atomic number material (lead) will 
attenuate the bremsstrahlung radiation produced. However, high atomic number 
materials such as lead or tungsten are suggested by Van Pelt and Drzyzga [35] 
and McLintock [36] as sufficiently effective shield materials for beta emitters. If 
the shield wall is thick enough there can be absorption of some bremsstrahlung 
emissions [36].  Standard tungsten or lead syringe shields have the advantage of 
thinner walls than Perspex but they are heavier.  Other authors; Zhu [7, 10], 
Christian [24], Kent State University [29], Michigan State University [30] and 
Jodal [31] strongly warn against solely using lead/tungsten shielding. One author, 
Fletcher [37], has written a computer program to determine the shielding 
thickness for polyenergetic beta–gamma sources and considers the shielding of 
the bremsstrahlung and gamma emissions.  
 
The importance of finding the most effective shielding for beta-emitting 
radionuclides has become even more necessary in recent years since newer 
radionuclide therapies require staff to handle much higher quantities of 
radioactivity (as high as several GBq’s).  If not handled correctly, very high finger 
doses can be recorded in seconds.  Even with correct handling finger doses may 
lead to operators needing to be designated as classified workers (i.e. doses can 
exceed 150mSv which is 3/10th of the annual finger dose limit) [38-39]. One 
reported case, Cremonesi et al. [2], resulted in radiodermatitis of 3 fingertips 
where a worker held a vial containing 16.7GBq 90Y for ~ 10 seconds with no 
tongs. The estimated dose to the damaged tissues (<1cm2/finger) was 12Gy.  
However a ring thermoluminescent dosemeter (TLD), worn a few centimeters 
 3 
 
 
from the fingertip, only indicated the dose to be 70mGy (and this included routine 
work for a month). Complete recovery occurred within ~6 months. 
 
The interest for this research was sparked by the introduction of 90Y Zevalin (a 
radiopharmaceutical used for the treatment of rituximab relapsed or refractory 
CD20 follicular B cell Non-Hodgkin’s Lymphoma patients).  Up to 2.5GBq 90Y are 
required to be handled by the radiopharmacy staff involved in preparing the 
product and up to 1.2GBq by the operator connecting up the infusion. In the 
literature finger doses of up to 47mSv per treatment have been reported by 
Murray et al. [3]. Based on these figures an operator would need to become a 
classified worker after only 4 procedures a year.  The only alternative would be to 
restrict their work for the rest of the year to ensure they did not exceed the 
150mSv/year limit.  The latter option would very likely cause severe service 
implications for most Nuclear Medicine departments.  
 
The aim of this research was, therefore, to establish the most effective material 
to shield different beta-emitting radionuclides. In finding the most effective 
shielding, more manipulations could be made by a limited number of staff and 
finger doses maintained under the classified limit.  The shielding properties of 
different atomic number materials including tungsten, Perspex and a combination 
of lead and plastic were investigated. Optimising the shielding also had to 
account for the ease of operator handling, particularly the shield weight and 
physical dimensions.  The wall thickness affected ergonomics as well as 
radiation safety. 
 
Clinical context 
 
As has been stated above, 90Y Zevalin is used to treat rituximab relapsed or 
refractory, low-grade or follicular B cell Non-Hodgkins Lymphoma. It is also 
indicated for the treatment of previously untreated follicular Non-Hodgkins 
Lymphoma patients who have achieved a partial or complete response to first 
 4 
 
 
line chemotherapy. The treatment regime consists of two visits for the patients.  
Visit 1: The patient undergoes a Rituximab infusion. (Pre-treatment with rituximab 
is necessary to clear circulating B cells enabling the 90Y Zevalin to deliver 
radiation more specifically to the lymphomas).  
Visit 2: 7 days later the patient receives a further Rituximab infusion followed by 
the 90Y Zevalin infusion.  
Zevalin is a monoclonal antibody composed of; 1) the antibody (Ibritumomab) 
and 2) the chelator (tiuxetan).  The monoclonal antibody, ibrItumomab tiuxetan 
(Zevalin), targets the antigen CD20 which is located on the surface of 95% of B-
cell lymphomas.  The radiation emitted from the radiolabelled antibody not only 
affects the cell it directly attaches to but also the neighbouring cells, due to the 
‘cross-fire’ effect.   
 
However, the findings of this research will not be limited to the application of 90Y 
Zevalin.  It will be equally applicable to other 90Y labelled radiopharmaceuticals 
used for other therapeutic purposes e.g. 90Y radiolabelled peptides used to treat 
neuroendocrine tumours, 90Y citrate for chronic synovectomy and 90Y SIR 
spheres (or Theraspheres) used to treat liver cancer.  
 
A further point to consider is that the findings for the high energy beta of 90Y 
might be replicated for lower energy beta emitting radionuclides e.g. 32P used to 
treat polycythaemia rubra vera and 89Sr used for bone pain palliation, as well as 
the beta/gamma emitting 177Lu labelled radiopharmaceutical used to treat 
neuroendocrine tumours and 153Sm used for bone palliation.    In manipulating all 
these therapeutic radiopharmaceuticals, extremely high finger doses can be 
recorded in a very short space of time if not handled appropriately.    
 
Therefore, in addition to 90Y, it was also decided to investigate the beta emitting 
radionuclide 32P.  32P was more readily available (and less costly) than any other 
beta emitting radionuclide which may have been considered.  The approach 
 5 
 
 
taken was aimed at conclusions being reached from both practical 
measurements and theoretical analysis.  
 
Methods of Analysis 
 
Three different methods of analysis were performed to corroborate any findings. 
For each method three syringe shields were used; a) Perspex; b) tungsten and c) 
a commercial Zevalin shield (a combination shield of lead/plastic). Using these, 
results were obtained for 90Y and for 32P in l0ml and 1ml syringes. Some 
measurements were also obtained with unshielded syringes. 
 
The first method used extremity TLDs to give an indication of finger dose.  The 
effect of backscatter from the finger on the doses recorded was also investigated. 
For the shielded sources, this relates to possible backscatter of bremsstrahlung 
creating an increased finger dose. However, publications relate mainly to beta 
backscattering [40-45], which is only of relevance for unshielded sources.  
Although these should never be handled directly, some backscatter 
measurements were made on unshielded syringes for comparison. 
 
The second method involved a series of dose rate measurements at differing 
distances with a selection of dose rate monitors. This represents the effect of the 
shielding on whole body dose. This also compares the response of different dose 
rate meters for the measurement of beta dose rates and also bremsstrahlung 
dose rates.  
 
The third method involved spectral analysis using a hyperpure germanium 
detector. Only shielded syringe measurements using Perspex, tungsten and the 
Zevalin shields were performed. The analysis of this data allowed a direct visual, 
as well as a quantitative, comparison of the bremsstrahlung spectra obtained 
using the various types of shielding.   
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CHAPTER 2  RADIOACTIVE DECAY OF A BETA-EMITTING 
RADIONUCLIDE 
 
A Beta ( -) particle is a high energy electron emitted when there are too many 
neutrons in the nucleus. The nucleus becomes stable through the conversion of 
one of its neutrons by the process: 
n → p + - +  + energy 
where:  n   = neutron; p=proton; - = beta particle;  = antineutrino 
i.e. the neutron is transformed into a proton within the nucleus.  The energy 
released in the transition is shared between the beta particle and an anti-
neutrino.  However, the sharing of kinetic energy is not equal.  Sometimes the 
electron receives more of the energy, and the antineutrino less, or vice versa. As 
a result the energy of a beta particle varies in a continuous energy spectrum 
ranging from zero up to the maximum as shown in Fig. 2.1 below. The average 
beta particle energy is about one-third of the maximum, Martin and Sutton [17]. 
 
 
Fig. 2.1  General shape of the spectrum of -particle energy. 
 
 
E max 
Ē ≈ 0.3E max
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Negatively charged beta particles undergo a large number of interactions when 
they pass through matter. Collisions with atomic electrons lead to energy losses 
through ionisation and excitation. Such inelastic collisions are the main cause of 
kinetic energy loss of the beta particle. Since beta particles have the same mass 
as orbital electrons they are easily deflected during collisions.  As a consequence 
they follow a tortuous route through a material and have a maximum range.  For 
example the range of the beta particles of 90Y in tissue is quoted as 11.9mm by 
Welsh [1] and 1.6mm in lead by Jodal [31].  
 
However, elastic interactions with the field of the nucleus can also cause large 
changes in direction.  These occur much less frequently than the interactions 
with the atomic electrons. As the beta particle is deflected and slowed in its path, 
there is a release of energy in the form of x-rays, called bremsstrahlung radiation 
(braking radiation). The conservation of energy and momentum must be 
maintained; therefore the energy of the incident beta particle is equal to the sum 
of the energy of the beta particle after deflection and the bremsstrahlung x-ray. 
The bremsstrahlung x-rays are released in a continuous spectrum because of the 
variations in kinetic energy and path geometry of the beta particle.   
 
Therefore, even a pure beta emitting radionuclide has associated x-ray 
emissions from bremsstrahlung. Bremsstrahlung interactions increase in 
probability with the energy of the beta particles and with the atomic number of the 
absorber.  The average energy (Eav) of the bremsstrahlung produced by -
particles with a maximum energy E  keV, when interacting with a material of 
atomic number Z, will be approximately: 
 
Eav = 1.4 x 10
-7ZE 2 keV.        (2.1) 
 
Equation 2.1 shows that the average bremsstrahlung energy is proportional to 
the atomic number of the material the beta particle is travelling through and also 
increases with the square of the beta particle maximum energy.  For example, for 
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90Y beta particles travelling through tissue (or saline) (Z=7.6), the average 
bremsstrahlung energy is only 5keV but travelling through lead (Z=82) is 60keV. 
The bremsstrahlung spectrum will also be affected by the material the betas are 
travelling through. When electrons hit the surface of a thick object, the 
bremsstrahlung emissions may occur at some depth below the surface and so 
are attenuated before they emerge from the material, with the low energy 
photons being attenuated more [17].  
 
An important feature of bremsstrahlung is that it is electromagnetic radiation 
whose shielding requirements differ from those of the beta emitter that produces 
it.  This is particularly important for a pure beta emitter where the possible need 
to shield against electromagnetic radiation may not be appreciated. 
 
There are in fact two types of bremsstrahlung production from  emitters 
consisting of external and internal bremsstrahlung as reported by McLintock [36]. 
The external bremsstrahlung is caused by the interactions of the beta particle 
with the nuclei of the material it is traveling through, as described above. Internal 
bremsstrahlung arises from the interaction of the emitted nuclear beta particle 
with the nucleus of the source radionuclide itself. Both external and internal 
interactions generate continuous spectra of bremsstrahlung.  In addition both 
interactions can generate characteristic x-rays by creating vacancies in the inner 
electron shells.  For external interactions, this will be characteristic x-rays for the 
material the beta is travelling through.  
 
McLintock [36] presents graphical data from several different authors which give 
an indication of the relative contributions of external and internal bremsstrahlung 
to the total bremsstrahlung yield.   For 32P the relative contribution of the internal 
bremsstrahlung to the total bremsstrahlung yield for tissue (Z=7.6) is 
approximately 0.43 and for lead (Z=82) is approximately 0.05. 
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For radiation protection purposes, the predominant processes of interest are 
those which lead to the continuous spectra of bremsstrahlung x-rays. By 
comparison, the characteristic x-ray production has only a minor effect. 
 
Bremsstrahlung Spectra 
 
Bremsstrahlung forms a continuous spectrum of x-rays covering the energy 
range from zero up to Emax, the maximum energy of the  particle.  The 
distribution of energies is however, highly skewed to the lower energy emissions. 
Spectra measured in practical situations also reflect the absorption of the 
bremsstrahlung in the source and in the container/shielding.  An example of a 
measured bremsstrahlung spectrum for 90Y in a 10ml syringe shielded by a 
tungsten shield is shown in Fig. 2.2. 
0
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Fig. 2.2 Typical bremsstrahlung spectrum for ~20MBq 90Y in a tungsten 
syringe shield @ 25cm from Germanium detector. 
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It can be seen that the spectrum consists of a broad range of bremsstrahlung x-
rays skewed towards the lower energies and which peak at about 70keV. The 
narrow peak observed on the spectrum represents the K  characteristic x-ray 
fluorescent peak of tungsten (59keV), superimposed on the lower energy region 
of the spectrum. 
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CHAPTER 3   PHYSICAL DATA 
 
3.1  90Y [46-48] 
 
Half life: 2.67 days  
 
Type of Decay: Beta ( -) 
 
Maximum Particle energy:  2.28MeV  
Average Particle energy:  0.93MeV 
 
Main Production modes:  90Sr ( -) 90Y  
90mY (I.T.) 90Y 
89Y (n, ) 90Y (possible 91Y impurities) 
 
Decay Scheme: disintegrates by beta minus emission mainly (99.98%) to the 90Zr 
ground state level. 
 
    9039 Y  
90
40 Zr 
 
Range (maximum distance the beta radiation can travel): Jodal [31] 
In Perspex = 10.3mm  
In lead = 1.6mm  
In air = 8.2m; Martin and Sutton [17] 
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3.2. 32P [46, 48-49] 
 
Half life: 14.26 days 
 
Type of Decay: Beta ( -) 
 
Maximum Particle energy: 1.71MeV   
Average Particle energy:  0.69MeV 
 
Main Production modes:  31 P (n, ) 32P  
32 S (n,p) 32P (possible 33P,35S impurities) 
34S (d, ) 32P 
 
Decay Scheme: disintegrates by beta minus (100%) directly to the 32S ground 
state level. 
 
    3215 P  
32
16 S 
 
Range (maximum distance the beta radiation can travel): Van Pelt and Drzyzga 
[35] and McLintock [36] 
In Perspex = 7mm  
In lead = 0.7mm  
In air = 6m; Martin and Sutton [17] 
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CHAPTER 4     EXPERIMENTAL DESIGN 
 
4.1 Introduction 
 
The experimental design was developed to find answers to the following 
questions:- 
1. What is the effect of different shielding materials on surface dose rates 
from 90Y and 32P? 
2. What is the effect of backscatter from the finger on the doses recorded 
when using different shielding materials?  
3. What is the effect of different shielding materials on the whole body 
dose from 90Y and 32P? 
4. What is the effect of different shielding materials on the 
bremsstrahlung spectra for 90Y and 32P? 
5. What is the dose response to beta particles and also to 
bremsstrahlung for different types of TLDs and dose rate monitors?  
 
To ascertain answers to questions 1, 2 & 5: 
Different types of TLDs (with and without Perspex backscatter to mimic the 
finger) were placed on the surface of shielded and unshielded sources. The 
procedure will be detailed in Chapter 5. 
 
To ascertain answers to question 3 & 5: 
Different dose rate monitors were used to record readings at various distances 
(0, 30 and 50cm) from shielded and unshielded sources. This process will be 
described in detail in Chapter 6. 
 
For question 4:  
A germanium detector was used to record the bremsstrahlung spectra produced 
from shielded sources, correcting for germanium detector efficiency. This 
investigation method will be discussed in Chapter 7.  
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4.2 Technical specification of the syringe shields 
 
Three different types of syringe shield were used in conjunction with the 10ml 
and 1ml syringes containing 90Y and 32P:- 
1. Perspex 
2. Tungsten 
3. A commercial Zevalin hybrid shield. This uses a plastic/lead/plastic 
combination of materials.  
 
For technical specifications of the 10ml shields – see Fig. 4.1, Fig. 4.2 and 
Fig. 4.3. 
 
For technical specifications of the 1ml shields – see Fig. 4.4, Fig. 4.5 and   
Fig. 4.6. 
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4.2.1 Technical specification of the 10ml syringe shields used 
 
 
 
 
 
 
  
 
 
 
 
 
 
Fig. 4.2 
10ml tungsten shield 
2.8mm wall thickness 
 
Lead glass window 
thickness is 6.6mm. 
 
10.8mm 
2.7mm 
Fig. 4.1 
 
10ml Perspex shield 
 
 
 
Thickest wall: 10.8mm 
 
Note the tapered  
edge on the underside  
of the shield. 
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                 Inner plastic                      Lead  
Fig. 4.3 
10ml Zevalin shield 
Inner plastic : 6.4mm 
Lead  : 1.6mm 
Outer plastic : 3.2mm 
Plastic window: 18.0mm.  
 
Outer 
plastic 
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4.2.2 Technical specification of the 1ml syringe shields used 
 
 
 
 
 
 
 
 
 
        
         Inner plastic                    Lead 
   
 
 
10mm 
3.5mm 
Fig. 4.4 
 
1ml Perspex shield 
 
Thickest wall: 10mm 
 
Note the tapered edge on 
the underside of the 
shield. 
Fig. 4.5 
 
1ml tungsten shield 
1.9mm wall thickness 
 
Lead glass window     
thickness is 5.5mm. 
 
 
Fig. 4.6 
 
1ml Zevalin shield 
Inner plastic : 10.7mm 
Lead  : 1.6mm 
Outer plastic : 3.2mm 
Plastic window: 22.0mm.  
 
 
Outer 
plastic 
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CHAPTER 5   TLD MEASUREMENTS 
 
5.1 Introduction 
 
Very high finger doses can be recorded in a very short time interval when 
manipulating beta emitting radionuclides if inappropriate handling techniques are 
used or shielding is not employed.  Cremonesi et al. [2] reported a case of 
radiodermatitis from handling an unshielded vial of 16.7GBq 90Y for about 10 
seconds.  During the course of this research the responses of three different 
types of TLDs routinely used within Nuclear Medicine departments were 
compared for the assessment of the surface dose on shielded and unshielded 
syringes. An assessment was also made of the effect of backscatter on the dose 
measurements to compare with the results of Galloway [40], Buffa et al. [41], 
Chibani [42], Kwok et al. [43], Lee and Reece [44], Nunes et al. [45].  
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5.2 Materials and Methods 
 
5.2.1 Technical Specification of Extremity TLDs 
 
Three different manufacturers’ TLDs were used during the course of this 
research. 
 
Fig. 5.1   NE-Technology LiF-7 powder TLD 
 
This is a Tape Dosimeter comprising of a special detecting element of a very 
thin layer of LiF-7 powder, sandwiched between two strips of hard wearing 
plastic.  Each dosemeter has a unique barcode and number for identification 
purposes.  The bilaminar plastic acts as a thin window (3-4 mg.cm-2) which is 
physically strong and resistant to chemical attack. The standard dosemeter is 
supplied in a finger stall and the active element is ideally situated at the 
fingertip.  A window is cut out of the finger stall to prevent its material from 
affecting the dosimetric performance. The dosimeter is worn with the bar code 
next to the skin and the silver layer facing outwards for routine extremity 
finger dose monitoring and those conditions were replicated for the 
experimental measurements.  
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Table  5.1  Technical specification of the NE Technology LiF-7 TLD 
 
Dosimetric characteristics 
Material: LiF-7 
Window thickness: (3-4 mg.cm-2)   
Batch homogeneity: <12% SD for 15 samples 
Linearity: ±10% approximately (0.5 mSv – 1 Sv) 
Detection threshold: 150 Sv (includes allowances for storage time) 
Photon response: 15 keV – 3 MeV: ± 28% 
Beta response: 0.5 MeV – 3 MeV: ± 10%  
 
The variation quoted against the photon and beta response values is due to fact 
that the TLDs were not individually calibrated.  This type of TLD was not re-
usable and the range quoted covers the maximum possible energy response 
since the TLDs were made and supplied in batches. 
 
The accuracy for personal dosemeters of this type is quoted as being ±20%. 
 
This type of TLD was worn by staff handling beta emitting radiopharmaceuticals 
as part of routine clinical preparation and handling. The TLD measures 
equivalent dose from external radiation via Hp(0.07) in mSv i.e.  skin dose at 
0.07mm (as recommended by ICRP –see Chapter 8 Section 8.1.1). 
 
However, during this research the Head of the Approved Dosimetry Service at 
Velindre recommended that these were not the most accurate type of TLD.  This 
would particularly apply to recorded doses <1mSv i.e. measurements made with 
low activities and shielding. 
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Fig. 5.2 LiF TLD-100 Chips 
 
 
These chips were recommended (by the Head of the Approved Dosimetry 
Service) as being more accurate for this research into extremity dose 
measurements. 
Each chip measured 3mm x 3mm with a depth of 0.9mm and was protected 
in a sachet with a plastic thickness of 0.2mm. On occasions more than one 
chip was placed in a sachet. 
 
Special features of TLD-100 (LiF:Mg,Ti) 
 Independent of dose rate up to 100 MGy/s 
 Nearly tissue equivalent 
 ± 15% sample-to-sample uniformity 
 Repeatability to within 2% or better 
 Useful range 10 Gy - 10Gy 
 
This TLD gives a measurement of absorbed dose to the skin in mGy (the 
industry standard in the United States of America).  After contact with the 
companies supplying these TLDs, they state that to convert their results to 
mSv an additional quality factor needs to be incorporated, which for betas is a 
factor of 1. For presentation purposes in this thesis, all TLD results using 
these chips will be reported in mSv for consistency. 
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Fig. 5.3 Global dosimetry MeasuRingTM 
 
 
The majority of the finger dose measurements recorded for the operators 
dispensing / administering the 90Y Zevalin infusions were obtained using the 
LiF-7 powder TLDs as illustrated in Fig. 5.1. However, during the course of 
this research the TLDs were changed for staff monitoring to those illustrated 
in Fig. 5.3. The MeasuRing TLD has a TLD-100 chip in a finger strap as 
shown.  Where detailed, this TLD was used for some measurements. 
 
Table 5.2  Technical specification of the Global MeasuRing TLD 
 
 Dosimetric specifications  
Dosimeter type: Natural lithium fluoride single TLD-100 chip 
Minimum Reportable dose: 0.2 mSv  
Useful Dose Range: 0.2 mSv – 10 Sv 
Photon Energy Response: 5 keV – 6 MeV 
Beta (MAX) Energy Response: 0.766 MeV – 5 MeV 
 
The TLD measures equivalent dose from external radiation via Hp(0.07) in mSv 
i.e.  skin dose. 
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5.2.2 Data Acquisition Techniques 
 
Several different approaches were taken to examine the surface dose rates on 
syringes and syringe shields.  Normally two TLDs were used for each dose 
assessment, one with a Perspex backing to simulate the tissue of the fingers and 
so estimate any effect due to backscatter.  Initial results were made with the 
syringe shields laid horizontally on a 1cm thick Perspex sheet with a TLD taped 
to the top and also one placed underneath the shields (Fig. 5.4).  However, as 
will be described, settling of the radiopharmaceutical meant that later results 
were made with the syringe supported vertically.  In this orientation one TLD 
could be taped to one side and a second TLD could be taped onto the opposite 
side with a backing of a Perspex block to simulate backscatter.  Any settling 
should then affect both TLDs in the same way. 
 
Data was acquired for 90Y and for 32P in 10ml and 1ml syringes, with results 
obtained for Perspex, tungsten and Zevalin shields as well as for unshielded 
syringes. In addition one set of results was obtained for 32P in a 5ml syringe to 
compare with published values. 
 
Several different TLDs (Section 5.2.1) were used to compare their response to 
both betas (the unshielded syringe) and to bremsstrahlung (the shielded syringe). 
A further series of measurements were made with TLDs placed at fixed distances 
(up to 9mm) from the tungsten shield.  This was to examine the shielding 
component of the distance effect for the thick wall of the Perspex and Zevalin 
shields compared to the thinner wall of the tungsten shield. 
 
Exposure time of the TLDs for the 10ml 90Y syringe (Section 5.3.1, 5.3.3) ranged 
from 10 minutes up to 3805 minutes in order to achieve the best accuracy of 
measured dose possible (i.e. measured doses significantly greater than 
background).  For the 1ml 90Y syringe (Section 5.3.4, 5.3.5) the exposure time of 
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the TLDs ranged from 10 minutes up to 2341 minutes.  This accommodated 
situations where only low activities of 90Y were available.   
 
For the 10ml 32P syringe (Section 5.4.1), the TLDs were exposed for time periods 
of between 736 minutes and 1426 minutes; for the 1ml 32P (Section 5.4.2) the 
time period was between 910 minutes and 1453 minutes.   
 
More detailed methodology for 10ml syringe TLD exposures: 
 
As described above, initial measurements were performed with the syringe laid 
horizontally. The 10ml syringe was placed, in turn, in the three different syringe 
shields. To ensure that any activity in the blind hub did not affect these readings 
the blind hub was also shielded.  Two TLDs and a 1cm thick block of Perspex 
were incorporated into the experimental design for each individual shield 
measurement.  The first TLD was fixed directly on top of each shield to give a 
dose without any backscattering medium influencing the value; these are referred 
to as ‘N’.   At the same time, a second TLD was sandwiched between the shield 
and a 1cm block of Perspex to mimic backscatter, and these results are referred 
to as ‘B’.   An example of the setup (for the Perspex shield) is shown in Fig. 5.4, 
which also indicates ‘N’ and ‘B’.  Unshielded syringe measurements were also 
performed with the TLDs positioned as described above for the shielded 
measurements. 
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Fig. 5.4    10ml syringe in Perspex shield placed horizontally. One TLD fixed 
on top ‘N’, and one fixed underneath ‘B’ with a backing of 1cm Perspex. 
The TLDs were placed centrally over the active volume. 
 
The thickness of the tungsten shield wall is much less than that of the Perspex 
and Zevalin shields.  This means that the TLDs are not at the same distances 
from the surface of the syringe. The effect of this distance on the dose 
measurements was investigated by placing TLDs at varying distances (with an 
air gap) from a tungsten shielded syringe. In this case a small block of Perspex of 
1cm thickness, to simulate backscatter, was placed directly behind each of the 
TLDs placed at a distance from the tungsten shield. Various thicknesses of 
spacers (produced by the Mechanical Workshop at Velindre NHS Trust) were 
used to ensure accurate distance placement of the TLDs from the shield.  The 
radiopharmaceutical used for some of the measurements changed from 90Y 
Zevalin to 90Y citrate, since this was more readily available. 
 
However, concerns were raised regarding the unexpected disparity between the 
LiF-7 powder TLD results obtained for the unscattered ‘N’ and backscattered ‘B’ 
readings for the tungsten shield when the only difference in method involved the 
radiopharmaceutical used.  The LiF TLD-100 chip was introduced into the 
N 
B 
1cm thick block of 
Perspex 
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experimental design, as it was recommended that this type of TLD was more 
accurate for low dose rate work associated with low activities.  
 
The explanation for the discrepancy, however, was that the 90Y citrate (a colloidal 
suspension) was settling out gravitationally in the syringe during the 
measurements. As will be shown in Section 5.3.1 this resulted in a modification 
to the experimental design with the syringe supported vertically (see Fig. 5.5). 
With this arrangement, one TLD (LiF-7 powder or LiF TLD-100 chip) was still 
attached directly to one surface of the syringe shield –referred to as ‘N’ (i.e. no 
backscattering medium contributed to the result).  The other TLD was placed 
directly opposite, sandwiched between the shield surface and a 9.8mm thick 
block of Perspex giving the backscatter result ‘B’. In this way any settling should 
affect both TLD results in the same way. 
 
                                                     
                                                      
Fig. 5.5 Vertical positioning of the 10ml tungsten syringe shield with 5ml 
90Y citrate with two TLDs placed on opposite sides of the shield. One is 
taped directly onto the shield surface ‘N’ and one has a Perspex block 
placed behind it to provide backscatter ‘B’. 
 
9.8mm 
thick flat 
block of 
Perspex 
 
N 
B 
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However, the block of Perspex did not allow all of the TLD to be completely in 
contact with the shield wall due to the curvature of the shield (Fig. 5.6). Hence, 
this was not truly a comparable measurement to assess dose or backscattering 
effects compared to the TLD with no scattering medium.  
 
               
 
To overcome any possible effect of this gap on the backscatter TLD 
measurements, sections of curved 1cm thick Perspex were specifically designed 
(by the Mechanical Workshop at Velindre NHS Trust) to fit snugly around each 
shield, as shown in Fig. 5.7. The TLD measuring the backscatter component was 
therefore completely sandwiched between the shield surface and the backscatter 
material. 
 
 
Fig. 5.7 
 
Curved 1cm Perspex 
backscatter sections to 
fit various syringe 
shields and syringes. 
 
Fig. 5.6 
Enlarged section of Fig. 5.5 
showing the gap for the 
backscatter TLD due to the 
curvature of the syringe 
shield. 
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An additional 1cm thick Perspex block (Fig. 5.8) was also made to act as a 
backscatter material for a TLD placed against the tapered edged wall of the 
Perspex shield.  
  
 
 
The resulting experimental design is illustrated with various projections of a 10ml 
tungsten shield (Fig. 5.9; Fig. 5.10; Fig. 5.11; Fig. 5.12) and a 10ml Perspex 
shield (Fig. 5.13).  (For ease of photography: the retort stand used to support the 
shield vertically in space is not shown). 
 
                                                    
              
Fig. 5.8 
 
1cm Perspex 
backscatter sections 
for use on 10ml 
Perspex shield.  
 
Fig. 5.9 
 
1cm curved 
Perspex 
providing a 
snug fit to the 
shield. 
Fig. 5.10 
 
‘Head on’ 
view of 
acquisition 
set-up.  
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The 1cm block of Perspex (designated ‘TE’) in Fig. 5.13, better represents where 
an operator either dispensing or administering an injection might place their 
fingertips.   
 
 
B 
     Fig. 5.12 
 
     Projection 
     showing 
     TLD behind                                                                                                                                        
     scattering  
     media – 
     referred to as   
    ‘B’. 
Fig. 5.11 
 
Projection 
showing TLD 
without 
scattering 
media –referred 
to as ‘N’. 
Fig. 5.13 
 
Projection showing the small 
block of Perspex used for the 
tapered end measurement of 
the Perspex shield – referred to 
as ‘TE’. 
N 
TE 
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More detailed methodology for the 1ml syringe TLD exposures: 
 
A similar set of measurements was made with a 1ml syringe and shields for      
90Y and 32P. Similar issues of settling of the 90Y citrate (as observed for the 10ml 
measurements) were experienced for the 1ml results.   
 
There was also an additional problem with the 1ml syringe of how to shield all the 
syringe contents effectively. 
 
The first series of measurements were performed with the syringe contents 
totally shielded and a ‘clean’ needle attached to the syringe. As much of this 
needle as possible was also shielded. (A standard blind hub could not be used 
since its diameter was too large to allow it to be drawn back into the shield). As 
shown in Fig. 5.14; 2 TLDs were used and a 1cm block of Perspex was 
incorporated to mimic backscatter, in the same manner as outlined for the 10ml 
situation. Similarly, the TLD placed directly on top of each syringe shield is 
referred to as ‘N’ and the second TLD sandwiched between a 1cm block of 
Perspex and the shield is referred to as ‘B’.    
 
 
 
Fig. 5.14 
 
1ml tungsten shielded 
syringe.  The needle 
cannot be completely 
shielded, but is a ‘clean’ 
needle. 
1cm block 
of Perspex 
 
N 
B 
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The same approach as used for the 10ml syringe was taken to negate the 
settling issue of the 90Y citrate.  The syringe was supported vertically with the 
TLDs attached directly opposite each other. As before, as much of the needle as 
possible was shielded. The Perspex backscatter block was 9.8mm thick (referred 
to as ‘B’).   The TLD results without any backscatter are referred to as ‘N’ (Fig. 
5.15). 
 
                     
 
 
As for the 10ml situation curved Perspex backing blocks later replaced the flat 
block of Perspex to allow the TLD to be enveloped totally to the respective shield 
as illustrated in Fig. 5.16.  
In addition, a blind hub from a three way tap was found to have suitable 
dimensions to allow the syringe contents to be sealed and withdrawn fully into 
the syringe shield, as illustrated in Fig. 5.16. Therefore, no residual activity in the 
needle could contribute to the TLD readings. 
 
 
Fig.  5.15 
 
TLDs placed on either side 
of the tungsten shield; one 
with a 9.8mm Perspex 
backing block to simulate 
backscatter.  
N 
B 
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TLD results are also presented for operators involved in the handling, dispensing 
(Table 5.22) and administration (Table 5.23) of 90Y Zevalin during routine clinical 
therapeutic procedures.  
Curved 
1cm thick 
Perspex 
Fig. 5.16 
1ml syringe with tungsten shield fitted 
and supported vertically. 2 TLDs used; 
one with 1cm thick curved Perspex 
backing. Blind hub shielded. 
 
N 
B 
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5.2.3 Data Analysis 
 
Since some measurements were made over several days, due to low available 
activity, use of shielding and the need for measured doses significantly greater 
than background, decay of the radionuclide had to be taken into account. An 
Excel spreadsheet was created to calculate the area under the activity-time curve 
for the exposure time (in hours) of the TLD.  This calculation was applied 
irrespective of the exposure time to give the cumulated activity the TLD had been 
exposed to over that time period –Equation 5.1.  
 
Cumulated activity over the exposure time period for the TLD 
      =A[t1] *
2
1
t
t
e
- tdt                            (5.1)  
where: 
A[t1] = activity (in GBq) at the start time of the measurement 
t1 = start time of measurement;  
t2 = time at end of measurement; 
=(0.693/64.1hours) for 90Y; =(0.693/14.26days) for 32P. 
 
This equates to       A[t1] *  -
1
{ 12 tt ee }       GBq.h                         (5.2) 
 
Assuming t1=0, Equation 5.2 then becomes 
    A[t1] * }1{
1 )
diff
t
e              GBq.h                (5.3) 
Where tdiff = elapsed time for the measurement in hours 
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The TLD value (in mSv) was divided by Equation 5.3 
 
      
 
Corrected value =  
     TLD value
 
     
   mSv/h/GBq   
 
A[t1] * }1{
1 )
diff
t
e  
  
 
All measured TLD dose values are therefore corrected for cumulated activity 
using Equation 5.4 and these are presented in Tables 5.3 to 5.21.  This in effect 
normalises all measured dose values to unit activity (GBq) and time (hours) and 
corrects for decay.  
 
      
(5.4) 
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5.3 Results for 90Y 
 
5.3.1  TLD results with 10ml syringe laid horizontally 
 
A 10ml syringe containing 1.08GBq of 90Y Zevalin in 7ml of solution was placed, 
in turn, in the three different syringe shields as illustrated in Fig. 5.4.  A 10 minute 
exposure of the TLD was made for each of the three shields investigated. The 
results are reported in Table 5.3. 
 
Table 5.3  10ml syringe with 1.08GBq 90Y Zevalin in 7ml in three shields 
placed horizontally (Fig. 5.4). One TLD fixed on top ‘N’ and one fixed 
underneath ‘B’ with a backing of 1cm Perspex.  
 
Shield 
Position of LiF-7 
TLD relative to  
the shield 
Corrected value 
mSv/h/GBq 
 
Ratio 
B/N 
Perspex 
 
N 3.12  
1.21 B 3.79 
Tungsten 
 
N 1.67  
1.4 B 2.33 
Zevalin 
 
N 0.33  
1.0 B 0.33 
 
The Zevalin shield gives the lowest dose figures in Table 5.3. However the 
bulkiness of the Zevalin shield meant that operators found it very cumbersome to 
use.  The Zevalin shield has a wall thickness of 11.2mm and the Perspex shield 
a thickness of 10.8mm, whereas the tungsten shield has a wall thickness of 
2.8mm.  
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To assess the effect of distance of the TLD from the tungsten shield, 6ml of 90Y 
citrate with a pharmaceutical form of a colloidal suspension was used. Different 
positions of the TLD relative to the horizontal shield were selected. The activity 
range for the measurements was 53MBq to 106MBq.  The results are reported in 
Table 5.4. 
 
Table 5.4  10ml syringe with 6ml 90Y citrate in the tungsten shield and 
TLDs placed at various distances from the shield.  
 
Position of LiF-7 TLD relative to the shield Corrected value 
mSv/h/GBq 
Directly on shield barrel     N 0.21 
1mm 0.19 
4mm 0.24 
6mm 0.12 
  9mm* 1.38 
B* 6.41 
Directly on lead glass window 0.34 
Directly on syringe (under shield) 168 
 
* measurement performed on a separate occasion to the other measurements 
presented in Table 5.4. 
 
The 9mm distance measurement was performed to make it an almost equivalent 
distance the TLD would have been from the solution shielded by the Zevalin 
shield (allowing for the 2.8mm thickness of the tungsten shield).  
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These results raised concern regarding the disparity between the results against 
line ‘N’ and ‘B’ for the tungsten readings in Table 5.4 compared to Table 5.3.  In 
addition the result at 9mm was not consistent with the values for the other TLDs 
placed at distance from the shield. 
 
The experimental procedure was repeated to check for consistency of results or 
a possible flaw in the experimental design.   
 
Concurrently with the consistency check on the LiF-7 powder TLD, a LiF TLD-
100 chip was placed directly alongside it for exactly the same length of time at 
each measurement distance. The method of data collection was still as described 
for Fig. 5.4.  The results are presented in Table 5.5.  As above, all measurements 
made with an air gap from the shield were carried out with 1cm Perspex backing 
behind the TLD. Specifically manufactured spacers were used to accurately 
position the TLD at the required distance.  In this case the activities were 
between 218MBq and 283MBq of 90Y citrate in 6ml solution for the shielded 
measurements and 46MBq 90Y citrate for the unshielded syringe measurements.   
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Table 5.5 6ml 90Y citrate in the 10ml syringe. LiF-7 and TLD-100 
dosemeters TLDs placed at various distances from the shield.  One TLD 
also fixed on top ‘N’ and one fixed underneath ‘B’ with a backing of 1cm 
Perspex.  
 
Shield Position of TLD chip  
relative to shield 
LiF-7 TLD  LiF TLD-100 
Corrected value 
mSv/h/GBq 
No shield N 7070 3570 
B 6730 71600 
Tungsten N 1.34 0.93 
1mm 5.00 4.24 
4mm 1.12 1.01 
9mm 1.00 0.76 
B 8.14 5.14 
Lead glass window 2.30 1.14 
 
 
The dose response of the LiF-7 powder TLD and the LiF TLD-100 clearly show 
differences.  The results for TLD-100 are consistently lower than the 
corresponding results for the LiF-7 TLD for the tungsten shield (reduction range 
10% to 50%). 
An unexpected increase is observed for the TLD measurements made at 1mm 
from the tungsten shield. This is observed for both types of TLDs. It was not 
expected that these results would be so much higher than the corresponding 
measurements made with the TLDs placed directly on the shield (even with a 
backscatter medium).    
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The tungsten results reflect bremsstrahlung only whereas the unshielded results 
are dominated by the beta response. For these, the TLD-100 result without 
backscatter ‘N’ is 50% lower than the LiF-7 result.  However, the TLD-100 result 
with backscatter ‘B’ gives a factor of x11 increase. 
 
These results also demonstrated a discrepancy between the 90Y Zevalin results 
for tungsten indicated by ‘N’ and ‘B’ in Table 5.3 and the corresponding 90Y 
citrate results indicated by ‘N’ and ‘B’ in Table 5.5. It was considered that 
possible explanations could be; a) problems with accuracy of TLDs or b) 
differences between the 90Y Zevalin and 90Y citrate that were affecting the 
measurements. 
 
To establish the reproducibility of the results for the LiF TLD-100 chips a second 
series of measurements were made. In this case, 201MBq to 429MBq of 90Y 
citrate in 5ml of solution was used for the shielded measurements and 25MBq in 
5ml solution, used for the unshielded situation. 
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Table 5.6 10ml syringe with 5ml 90Y citrate, unshielded or in three 
shields, placed horizontally (Fig. 5.4). LiF TLD-100 used, one fixed on top 
‘N’ and one fixed underneath ‘B’ with a backing of 1cm Perspex.  
  
Shield 
Position of LiF TLD-100 chip 
relative to shield 
Corrected value 
mSv/h/GBq 
Unshielded  
 
N 2590 
B 71600 
Perspex  
 
N 1.72 
B 6.39 
Tungsten N 1.09 
1mm 4.94 
4mm 1.67 
9mm 0.80 
B 4.44 
Lead glass window 0.97 
Zevalin  
 
N 0.37 
B 0.91 
 
These results are consistent with the previous set of LiF TLD-100 results (Table 
5.5). The unexpected TLD result for the measurement made at 1mm from the 
tungsten shield in Table 5.5 is reproduced in Table 5.6.  One possible 
explanation it that it could be due to very acute angles of gamma transmissions 
very close to the surface of the shield and an effect of geometry at such a close 
distance which is not normally measured. However, these findings need to be 
further investigated using Monte Carlo modelling.  
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It should also be noted that the backscattered result for the TLD placed 9mm 
from the tungsten shield is similar to the equivalent TLD result ‘B’ for the Zevalin 
shield.  This supports the theory that the TLD dose recorded by using the Zevalin 
shield will be lower, due in part to its larger wall thickness as the dosemeter is 
further from the source than with the tungsten shield. Note that this variation of 
dose with distance does not follow the inverse square law since the source i.e. 
the syringe is not a point source in relation to the TLD but is a linear source. 
 
The backscatter readings appeared much higher with 90Y citrate than with   90Y 
Zevalin. The ratio of backscattered to unscattered readings (x30) for the 
unshielded syringe was much higher than would be expected from backscatter 
alone. In addition the ratio for the 10ml readings was higher than for the 1ml 
readings (shown later in Table 5.13).  
 
 
5.3.2 Gravitational settling of 90Y citrate 
 
One possible explanation for the discrepancy was if the 90Y citrate (a colloidal 
suspension) was settling out gravitationally in the syringe during the 
measurements. To investigate this, serial measurements of activity in a localized 
part of the syringe were made with a horizontal axis germanium detector.  A 10ml 
syringe was placed vertically at a distance of 25cm from the detector. This was 
shielded by a lead block which covered the bottom half of the syringe contents. 
Immediately prior to placement behind the lead block the syringe was vigorously 
inverted to mix the contents. Spectra were obtained at intervals over a period of 
80 minutes, and summed to give total counts. 
 
Fig. 5.17 shows the data obtained. This clearly shows the activity falling to a 
plateau by 20 minutes, decreasing by a factor of three over the measurement 
period of 80 minutes. By 20 minutes the counts in the top half of the syringe had 
more than halved. Similarly, an increase in activity was observed for the situation 
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of the lead block shielding the top half of the syringe and the germanium detector 
monitoring the bottom half.   
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Fig. 5.17  Germanium detector showing decreasing counts with time when 
lead block used to shield bottom half of syringe. 
 
This clearly demonstrated that there was a gravitational settling issue associated 
with 90Y citrate. Unfortunately due to the relatively low frequency and high cost of 
90Y Zevalin, this experiment could not be carried out with that 
radiopharmaceutical.  
However, assuming there is not such a gravitational issue with 90Y Zevalin, this 
observation would explain the higher readings observed with 90Y citrate for the 
TLD (result ‘B’) under the shield when this was placed horizontally, compared to 
the corresponding values seen with 90Y Zevalin.  
 
It is also possible that the effect was not as noticeable for the 90Y Zevalin since 
results were obtained in much quicker measurement periods due to the high 
activities used.  
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5.3.3 TLD results with 10ml syringe supported vertically 
 
To try and overcome this influence of gravitational settling, repeat measurements 
were made with the syringe supported vertically. The syringe contents were 
always shaken before each measurement and then left to stand for at least 20 
minutes. Regardless of which type of TLD was used the pairs of TLD ‘window’ or 
chips were always placed directly opposite each other and at the same height 
from the tip of the syringe, see Fig. 5.5.  In this way it was hoped to try and 
negate, as much as possible, any influence from the settling effect on the 
comparative values at least. The resulting non-uniform activity distribution 
throughout the volume of the syringe had to be accepted and measured doses 
were still normalised to syringe activity.  
                                                     
Predominantly the measurements were performed using the LiF TLD-100 chips. 
These results are presented in Table 5.7. 44MBq to 117MBq of 90Y citrate was 
used for shielded measurements whereas approximately 9MBq 90Y citrate was 
available for the unshielded measurements.  
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Table 5.7 5ml 90Y citrate in the 10ml syringe supported vertically as 
illustrated in Fig. 5.5. One TLD ‘N’ is taped directly to the syringe or shield 
surface and one with flat 9.8mm Perspex backscatter ‘B’. 
 
Shield 
Position of LiF TLD-100  
chip relative to the shield 
Corrected 
value 
mSv/h/GBq 
Ratio 
B/N 
Unshielded  
  
N 3580 1.19 
B 4260 
Perspex 
 
N    2.4 1.17 
B   2.8 
Tungsten 
 
N  4.9 1.02 
B  5.0 
Zevalin  
 
N 0.49 1.27 
B 0.62 
NB. For the Perspex shield the TLD was placed on the side edge of the shield so 
that it was always the thickest section of the shield through which the dosemeter 
was exposed.   
 
A repeat set of measurements were also made using the Perspex shield only to 
compare the TLD-100 and the LiF-7 TLD response. 5ml 90Y citrate 
(57MBq 71MBq) contained within the Perspex syringe shield was available for 
the comparative TLD measurements. These results are presented in Table 5.8. 
Given the fact that the syringe contents were shaken to the same degree and the 
TLDs placed at the same position, it would be expected that the LiF TLD-100 
values would agree with those for Perspex in Table 5.7.  These results show 
almost a factor of 2 difference and therefore highlight again the difficulty in 
obtaining accurate finger dose assessments. 
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Table 5.8 5ml 90Y citrate in the 10ml syringe supported vertically as 
illustrated in Fig. 5.5.  One TLD ‘N’ is taped directly to the shield surface 
and one with 9.8mm Perspex backscatter ‘B’. 
 
 
Shield 
Type of TLD Position of TLD relative 
 to the shield 
Corrected value 
mSv/h/GBq 
Perspex 
  
 
LiF-7 N 2.9 
B 2.7 
LiF TLD-100 N 4.7 
B 5.2 
 
 
By positioning the syringe vertically, the results suggest that the effect of settling 
has now been largely removed.  It also shows that the effect of backscatter does, 
in the vast majority of results, increase the dose recorded by the TLD. However, 
the block of Perspex did not allow all of the TLD to be completely in contact with 
the shield wall due to the curvature of the shield (Fig. 5.6). Hence, this was not 
truly a comparable measurement to assess dose or backscattering effects 
compared to the TLD with no scattering media.  
 
Using the curved Perspex sections (Fig. 5.7) another set of measurements was 
performed for a shielded 10ml syringe containing 90Y citrate in 5 ml solution 
(385MBq to 597MBq). In this case a slightly thinner walled tungsten shield 
(2.2mm vs. 2.8mm) was used since the one used for all previous measurements 
had been contaminated in clinical use.  Again the contents of the syringe were 
shaken and left to settle before the measurements commenced.  The syringe and 
shield were supported vertically in a retort stand (as illustrated in Fig. 5.10, 5.11, 
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5.12).  On this occasion a TLD (with a 1cm Perspex backscatter) was also placed 
against the tapered lower wall of the Perspex shield (designated ‘TE’), shown in 
Fig. 5.13. This should give a better representation of where an operator either 
dispensing or administering an injection might place their fingertips.  However, 
with the syringe withdrawn into the shield the TLD could only be placed on a 
thicker part of the tapered wall rather than at the minimum thickness. For this set 
of results LiF TLD-100 chips were used. The results are presented in Table 5.9. 
 
Table 5.9  5ml 90Y citrate in a 10ml syringe supported vertically. One TLD 
‘N’ is taped directly to the syringe or shield surface and one with curved 
Perspex backscatter ‘B’ (as illustrated in Fig. 5.12). 
  
TE = thin tapered edge with backscatter 
Shield 
Position of LiF TLD-100  
relative to the shield 
Corrected value 
mSv/h/GBq 
Ratio 
B/N 
 
Perspex  
 
N 2.74  
1.03 B 2.81 
TE 4.91 
Tungsten  
 
N 1.64  
1.10 B 1.81 
Zevalin  
N 0.71  
0.92 B 0.65 
 
Comparing the results in Table 5.9 to those in Table 5.7 the variability in 
measured TLD dose values can be seen.  This variability makes any 
interpretation of the effect of the curved Perspex backscatter block compared 
with the flat backscatter blocks difficult. However, the ‘B/N’ ratios are of a similar 
order of magnitude. 
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Table 5.9 again shows the Zevalin shield to be the most effective for dose 
reduction. The Perspex shield is the least effective.  The increased ‘TE’ result for 
the Perspex tapered wall is a factor of 7 higher than that for the Zevalin shield 
and 2.5 times higher than that for the tungsten shield. 
 
As has been previously mentioned, the effect of the shielding should be 
considered in relation to how it would be used in everyday practice, and take into 
account the design features of each shield.  An additional set of measurements 
was therefore made by placing a TLD underneath each shield in turn as shown in 
Fig. 5.18.   The syringe containing 1.17GBq of 90Y Zevalin in 8.3ml was pushed 
through the shield to replicate what would happen in clinical practice i.e. the 
standard blind hub on the syringe was not shielded.  For the Perspex shield this 
also meant that the TLD position was at a thinner part of the tapered wall. The 
results recorded are as shown in Table 5.10. The measurements were made 
over 10 minute intervals. 
 
 
                                   LiF-7 TLD 
 Fig. 5.18  The LiF-7 TLD is placed underneath the shield.  
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Table 5.10  8.3ml 90Y Zevalin in 10ml syringe with LiF-7 powder TLD – 
blind hub not shielded.   
 
Shield  Corrected value 
mSv/h/GBq 
Perspex (TE) 79.1 
Tungsten 1.14 
Zevalin 0.0 
 
The Perspex results in Table 5.10 are considerably greater than the 
corresponding Perspex results in Table 5.9.  This is because the values in Table 
5.10 are obtained with the TLD placed under the thinner tapered section of the 
shield. The results in Table 5.9 and Table 5.10 support all the previous results 
which demonstrate the Zevalin hybrid shield as being the most effective shield, 
followed by tungsten. The least effective shield is Perspex particularly when the 
effect of the tapered wall is considered.  
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5.3.4 TLD results with 1ml syringe laid horizontally 
 
Initially a 1ml Perspex (Fig. 4.4) and tungsten (Fig. 4.5) shields were the only 
shields available for comparison. The TLD results were acquired using the 
experimental set-up as illustrated in Fig. 5.14. The syringe contained ~325MBq 
90Y Zevalin in 0.4ml of solution.  The results are presented in Table 5.11. 
 
Table 5.11  0.4ml 90Y Zevalin in 1ml syringe supported horizontally.  One 
TLD ‘N’ is taped directly to the shield surface and one with 1cm Perspex 
backscatter ‘B’. 
 
 
 
NB Perspex ‘B’ reading corresponds to the tapered section of the shield. 
 
A repeat set of measurements was carried out using the same experimental set-
up as described above but in this case with 90Y citrate. 0.2ml of 90Y citrate 
(101MBq) was contained in a 1ml syringe. These results are shown in Table 
5.12. 
Shield 
Position of LiF-7 powder 
TLD relative to the shield 
Corrected value 
mSv/h/GBq 
Perspex  
 
N 4.47 
B 15.0 
Tungsten  
  
    N 11.3 
B 9.12 
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Table 5.12  0.2ml 90Y citrate in 1ml syringe supported horizontally.  One 
TLD ‘N’ is taped directly to the shield surface and one with 1cm Perspex 
backscatter ‘B’. 
 
Shield 
Position of LiF-7 powder TLD  
relative to the shield 
Corrected value 
mSv/h/GBq 
Perspex  
 
N 5.50 
B 18.1 
Tungsten  
 
N 11.1 
B 14.9 
 
 
When no backscatter material was involved, the results for 90Y citrate are very 
similar to those of 90Y Zevalin. The 90Y citrate results are higher than the 90Y 
Zevalin results when the Perspex backscatter material was used.  This may 
represent the effect of settling as seen with the 10ml results. However, any 
settling effect is much less pronounced with the 1ml syringe, most likely due to 
the smaller diameter of the syringe. If the measured backscatter figure was taken 
into account, the 1ml tungsten appeared to be the better shield to use.  
 
A further series of measurements were made with the LiF TLD-100 chips for 
comparison with the LiF-7 results. The experimental set-up was exactly the same 
as described in Fig. 5.14.  In this case measurements were also made directly on 
the surface of the syringe (unshielded results). 30MBq of 90Y citrate in 0.4ml of 
solution was used. Table 5.13 shows the results of these measurements. 
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Table 5.13  0.4ml 90Y citrate in 1ml syringe laid horizontally.  One TLD ‘N’ 
is taped directly to the syringe or shield surface and one with 1cm Perspex 
backscatter ‘B’. 
 
Shield 
Position of LiF TLD-100 
 relative to the shield 
Corrected value 
mSv/h/GBq 
Unshielded  
 
N 46,400 
B 444,000 
Perspex  
  
N 3.78 
B 12.2 
Tungsten  
  
N 5.50 
B 10.3 
 
 
As can be seen, the backscatter results derived from the TLDs placed 
underneath the shield are significantly higher than the corresponding TLD results 
on top of the shield. In particular the unshielded values, which essentially 
measure the beta dose, are increased by a factor of about x10. It was these 
results, together with the 10ml results which drew attention to a possible settling 
issue with the 90Y labelled product (90Y citrate) as described in Section 5.3.2. 
 
5.3.5 TLD results with 1ml syringe supported vertically 
 
In an attempt to negate this issue as described previously for the 10ml syringe 
(Section 5.3.3), the syringe and shield were supported vertically as in Fig. 5.15. 
The contents of the syringe were shaken before each measurement commenced 
and left to settle for 20 minutes minimum before attaching the TLDs.   TLD-100 
chips were used for the results presented in Table 5.14. Unfortunately only a low 
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activity of 6MBq (in 0.4ml) was available for these measurements which may 
affect the accuracy of the results.   
 
Table 5.14 0.4ml 90Y citrate in 1ml syringe supported vertically (Fig. 5.15).   
One TLD ‘N’ is taped directly to the shield surface and one with 9.8mm 
Perspex backscatter ‘B’. 
 
Shield 
Position of LiF TLD-100 
 relative to shield 
Corrected value 
mSv/h/GBq 
Unshielded  
 
N 12800 
B 11900 
Perspex  
 
N 4.94 
B 4.44 
Tungsten  
 
N 5.43 
B 12.1 
 
 
The results for Perspex and tungsten without backscatter ‘N’ are of a similar 
order of magnitude to those in Table 5.13. The backscatter result for Perspex is 
lower than in Table 5.13.  However the backscatter result for tungsten is 
essentially the same. This may reflect some variation in the 90Y citrate 
concentration despite the vertical arrangement to try and overcome this. 
However, the unshielded results (‘N’ and ‘B’ in Table 5.14) are similar and do not 
demonstrate the large differences seen in Table 5.13. This would seem to 
indicate that supporting the syringe vertically does counteract the gravitational 
settling effect.  The variation seen with tungsten may also be contributable to the 
very low activity available for these measurements. 
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A second series of measurements were made with LiF-7 TLDs for comparison 
with the TLD-100 results in Table 5.14, using the Perspex shield only.  A 9.8mm 
Perspex backing block was attached to one of the TLDs simulated backscatter, 
as shown in Fig 5.15.  Results are shown in Table 5.15. 
 
Table 5.15 0.4ml 90Y citrate in 1ml syringe in Perspex shield supported 
vertically (Fig. 5.15). One TLD ‘N’ is taped directly to the shield surface and 
one with 9.8mm Perspex backscatter ‘B’. 
 
Shield 
Position of LiF -7 powder 
 TLD  
Corrected value 
mSv/h/GBq 
Perspex 
 
N 7.04 
B 7.08 
 
Comparing the results of Table 5.15 and Table 5.14 it can be seen that the TLD-
100 results are only 60% of the LiF-7 results. This reduction is similar to that 
seen for the 10ml 90Y shielded syringe results.  This has implications for 
appropriate dose monitoring for finger dose. 
 
As for the 10ml situation, curved 1cm thick Perspex sections (Fig. 5.7) were 
subsequently constructed which matched the outer curvature of the 1ml tungsten 
and Perspex shields. In addition a blind hub from a three way tap was found to 
have suitable dimensions to allow it (together with the syringe contents) to be 
withdrawn totally into the shields.  This meant no residual activity in the needle 
could contribute to the TLD readings. A repeat set of readings with these 
conditions was therefore carried out using TLD-100 chips. 
 
An additional measurement was also made for the thinner tapered section of the 
Perspex shield using a 9.8mm block of Perspex as the backscattering material.  
This position at the tapered underside of the shield is very likely to be where an 
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operator might place their finger during dispensing/administration of the product. 
It should be noted, however, that only a small proportion of the syringe contents 
would be close to this area as the syringe and blind hub had been withdrawn 
totally into the shield. The experimental set-up was as illustrated for Fig. 5.16.  
74  90MBq 90Y citrate (in 0.4ml) was used for the shielded measurements.  The 
0.4ml solution measured approximately 2MBq 90Y citrate when used for the 
unshielded measurements. The results are reported in Table 5.16. 
 
Following concerns over the variation in results being obtained with the LiF TLD-
100 chips it was suggested that one reason might be if the TLD chips were 
inverted during processing and hence read from the side opposite to that 
exposed. To examine this, the sachets for the unshielded syringe measurements 
(i.e. measuring betas) had two chips.  When read, one chip was inverted.   With a 
low energy beta component, the inverted chip might give a lower reading as 
more energy from the betas would be absorbed closer to the exposed side.   
 
The results are reported in Table 5.16. For the unshielded results, the chips 
without backscatter are denoted ‘NI’ for the inverted chip and ‘NN’ for the non-
inverted chip. The chips with backscatter are denoted ‘BI’ for the inverted chip 
and ‘BN’ for the non-inverted chip.  
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Table 5.16 0.4ml 90Y citrate in 1ml syringe supported vertically with blind 
hub shielded (Fig. 5.16).  
 
N = no backscatter 
TE = thin tapered edge with backscatter 
B = thick edge with backscatter  
NN and NI = unshielded syringe - no scatter (2 chips/packet - one of which was 
inverted during processing; the other left in its original orientation)  
BN and BI = unshielded syringe with backscatter (2 chips/packet - one of which 
was inverted during processing; the other left in its original orientation); 
 Shield 
Position of LIF TLD-100 
 relative to shield 
Corrected value 
mSv/h/GBq 
Unshielded  
  
NN 12600 
NI 13400 
Unshielded  
 
BN 13400 
BI 13500 
Perspex  
 
N 6.25 
B 4.87 
TE 10.9 
Tungsten  
 
N 14.8 
B 10.7 
 
 
The results for the unshielded syringe did show a small tendency for the inverted 
chip to read higher but this was small compared to the discrepancies noted for 
the TLD results in Table 5.14 and Table 5.16. Therefore, the potential for chip 
inversion to affect dosimetry results would appear to be small. 
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In addition the results for Perspex and tungsten are all higher than previously 
shown in Table 5.14.  This is despite the total contents of the syringe and blind 
hub being totally shielded (Table 5.16) compared to the situation in Table 5.14 
when part of the needle could not be shielded. Also, unexpectedly, the 
backscatter results for Perspex and tungsten in Table 5.16 are lower than the 
unscattered results. The tapered wall of the Perspex shield gives approximately 
double the dose value than the main wall. 
 
A 1ml Zevalin shield (Fig. 4.6) was later made available. Surface dose rates were 
measured with the TLD-100 chips, both with and without 1cm curved 
backscatter. At the same time, measurements were also made with the Perspex 
and tungsten shields for comparison.  A volume of 0.2ml of 90Y Zevalin (with an 
available activity of 33MBq to 72MBq) was used. All measurements were 
acquired with the syringe supported vertically in the retort stand (Fig. 5.16).  In 
addition measurements were made through the thin tapered wall of the Perspex 
shield.  
 
For the results presented in Table 5.17, TLD-100 (LiF:Mg,Ti) TLDs were supplied 
by the Regional Radiation Protection Service in Birmingham.  
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Table 5.17 Surface dose rates from 0.2ml of 90Y Zevalin in a 1ml syringe. 
One TLD ‘N’ taped directly to the shield surface and one with 1cm Perspex 
backscatter ‘B’. 
 
TE =  Thin tapered edge with backscatter; 
Shield 
Position of 
TLD-100  
relative to 
shield 
Corrected value 
 
mSv/h/GBq 
Ratio 
B/N 
 
Perspex  
 
N 5.54  
1.25 B 6.92 
TE 8.54 
 
Tungsten 
N 13.1 1.26 
B 16.5 
 
Zevalin  
N 0.66 1.14 
B 0.75 
 
Table 5.17 shows conclusively the Zevalin hybrid shield as being the most 
effective shield.  For the 1ml syringe containing 90Y, the majority of results would 
indicate that Perspex is superior to tungsten. The distance of the fingers from the 
syringe provided by the Zevalin and Perspex shields may contribute to some of 
the dose reduction compared to tungsten.  However, the values for tungsten are 
acceptable for routine use. Contrary to the values in Table 5.16, the backscatter 
values for Perspex and tungsten in Table 5.17 are 25% higher than the 
unscattered values. This would better reflect the expected increase in the 
backscatter results. 
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5.3.6 TLD results with 5ml syringe supported vertically 
 
As a further check on TLD accuracy, it was decided to expose the LiF TLD-100 
chips in contact with a 5ml unshielded syringe.  This was to compare with 
published data for 90Y by Delacroix et al. [27].  This gave a figure of 
43.5mSv/h/MBq for contact with an unshielded 5ml syringe containing 2.5ml of 
90Y.   
 
9.4MBq 90Y citrate in 2.5ml of solution was dispensed into a 5ml syringe.  The 
contents were again shaken and left to settle for at least 20 minutes.  The syringe 
was supported vertically in a retort stand and three LiF TLD-100 strips were 
wrapped around the syringe as illustrated in Fig. 5.19. Each TLD-100 strip 
contained two chips and one of the chips of strips ‘C’ and ‘E’ was inverted during 
reading. This resulted in TLD ‘D’ running along the vertical length of the syringe 
and TLD ‘C’ and ‘E’ running at 900 to the direction of the syringe.  
 
 
If the results were reproducible TLD ‘C’ and TLD ‘E’ should read the same and 
correlate with the value stated by Delacroix et al. [27].  TLD ‘D’ was placed 
slightly higher to ascertain what (if any) variation in dose is noted with distance 
due to any settling.   The lower of the 2 chips in TLD ‘D’ was placed in line with 
the chips in TLD ‘C’ and TLD ‘E’.  Due to the detailed geometry of the situation 
no backscattering media was applied. 
Fig. 5.19 
 
TLD-100 chips wrapped 
around a 5ml unshielded 
syringe in this pattern of 
orientation. 
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Table 5.18  LiF TLD-100 exposed for a 5ml syringe containing 2.5ml 90Y 
citrate. TLDs taped to unshielded syringe as illustrated in Fig. 5.19. 
 
NN = TLD chip kept upright to process the side exposed 
NI = TLD chip inverted for processing; 
Shield 
LiF TLD-100  
number 
Corrected value 
mSv/h/GBq 
No shield 
 
 
C 
 
NN 4820 
NI 3950 
D 
 
NN 6970 
NN 3760 
E 
 
NN 4890 
NI 5200 
 
Chips marked ‘NN’ for TLDs ‘C’ & ‘E’ should ideally read the same, as should 
one of the chips for ‘NN’ on TLD strip ‘D’. However, it can be seen that this is not 
the case. (Unfortunately the chips could not be individually numbered so it is not 
possible to differentiate which result belongs to which position for TLD strip ‘D’). 
There is an additional complication in that inverting one of the chips during 
processing appears to reduce the reading in one case (for TLD associated with 
‘C’) and increases it for TLD associated with ‘E’.  This is another example of the 
need to find suitable TLDs with consistent response for measuring finger doses 
when exposed to beta emitting radionuclides. 
 
The results from these measurements are a factor of 10 lower compared with the 
value quoted by Delacroix et al. [27].  This could be partly due to the settling in 
the larger syringe but the total effect of that was not quantified. It may also relate 
to the response of the TLDs to betas, with the plastic covering having some 
attenuation effect and reducing the response. 
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5.4 Results for 32P 
 
5.4.1 TLD results for 32P in a 10ml syringe  
 
Replicating the situation for the 10ml syringe containing 90Y, the 10ml syringe 
containing 32P was placed in turn in the three different syringe shields.  To 
discover the true effect of each shield the measurements were performed with 
the syringe contents and the standard blind hub shielded (as described in Fig. 
5.4). 
   
For the 10ml measurements detailed in this section, the activity ranged from 65 
to 83MBq 32P in 5.5ml of solution.  
 
As for the 10ml measurements involving 90Y, the effect of distance on the surface 
dose was investigated by placing TLDs at varying distances from a tungsten 
shielded syringe.  A backscatter material of 1cm of Perspex was placed behind 
each of the TLDs during these measurements and spacers were used to position 
the TLDs at accurate distances from the shield. As a concurrent process, several 
of the measurements performed above with LiF-7 powder TLDs were also 
performed alongside LiF TLD-100 chip measurements.  These concurrent 
measurements will be denoted by * in Table 5.19.  These measurements were to 
ascertain the relative response of the two types of TLDs to exposure from 32P. 
The results are presented in Table 5.19. 
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Table 5.19 10ml syringe containing 5.5ml 32P laid horizontally with blind 
hub shielded.  One TLD taped on top ‘N’ and one fixed underneath ‘B’ with 
a backing of 1cm Perspex. 
 
Shield 
 
 
 
Position of TLD relative  
to shield 
LiF-7 powder LiF TLD-100 
Corrected value 
mSv/h/GBq 
No shield  
 
N  9580*  4950* 
B  6890*  3330* 
Perspex  
 
N  1.67*  1.59* 
B  1.95*  2.62* 
Tungsten  
 
 
 
 
 
N 1.01 0.75 
1mm 0.50 - 
4mm  0.53*  0.24* 
9mm 0.36 - 
B  0.36*  1.09* 
Lead glass window 0.89 0.37 
Zevalin  
 
N 0.19 - 
B 0.29 - 
 
* Concurrent measurements using LiF-7 and TLD-100. 
 
For the unshielded results (i.e. betas) the TLD-100 results are 50% lower than 
the LiF-7 results. This is a similar reduction as observed with 90Y. Although the 
overall trend for the shielded results (bremsstrahlung dose) is for the LiF TLD-
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100 chips to read lower doses than the LiF-7 powder TLD this is not as 
conclusive as it was for the 10ml 90Y shielded syringe.  This table of results 
demonstrates the Zevalin hybrid shield as being the most effective shield for 
minimizing finger dose, followed by tungsten. The least effective shield is 
Perspex.  As for 90Y, the backscattered result for the TLD placed at 9mm from 
the tungsten shield is similar to the equivalent TLD result ‘B’ for the Zevalin 
shield. This indicates that distance from the syringe is a factor in the lower values 
observed with the Zevalin shield. 
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5.4.2 TLD results for 32P in a 1ml syringe  
 
The first series of measurements were performed with the syringe laid 
horizontally (as illustrated in Fig. 5.14) and used the 1ml Perspex and tungsten 
shields. 
 
The syringe contained between 42MBq to 57MBq 32P in 0.4ml of solution for the 
shielded measurements and as low as 1MBq for the unshielded assessment. 
 
Two sets of LiF-7 measurements were made using the unshielded syringe. 
These were performed to check the reproducibility with different activities of 32P.  
In addition, LiF TLD-100 chips were placed alongside the LiF-7 powder TLDs as 
described for the 10ml acquisitions to try and establish a relationship between 
the two types of TLDs.  (Unfortunately many of these readings had to be 
discarded as several chips were dropped during the processing/reading stage 
and their identification therefore lost. Due to the elapsed time between obtaining 
the measurements and the reading stage, the activity remaining in the syringe 
was too low to warrant repeating the measurements.  The cost of ordering 
additional 32P specifically to repeat these measurements could also not be 
justified). Table 5.20 reports the results of these measurements. 
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Table 5.20 1ml syringe containing 0.4 ml 32P laid horizontally.  One TLD 
‘N’ taped directly to the shield surface and one with 1cm Perspex 
backscatter ‘B’. 
 
   
Shield 
 
 
 
 
Position of TLD 
relative to shield 
LiF-7 powder  
 
 
LiF TLD-100 
 
Corrected value 
mSv/h/GBq 
No shield  
 
N 86600 - 
B 93500 - 
No shield            
(Repeat 
measurement) 
N  94000*  38300* 
B  113000* 
 
 54200* 
Perspex  
 
N 3.85 - 
B 5.01 - 
Tungsten 
                             
N 3.14 - 
B  7.34  3.50 
 
* Both TLD types were exposed concurrently. 
 
A different dose rate/GBq was noted for the two sets of LiF-7 powder results 
relating to the unshielded syringe, but some of this discrepancy could be due to 
the very low activity available and how accurately that activity could be 
measured.   The unshielded measurements resulted in the backscatter reading 
being higher than the unscattered reading (with a mean increase of 23%). 
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The TLD-100 dose is, as for the 90Y results, a factor of approximately 2 less than 
the LiF-7 powder TLD value. The shielded values are all less than those obtained 
for 90Y; this is because the lower beta energy of 32P means that less 
bremsstrahlung radiation will be produced. 
 
Table 5.20 shows that the dose reduction achieved with Perspex and Tungsten 
shields is essentially the same. The backscatter figure is higher than the 
unscattered figure (30% increase for Perspex, 134% increase for tungsten). 
 
Further measurements were performed using the experimental design as 
described in Fig. 5.16 and included the use of a 1ml Zevalin shield. In addition to 
a measurement through the thick wall of the Perspex syringe shield a TLD was 
also positioned to record the dose through the thinner tapered wall of the shield 
(as illustrated in Fig. 5.13 for the 10ml syringe).   
 
A further complicating factor was the change of supplier of the TLDs used.  The 
results in Table 5.21 present the findings using the Global Dosimetry MeasuRing 
TLD, which contains a TLD-100 chip.  
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Table 5.21 1ml syringe containing 0.3ml 32P supported vertically (activity 
range 81  89MBq used).   
 
N = no backscatter 
TE =  Thin tapered edge with backscatter 
B =  Thick edge with backscatter; 
Shield 
 
Position of Global MeasuRing  
TLD relative to shield 
Corrected value 
mSv/h/GBq 
 
Perspex  
 
 
N 3.90 
B 2.77 
TE 5.02 
Tungsten 
 
N 2.85 
B 2.47 
Zevalin  
 
N 0.39 
B 0.40 
 
Once again the hybrid Zevalin shield provides the most effective dose reduction.  
The results for the Perspex and tungsten shield mirror the results of Table 5.20 in 
equivalent dose reduction if only the thick wall of the Perspex shield is 
considered.  There is a discrepancy for the backscatter results for Perspex and 
tungsten; these are lower than the results without backscatter, and inconsistent 
with the results in Table 5.20. However, when the result for the tapered wall of 
the Perspex shield is taken into account, the tungsten shield is superior to the 
Perspex shield. 
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5.5 Results for 90Y Zevalin preparation and administration 
 
5.5.1 Extremity TLD results for operator dispensing 90Y Zevalin 
 
The TLD results give an indication of the expected benefit of the various syringe 
shields. In the course of this work, finger doses were also measured for 
operators dispensing and administering beta emitting radionuclides. This was 
particularly important for the administration of 90Y Zevalin, since this involves high 
activities of 90Y as well as intricate manipulation and administration procedures.  
One aspect of this work relates to the position of the TLD on the fingers of the 
operator. Several authors have shown the effect of wearing TLDs at the base of 
the finger as opposed to the fingertip.  The difference in readings can be very 
marked even for gamma emitting radionuclides; up to a factor of 6 difference has 
been reported but more normally a factor of 2 is quoted [21, 50-53]. The practice 
of wearing TLDs at the base of the finger as opposed to the fingertip is likely to 
be even more significant for beta emitting radionuclides. As a consequence, all 
TLDs worn by operators during these measurements were worn as close to the 
fingertip as possible to try and ensure the maximum dose to the finger was 
recorded. Table 5.22 presents the results. 
 
 68 
 
 
Table 5.22 a) Left hand finger doses recorded for the operator dispensing the 90Y Zevalin Infusion. 
 Operator 
 1 2 1 1 1 
Shield used 10ml and 1ml  
Perspex 
10ml and  
1ml  
Perspex 
10ml Zevalin;  
 1ml shield used 
-  not identified 
10ml Zevalin;  
 1ml shield used 
 - not identified 
10ml Zevalin;  
 1ml shield used  
 - not identified 
TLD type LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
MeasuRing  
(mSv) 
Left thumb  8.22 1.15 0.74 0.00 0.57 
Left forefinger 29.7 1.68 1.17 0.13 0.00 
Left middle finger  7.5 2.93 0.28 1.03 0.36 
Left ring finger 30.3 2.75 0.89 18.7 0.32 
Left little finger 8.42 5.11 4.43 0.51 0.25 
Mean Dose (left )  16.8 2.72 1.50 4.07 0.30 
Median Dose (left) 8.42 2.75 0.89 0.51 0.32 
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Table 5.22 (cont) b) Right hand finger doses recorded for the operator dispensing the 90Y Zevalin Infusion. 
 
 Operator 
 1 2 1 1 1 
Shield used 10ml and 1ml 
Perspex 
10ml and  
1ml  
Perspex 
10ml Zevalin;  
 1ml shield used 
-  not identified 
10ml Zevalin;  
 1ml shield used 
-  not identified 
10ml Zevalin;  
 1ml shield used 
-  not identified 
TLD type LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
MeasuRing  
(mSv) 
Right little finger 1.48 19.9 0.33 0.74 0.26 
Right ring finger 4.93 5.02 0.31 0.34 0.25 
Right middle finger 4.78 5.13 0.28 0.15 0.26 
Right forefinger 6.18 13.6 0.48 0.12 0.26 
Right thumb 6.19 9.4 0.26 0.36 0.38 
Mean dose (right) 4.71 10.6 0.33 0.34 0.28 
Median dose (right) 4.93 9.4 0.31 0.34 0.26 
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Table 5.22 (cont) c ) Summary of Right and Left hand finger doses recorded for the operator dispensing the 90Y 
Zevalin Infusion. 
 
 Operator 
 1 2 1 1 1 
Shield used 10ml and 1ml 
Perspex 
10ml and  
1ml  
Perspex 
10ml Zevalin;  
 1ml shield used 
-  not identified 
10ml Zevalin;  
 1ml shield used 
-  not identified 
10ml Zevalin;  
1ml shield used 
-  not identified 
TLD type LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
LiF-7 TLD  
(mSv) 
MeasuRing  
(mSv) 
Mean dose (R + L) 10.8 6.66 0.92 2.21 0.29 
Median dose (R + L) 6.85 5.07 0.41 0.35 0.26 
Maximum dose 30.3 19.9 4.43 18.7 0.57 
Minimum dose 1.48 1.15 0.26 0.00 0.00 
Activity handled (MBq) 2390 2510 1900 1920 1910 
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Notes for Table 5.22 
 
Operator 1 is right handed; Operator 2 is left handed. The first two columns are 
training runs. Unfortunately Operator 1 could not recall which 1ml shield was 
used for columns 4 to 6 of Table 5.22. 
 
Different combinations of shields were used depending on availability at the time 
of the dispensing procedure. 
 
The mean, median, maximum and minimum finger doses are presented to 
compare with published data. The finger dose values in Table 5.22 a) and Table 
5.22 b) are clearly not normally distributed. Therefore the mean is not considered 
optimal and the median is included as a more appropriate parameter.  
However, from a radiation protection perspective the most important parameter is 
the maximum finger dose. Normally this is observed on the index finger of the 
non dominant hand. However, operators were aware of this fact and so were 
consciously using different finger digits closest to the source of radioactivity in 
order to share the dose out between fingers.  
In addition some published data normalises to 1.5GBq. This will be considered in 
the discussion section.  
 
Therefore, a summary of the values in Table 5.22 for use in the discussion is -  
Mean finger dose for all dispensers = 1.79mSv/GBq 
(Which normalised to 1.5GBq = 2.7mSv/1.5GBq). 
 
Median finger dose for all dispensers = 0.42mSv/GBq 
(Which normalised to 1.5GBq = 0.63mSv/1.5GBq). 
 
Range of finger dose [min, max] for all dispensers = [0.00mSv to 30.3mSv] 
(Which normalised to 1.5GBq = [0.00mSv to 19mSv]). 
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5.5.2 Extremity TLD results for operator connecting up 90Y Zevalin infusion 
 
The following components contributed to the TLD readings recorded by the 
operator: 
 
The injection arrived in the Zevalin shielded 10ml syringe.  The syringe was 
removed from the shield using forceps and placed into the Capintec CRC15Beta 
ionisation chamber set up with the appropriate calibration factor (activity too high 
to count in the beta counter). Once the activity had been recorded (as observed 
by two independent operators) the syringe was transferred to a 10ml tungsten 
shield in preparation for the infusion.  This shield was employed in preference to 
the Zevalin shield as it was the largest sized shield that could be accommodated 
by the Graseby infusion pump.  The shielded syringe was then attached to the 
infusion line.  Once the infusion was complete a saline flush was pushed into the 
shielded syringe via the three way tap. The infusion was recommenced to clear 
the remaining radiopharmaceutical from the extension line connected to the 
patient.   
The infusion set-up is illustrated in Fig. 5.20.  The whole assembly was shielded 
behind a lead ‘L’ during the infusion. 
 
                           
Fig. 5.20 Administration of 90Y Zevalin performed using the Graseby pump 
as illustrated above.  
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The TLDs were removed once dose rate measurements from the patient had 
been completed, all waste product disposals had been accomplished and 
contamination monitoring performed. The TLD results are shown in Table 5.23. 
 
Table 5.23 Finger dose readings recorded by the operator connecting up 
the 90Y Zevalin Infusion. 
 
Patient 1 2 3 
TLD type LiF-7 LiF-7 MeasuRing Ring TLD 
(worn at base  
Of finger) 
LiF TLD-100 
supplied by 
Birmingham 
Activity Handled 
(MBq) 
807 1188 1112 
Left thumb 
(mSv) 
3.48 * 0.67 N/A N/A 
Left forefinger 
(mSv) 
2.86 * 0.31 0.34 2.2 
Right thumb 
(mSv) 
0.51 0.3 0.21 N/A N/A 
Right forefinger 
(mSv) 
0.32 0.7** 0.3 0.35 0.6 
 
NB: Operator right handed on all occasions. 
* dose results to the left hand had to be ignored as the TLDs had been 
inadvertently misread by the Radiation Protection Service. (N.B. Due to the cost 
of this radiopharmaceutical (>£10,000/patient) this therapeutic procedure is not 
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commonly carried out and there was no opportunity to gather repeat finger dose 
data).  
** includes routine monthly workload of the operator (including I-131 work) due to 
shortage of TLDs. 
For patient 3: Several different types of TLDs were worn by the operator during 
measurement of activity and administration of infusion.  The reasons for this were 
two fold:  
1). there had been concern since switching to the MeasuRing strip TLDs that 
far more zeros were being recorded by operators wearing them for routine 
use than had been noted for the previous type of TLDs worn i.e. the LiF-7 
powder type;  
2).  the effect of distance on the dose recorded was also required for the ring 
type TLDs, worn further away from the fingertip than the strip TLD. 
 
These results again show a disparity between the responses of different types of 
TLDs available.  The greatest concern is over the validity of the readings 
recorded by the Global dosimetry MeasuRingTM TLDs.  The results in Table 5.23, 
together with the results for the Operator dispensing the radiopharmaceutical in 
Table 5.22 required further investigation, as it would appear unlikely that an 
operator handling 1.91GBq 90Y would receive a dose for their left forefinger 
below the minimum detectable limit of 0.2mSv.  
 
To calculate the mean dose for the operator connecting up the infusion it was 
decided to use the results produced using the TLDs supplied by Birmingham. 
 
Mean finger dose for operator administering the infusion = 1.3mSv/GBq 
(Which normalised to 1.5GBq = 1.95mSv/1.5GBq). 
Median finger dose for operator administering the infusion = 0.61mSv/GBq 
(Which normalised to 1.5GBq = 0.92mSv/1.5GBq). 
 
Range of finger dose [min, max] for all administrations = [0.21mSv to 3.48mSv] 
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5.6 Discussion:  
 
Review of the published data for finger (TLD) doses when handling 90Y and 
32P compared to the results of this research. 
 
The first issue to highlight in relation to the TLD results in the literature is that 
various references report calculated and measured finger dose but do not always 
specify the geometry, volumes or TLDs employed in each case.  This fact makes 
it difficult to relate many of the published results directly to the research 
presented here.  
 
    
5.6.1 Unshielded 90Y syringe:  
 
Comparative analysis of published data with this research. 
Zhu [7] refers to a calculated dose of 44Sv/h/GBq from handling an unshielded 
syringe of 5ml 90Y Zevalin.  This is in line with a figure of 43.5Sv/h/GBq quoted 
for contact with 2.5ml of 90Y in a 5ml syringe by Delacroix et al.  [27] and 36-
43.5Sv/h/GBq for the surface dose rate of a 5ml plastic syringe containing 1GBq 
of 90Y by Rimpler et al. [5, 13]. However, all these values relate to data provided 
by Delacroix et al. [27], published initially in 1998 and later revised in 2002. 
Delacroix et al. [27] calculates these values using the Varskin Mod 2 software 
code for beta radiation, as opposed to the measured values presented in this 
chapter. Zimmer et al. [54] does present measured values for 7.6ml 90Y Zevalin 
in a 10ml syringe of 11.2 Sv/h/GBq. The TLD used was not specified however. 
 
The 90Y results for 2.5ml of solution in a 5ml syringe from this research using the 
TLD-100 chips are a factor of 10 lower than the published data of Delacroix et al. 
[27] with a mean value of 4.9Sv/h/GBq.  This may be in part due to the thick 
plastic cover over the chip itself. As has been demonstrated (in the TLD results 
Sections 5.3.1, 5.3.4, 5.3.5, 5.4.1 and 5.4.2), the TLD-100 chips do have a 
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tendency to read lower than the LiF-7 powder TLD (albeit not by a factor of 10). 
Rimpler et al. [13] also reached the conclusion that the thick plastic cover means 
it is not possible to measure Hp(0.07) properly, at least for betas with lower 
energies. Some discrepancy may also be attributed to the positioning of the chips 
relative to the source centre – particularly as these results were obtained using 
the 90Y citrate solution with its gravitational settling issue. The position of the TLD 
relative to the concentration gradient of the beta emitting radionuclide in the 
syringe will have a bearing on the accuracy of the dose measured. Another 
contributory factor to the discrepancy can possibly be attributed to the calibration 
of the TLDs. 
 
Table 5.24 Summary of the LiF-100 TLD results from this research (Tables 
5.5, 5.6, 5.7, 5.13, 5.14, 5.16, 5.18) for the unshielded 90Y syringe.  
 
SYRINGE  SIZE 
(ml) 
VOLUME OF 
 SOLUTION  
(ml) 
LiF TLD-100 
Corrected value 
Sv/h/GBq 
  Syringe 
orientation 
Horizontal Vertical 
10 5  6  2.6  72 3.6  4.3 
1 0.4 46  444 12  13.5 
5 2.5  3.8  7.0 
 
  
Table 5.24 includes the results where the syringe was laid horizontally.  The 
effect of the settling of the 90Y citrate on the TLD result is clearly seen with the 
extremely high upper value.  The results have been included as this could relate 
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to the true effect encountered in a routine clinical situation when handling that 
product if it had been stored horizontally in a carrying box.  
 
It is to be expected that the dose rate/GBq for the 1ml syringe would be higher 
than that recorded from the 10ml syringe due to; a) the smaller diameter of the 
1ml syringe and b) the smaller volume of 90Y solution.  Both these factors will 
result in a greater concentration of radioactive solution closer to the TLDs and, 
also less attenuation of the beta particles in the solution.   (The wall thicknesses 
of the 1ml syringe and the 10ml syringe are comparable).  The result for the 5ml 
unshielded syringe sits in between the values obtained for the 10ml and 1ml 
syringe as might be expected from the intermediate value of the syringe 
diameter. 
 
An important factor to note for all the unshielded syringe results reported in Table 
5.24 is that, although a range of values are obtained, they all demonstrate the 
extremely high surface dose rates that occur. These clearly show that operators 
should never hold an unshielded syringe directly over the active area even for 
brief periods (e.g. positioning the syringe in an ionisation chamber for activity 
measurement). 
 
 
5.6.2 10ml shielded 90Y syringe: 
 
Comparative analysis of published data with this research. 
In trying to establish the most effective shielding for a 10ml syringe containing 
90Y, it proved very difficult to separate out the issues of; a) the settling of the 90Y 
citrate and b) what appear to be occasional spurious TLD results.  Both of these 
issues will be dealt with in more detail in Chapter 8 of the discussion, covering 
problems encountered during the course of this research. 
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A summary of all the TLD results derived during this research for the 10ml 90Y 
shielded syringe is presented in Table 5.25.  (For specific details relating to the 
LiF-7 TLD results see Table 5.3 and Table 5.8.  For LIF TLD-100 results see 
Tables 5.7, 5.8, 5.9). 
 
 
Table 5.25 Summary of the LiF-7 and LiF-100 TLD results for the shielded 
10ml 90Y syringe. 
 
Shield LIF- 7 TLD 
Mean Corrected value 
mSv/h/GBq 
LiF-100 
Mean Corrected value 
mSv/h/GBq 
 No scatter Backscatter No scatter Backscatter 
Perspex 3.0 3.3 2.6 2.8 
Tungsten 1.7 2.3 1.6 1.8 
Zevalin 0.33 0.33 0.60 0.64 
 
NB Results were ignored where settling clearly played a role. Insufficient results 
of the same type were available to calculate standard deviations for the above 
results. 
 
Zimmer et al. [54] has also directly compared similar types of shields (Table 
5.26).  Unfortunately, no dimensions of the shields were documented to allow 
direct comparison with the results in Table 5.25 above.  The type of TLD used 
was not specified.  
 
 79 
 
 
Table 5.26 Published data of Zimmer et al. [54] for 10ml 90Y TLD results 
using different shielding materials. 
 
 
 
 
Shield 
Zimmer et al. [54] 
TLD result 
7.6ml 90Y Zevalin 
mSv/h/GBq 
Perspex 2.8 
Tungsten 2.4 
Zevalin 1.7 
 
 
As can be seen, the results of Zimmer et al. [54] are consistent with Table 5.25 
regarding the order of preference for the syringe shields. The comparative values 
are also generally consistent.  However, the value obtained by Zimmer et al. [54].  
for the Zevalin shield is higher than the value obtained in Table 5.25.  
 
The ranges of TLD doses presented in Table 5.25 are suggestive of the Zevalin 
shield being at least a factor of 4 better compared with the available Perspex 
shield and a factor of at least 1.4 compared with the tungsten shield examined.   
 
In most cases it should be noted that the backscatter result is higher than the 
unscattered result for all the 10ml shields investigated whilst carrying out these 
90Y measurements.   The backscatter increase in contribution to the finger dose 
readings has a mean value of 3.5% for the Zevalin shield, 9% for the Perspex 
shield and 24% for the tungsten shield. The issue of backscatter will be 
discussed in more detail in Section 5.6.9. 
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5.6.3 Additional factors to consider in selecting the optimum 10ml shield 
for 90Y 
 
A further issue to consider when selecting the optimum shield is the bulky design 
of the Zevalin shield (Fig. 4.3).  It is not favoured by local operators during 
intricate radiopharmaceutical preparation nor does it lend itself to easy 
intravenous access.  The Perspex shield is also bulky but has a tapered wall 
section for ease of use during venous access (Fig. 4.1).  However, there is a risk 
of an associated increase in finger dose if the operator were to hold the Perspex 
shield at this position (Table 5.10). This would apply to aspects of both 
dispensing and administration. In addition some operators are using automatic 
delivery systems, e.g. infusion pumps, to minimise the finger dose as much as 
possible. This limits the size of the shield that can be selected since the large 
diameter Zevalin and Perspex shields do not fit into the syringe holder on the 
pump.  The 10ml tungsten shield does fit (although the pump needs to be 
specifically calibrated for that purpose).  
 
Additionally there is a cost factor which may need to be taken into account in 
deciding on the optimum shield for many Nuclear Medicine departments.  The 
reduction in finger dose when using the Zevalin shield compared to the tungsten 
shield is small.  Most Nuclear Medicine departments have tungsten shields 
readily available for routine clinical use.   
 
Therefore, if ergonomic handling and cost are also considered, the 10ml tungsten 
shield (preferred by many operators for ease of handling) is an acceptable 
alternative to the Zevalin shield. Practical aspects could therefore outweigh the 
extra shielding benefits of Zevalin making tungsten the shield of choice. 
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5.6.4 1ml shielded 90Y syringe: 
 
Results of this research. 
It also proved difficult to get consistent TLD readings for the 1ml syringe. The 
backscatter readings in general are still higher than the situation for the readings 
obtained with no scatter. The backscatter increase is approximately 14% for 
Zevalin, 25% for Perspex and 26% for tungsten.  The effect of backscatter will be 
discussed in more detail in Section 5.6.9. 
A summary of the LiF-100 TLD results (with backscatter) for the vertically 
orientated 1ml syringe is shown in Table 5.27. (Where applicable the mean 
corrected value of mSv/h/GBq) has been quoted). 
 
Table 5.27 Summary of the LiF-100 TLD results for the 1ml 90Y syringe. 
 
Shield 90Y Zevalin 
Corrected value 
mSv/h/GBq 
90Y Citrate 
Mean Corrected value 
mSv/h/GBq 
Perspex 6.92 4.66 
Tungsten 16.5 11.4 
Zevalin 0.75 (Not available) 
 
As for the 10ml 90Y results, there are insufficient repeat measurements to 
calculate standard deviations. 
 
The Zevalin shield is again the most effective at reducing finger dose to the 
operator.  The ranges of TLD doses are suggestive of Zevalin being better by 
almost a factor of 9 compared with Perspex and a factor of 20 compared with 
tungsten.  This is a much greater reduction than seen for the 10ml shields. This 
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is likely to be due to the fact that the 1ml Zevalin shield has a much greater wall 
thickness than the 10ml Zevalin shield (15.5mm and 11.2mm respectively).  In 
effect the 1ml Zevalin shield is the same as the 10ml Zevalin shield but with an 
extra inner liner of Perspex to suit the smaller diameter of the 1ml syringe. This 
substantially increases the distance of the TLDs from the 1ml syringe compared 
to the Perspex shield and tungsten shield.  In addition the 1ml tungsten shield 
has a thinner wall than the 10ml shield (1.9mm and 2.8mm respectively).  This 
not only means there is less attenuation but also the geometry of the 1ml syringe 
means that the relative source distance to the TLD is smaller for the 1ml tungsten 
shield.  This could also explain why the Perspex shield is better than the tungsten 
shield for the 1ml data.   
 
These measurements indicate that the 1ml Perspex is the second best 
alternative, after the Zevalin shield. However, this must be qualified by the fact 
that the operator must conscientiously keep their fingers at the position of the 
thicker wall of the shield and not hold the shield under the tapered wall. 
The dose measurement through the tapered wall of the Perspex shield is also 
likely to be an underestimate.  This is because the syringe and blind hub were 
withdrawn totally back into the shield to avoid any effect of residue in the blind 
hub.  This would not be the case in routine clinical practice.  
 
Therefore, if ergonomic factors are again taken into account, the 1ml Zevalin and 
1ml Perspex shields are both bulky and consideration may be given to using the 
1ml tungsten shield, with the same arguments as outlined for the 10ml situation. 
However, the dose reduction of the 1ml Zevalin shield is significant. 
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5.6.5 Preparation, dispensing and administration of 90Y Zevalin:  
 
Comparative analysis of published data with this research. 
For preparation/dispensing of 90Y Zevalin: 
Cremonesi et al. [2] quotes a mean dose to the fingertips of 2.9mGy (normalised 
to 1.5GBq). Murray et al. [3] quote an initial mean finger dose of 9.4mSv for the 
first four labeling preparations they performed which reduced to 1.7mSv for the 
next six preparations 
Cremonesi et al. [2] and Rimpler et al. [5, 13] have quoted median finger doses 
ranging from 2.2mGy 5.4mSv (the lower value is normalised to 1.5GBq).   
The range of doses to the fingertips for preparation of 90Y Zevalin, reported by 
Cremonesi et al. [2] is 0.2 41.8mGy (this range is normalised to 1.5GBq). The 
range quoted by Rimpler et al. [5] is 2 13mSv. (It is worth noting that for this 
author a maximum reading of 600mSv was observed when insufficient safety 
standards were applied and radiation protection measures were partly ignored).   
Murray et al. [3] report a maximum dose of 27mSv. 
 
For administration of 90Y Zevalin:  
Law et al. [8] quote mean left hand dose value of 0.48mSv/GBq. 
A median dose of 1mSv is quoted by Rimpler et al. [5].  
The range of doses to the fingertips is quoted as 0.4 7mSv Rimpler et al. [5] 
with a maximum of 47mSv by Murray et al. [3]. 
 
The mean values of measured TLD results for this research relating to the clinical 
applications of dispensing (1.78mSv/GBq - Table 5.22) and administration 
(1.35mSv/GBq - Table 5.23) for 90Y Zevalin appear to be either comparable or 
lower than the published results of other authors [2-3, 5, 8 ,13].  The respective 
median values; 0.42mSv/GBq for dispensing and 0.62mSv/GBq for 
administration also compare favourably with the literature.  It is hoped that the 
local TLD results can be driven down further as the technique is refined with 
experience gained e.g. reducing time spent during radiopharmaceutical 
 84 
 
 
preparation and increasing experience in the use of remote handling devices 
(e.g. tongs) where possible.  
 
Continuing efforts to achieve this goal have also been made by other authors 
with the adoption of different shielding approaches for dispensing or 
administering the therapeutic radionuclide to reduce the doses being recorded 
Cremonesi et al. [2], Murray et al. [3] and Law et al. [8].  
 
 
5.6.6 Unshielded 32P syringe:  
 
Comparative analysis of published data with this research. 
 
There is a similar lack of published dose data for 32P where, even though much 
lower activities are handled, significant finger doses can still be recorded in a 
very short period of time when dealing with an unshielded syringe.  
 
One author, Henson [4] quotes skin doses of 45mGy if a syringe containing 
370MBq of 32P in 5ml solution is held for 30secs. The dose increases to 75mGy if 
the volume in the syringe is reduced to 3ml and further increases to 225mGy if 
the volume is decreased to 1ml. These values are equivalent to 14.6Gy/h/GBq, 
24Gy/h/GBq and 73Gy/h/GBq with 5, 3 and 1ml respectively in the 5ml syringe. 
Delacroix et al. [27] reports 23.9Sv/h/GBq for contact with a 5ml plastic syringe 
containing 2.5ml of solution.  Although not directly comparable with any results 
from this research, Department of Health [15] quotes a dose rate to the hands 
which might exceed 100mSv/min from a leaking vial containing 74MBq 32P 
(equivalent to 81Sv/h/GBq).   
 
No TLD measurements were made using a 5ml syringe containing 32P during the 
course of this research.  However, TLDs were used to measure doses from an 
unshielded 10ml and 1ml syringe (Table 5.19 and Table 5.20). 
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Table 5.28 Summary of the LiF-7 TLD and LiF-100 TLD results from this 
research for the unshielded 32P syringe.  
 
 
SYRINGE SIZE 
 
(ml) 
VOLUME OF 
 SOLUTION 
(ml) 
LiF-7 POWDER 
Corrected value 
Sv/h/GBq 
LiF TLD-100 
Corrected value 
Sv/h/GBq 
10 5 .5 6.9  9.6 3.3  5.0 
1 0.4 87 113 38.3  54.2 
 
 
These results comply with the expected pattern of the highest dose being 
obtained from handling a 1ml syringe. As seen for 90Y, this is due to; a) the 
smaller diameter of the 1ml syringe and b) the increased concentration in the 1ml 
syringe. 
 
It is also noted that the LiF TLD-100 values in Table 5.28 for the 1ml syringe 
containing 32P solution are lower than those for the horizontal 1ml syringe 
containing 90Y (Table 5.24), as expected from the relative beta energies.   The 
results presented in Table 5.28 also appear to indicate that the TLD-100 chips 
give a dose reading for betas of about half that of the LiF-7 powder TLD. This 
reading will be dominated by the response to betas.  These results indicate that it 
is important that TLD measurements are calibrated for the specific beta emitter 
involved if an accurate assessment of the beta dose is required. 
 
Again an important factor to note for the unshielded 32P syringe is that the TLD 
results in Table 5.28 all demonstrate the extremely high surface dose rates that 
occur. These clearly show that operators should never hold an unshielded 
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syringe directly over the active area even for brief periods (e.g. positioning the 
syringe in an ionisation chamber for activity measurement). 
 
 
5.6.7 10ml shielded 32P syringe:  
 
Comparative analysis of published data with this research. 
McLintock [36] reports dose rates at surfaces of syringes containing 32P fitted 
with Perspex beta shields.  The author calculated dose rates based on the length 
of the solution and the radius of the syringe which was shielded by 7mm of 
Perspex. TLDs were also used to confirm the accuracy of the method of 
calculation. 
The result which most closely corresponds with the work presented here is that 
for a syringe radius of 0.75cm and a length of solution of 5cm.  (A 10ml syringe 
has a radius of ~0.65 0.7cm and a length of 5cm would approximate to about 
8ml of solution).  
The calculated value derived by the author is 2.7mSv/h/GBq and the measured 
value quoted is 2.3mSv/h/GBq; compared with the Perspex result of 
1.7mSv/h/GBq in Table 5.19.  
 
In reviewing the 10ml Perspex shield results against that published by McLintock 
[36] two factors must be considered.  McLintock [36] involved the use of a thinner 
Perspex shield which will result in a higher dose rate.  Counteracting some of this 
effect though will be the volume in the syringe (5.5ml for this research compared 
with approaching 8ml for the published data), as the lower volume would be 
expected to produce a higher TLD result. 
 
The TLD results from this research without backscatter gave a small range of 
1.59 1.67mSv/h/GBq for the Perspex shield. Given the uncertainties and 
approximations involved this is comparable to the data presented by [36] who 
reported 2.3mSv/h/GBq. 
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Derived from the LiF-7 powder TLD results in Table 5.19 the Zevalin shield is 
again the most effective shield for minimizing finger dose.  The dose reduction is 
approximately 5 times that of tungsten and 7 times that of Perspex. Backscatter 
again causes an increase in the dose results for two of the shields (16.7% for 
Perspex; 52.6% for Zevalin). It should also be noted that the backscattered result 
for the TLD placed 9mm from the tungsten shield is very similar to the equivalent 
TLD result for the Zevalin shield.  This supports the theory that the TLD dose 
recorded using the Zevalin shield will be lower than the tungsten shield due in 
large part to the distance created by its wall thickness.   
 
There is no clear relationship between the results for the two types of TLD used 
for the shielded syringes (measuring bremsstrahlung).  
 
 
5.6.8 1ml shielded 32P syringe:  
 
Results of this research. 
As for the 1ml 90Y solution, the 1ml Zevalin shield is the superior shield for 
reduction in dose (Table 5.21).  The Perspex and the tungsten shields show 
similar dose reductions, but they are a factor of 7 to 10 higher than the Zevalin 
shield. It is a clearer outcome for the 1ml 32P results that the tungsten shield is 
preferable to the Perspex shield and may also be preferable from an ergonomical 
perspective to the Zevalin shield despite the dose advantage of the latter. 
 
  
5.6.9 The effect of backscatter on TLD readings for 90Y and 32P 
 
It is important to know the impact of backscatter on the dose received by the skin 
of the fingers during preparation/administration. For a shielded source this relates 
to possible backscatter of bremsstrahlung radiation creating an increased skin 
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dose to the fingers. The results of this research support the theory that an 
increased skin dose will be recorded due to backscatter of bremsstrahlung.   
 
Galloway [40], Buffa et al. [41], Chibani [42], Kwok et al. [43], Lee and Reece [44] 
and Nunes et al. [45] have produced papers relating to the effects of backscatter 
of beta particles.  This would be relevant to the situation of unshielded beta 
sources. However, although it is clear from the results presented that such 
sources should never be handled, some backscatter measurements were made 
on unshielded syringes of 90Y and 32P for comparison. 
 
Of the references listed for backscatter of beta particles only Chibani [42] is 
equivalent to the measurements performed during this research.  
 
Galloway [40] investigated the angular dependence of the beta particle 
backscatter count rate. Buffa et al. [41] investigated backscatter dose factors 
using a Monte Carlo method developed using EGSnrc transport routines. The 
interest was in interfaces between dissimilar media which could affect therapy 
outcomes. Buffa et al. [41] states the beta backscatter dose factor had a huge 
magnitude in range, depending on source energy and atomic number.  Kwok et 
al. [43] used LiF-7 TLDs. However, the experimental results cannot be related to 
this research as Kwok et al. [43] reviewed the effect of dose rate at increasing 
separations from a soft tissue to bone interface for a point source of 32P.  Lee  
and Reece [44] used MCNP 4C to calculate the backscatter factors for 32P and 
90Sr/90Y. This author stressed the close correlation between electron 
backscattering and factors such as the geometry of the source and the scattering 
material, as well as the composition of the scattering material.  The only results 
quoted  for 32P are in a graphical form and the scattering materials do not appear 
to include Perspex (effective atomic number 5.9) or tungsten (atomic number 74) 
so again no direct comparison can be made with the results of this research.     
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Nunes et al. [45] calculated beta ray dose backscatter factors for 32P with respect 
to soft tissue using an extrapolation chamber.  The dependency of backscatter 
on atomic number and on source geometry was investigated, together with the 
variation of the factor with distance. Nunes et al. [45] measured the backscatter 
factor (BSF) by: i) recording the dose (Dh) initially when a beta emitting 
radionuclide was placed between two slabs of soft tissue equivalent material, and 
ii) re-measuring the dose (Di) when one of the slabs of soft tissue equivalent 
material was replaced with a scatterer. They also found the dose enhancement is 
proportional to log(Z+1) where Z is the atomic number of the scatterer.  
 
Chibani [42] used a Monte Carlo method to produce a backscatter correction 
factor. Backscatter correction factors are quoted as functions of radial distance 
and angular direction. For electron energies <1MeV the backscatter correction 
factor with energy was quite small. Chibani [42] compared their result with that of 
other authors, especially concentrating on papers which looked at depth dose 
distribution at a skin depth of 7mg cm-2 over an area of 1cm2.  The backscatter 
correction factor quoted for 32P by other authors ranged from 1.33 to 1.48 
depending on the methods used at this skin depth and over 1cm2.  Chibani [42] 
concluded that 1.33 is an underestimate.  
 
Reviewing the results of Table 5.19 raises uncertainties regarding the values for 
the unshielded 10ml syringe containing 32P.  It would appear unlikely that the 
backscattered result would be lower than the unscattered result.  Indeed if the B 
and N values were swapped the backscatter factor would be 1.48. From Table 
5.20 ratios ranging from 1.08 to 1.21 for the 1ml unshielded syringe using the 
LiF-7 TLD and 1.41 for the TLD-100 chips were obtained. It is important to point 
out that the results from this research were not corrected to 1cm2,  nor were point 
or planar sources used. 
 
Pook and Francis [55] indicated a beta backscatter factor of 1.21 for 90Y which 
would relate to the unshielded TLD measurements. The beta backscatter factor 
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obtained during this research for the unshielded 10ml syringe was 1.19 (Table 
5.7) and varied between 1.00 and 1.06 for the unshielded 1ml syringe (Table 
5.16). 
 
 
5.6.10  Summary of TLD results and Recommendation for TLD of choice 
 
The TLD results provide the following order of preference regarding the 
effectiveness of dose reduction for each shield:  
 
10ml 90Y syringe: 1st Zevalin; 2nd tungsten; 3rd Perspex. 
1ml 90Y syringe: 1st Zevalin; 2nd Perspex; 3rd tungsten. 
10ml 32P syringe: 1st Zevalin; 2nd tungsten; 3rd Perspex. 
1ml 32P syringe: 1st Zevalin; 2nd tungsten; 3rd Perspex. 
 
Of the TLDs investigated during the course of this research, the TLD 
recommended for use with beta emitting radionuclides would be the LiF-7 
powder TLD due to its thinner detector.  The TLD-100 chips enclosed in the thick 
plastic sleeves were too thick to measure the beta dose accurately.  Another 
critical factor which emerged during the course of this research was the 
importance of calibrating the TLDs used for the beta emitting radionuclides for 
accurate dose assessment.  Further work is required to determine the optimum 
TLD for use with beta emitting radionuclides. 
 91 
 
 
CHAPTER 6        WHOLE BODY DOSE MEASUREMENTS 
 
6.1 Introduction 
Although the finger dose is considered to be one of the most important areas 
from the aspect of syringe shields, the whole body exposure should also be 
considered. This section considers the dose rates from syringes of 90Y and 32P 
with and without the same syringe shields considered in Section 4.2. 
 
Measurements were made at 30cm and 50cm with different dose rate meters. An 
additional measurement (referred to as 0cm) was also made where the dose rate 
monitor was placed touching the edge of the syringe or shield.  For the 
measurement at 0cm it should be noted that when the syringe shield was in situ 
the monitor distance relative to the syringe is dependent on the shield thickness. 
Also the geometry of each detector’s volume relative to the syringe will have a 
substantial effect on the reading. However, this reading gives an indication of 
possible dose rates to the hands when holding syringe shields.  
 
A selection of meters was used since they have different detector configurations 
and so have varying responses to beta radiation and also to lower energy x-ray / 
gamma radiation. The latter may have an impact on the observed dose rate 
response for bremsstrahlung radiation, which has a significant proportion of low 
energy emissions.  The monitors are representative of the types that 
departments may have to carry out their own monitoring regime. Therefore it was 
considered useful to identify any differences they may have for monitoring the 
bremsstrahlung and/or beta radiation doses. In addition the dose rates for the 
unshielded syringes with and without the monitors’ beta shield present were 
investigated for any difference in response. 
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6.2 Materials and Methods 
    
6.2.1 Technical specification of monitors 
    
  
 
Detector Type:  
The monitor uses a gamma compensated G-M tube as the radiation detector, of 
an energy compensated type ZP1201.  
 
Gamma radiation: 
Energy range: 50keV to 1.25MeV (as stated by manufacturer). The supplied 
graph of relative response against energy in fact shows this range to be ±20%; 
below 50keV the response rapidly falls to zero, but at 1.25MeV the response 
appears to be rising. 
 
Beta radiation:  
The beta response is less than 1% for penetrating particles from 90Sr/90Y and 
negligible for other softer emitters.  
 
Scaling: 
Semi-logarithmic 0.1 to 1000 Sv/h 
 Fig. 6.1   Mini-Rad Series 1000 radiation dose rate monitor.  
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Detector Type: 
A 450cm3 ionisation chamber vented to atmosphere. 
NB No corrections for temperature and pressure were made. 
Aluminised Polyester window of density 7mg.cm-2. 
A sliding shield in front of the window excludes beta particles and also provides 
build-up to give measurement of ambient dose equivalent  H* (10). 
 
Gamma radiation: 
Energy range: 10keV to 6MeV. 
H1 (0.07) gamma response (shield open)   10keV – 1.4MeV    (±20% values).    
H*(10) gamma response (shield closed)     22keV – 1.4MeV     (±20% values).    
However response at 6MeV is within ±15% of response at 0.662MeV. 
 
Beta radiation:  
The beta response (shield open) is 1.01 for 90Sr/90Y, with a lower energy cut-off 
of 70keV.  
The energy cut-off for beta radiation is 1MeV with the shield closed (i.e. lower 
than the maximum beta energy of 90Y or 32P). 
 
Fig. 6.2 2120G Smartion monitor.  
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This model of Smartion (with the G suffix) uses an ion chamber with a response 
that is optimized for measurement of air kerma (Gy). The manual states that this 
model of Smartion will display the same numerical values as those of a model of 
Smartion (with an S suffix) which does read directly in Sv. For consistency are 
therefore expressed in Sv.  
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Detector Type: 
This monitor has a cylindrical 2” x 2” scintillation phosphor with a photomultiplier. 
The scintillator is housed at the front of the case and has a beta end window of 
0.005” aluminium. The unit is fitted with a removable 1cm polythene beta 
absorber cap.   
 
Gamma radiation: 
Energy range: 30keV to 7MeV. 
Gamma response   45keV – 2.5MeV    (±20% values).    
 
Beta radiation:  
Beta indication only – no calibration figure. 
 
Scaling:  
Logarthmic survey meter: 50 R/h to 50mR/h. 
 
(NB. Results for this monitor have been converted to Sv units for presentation 
purposes within this thesis).
Fig. 6.3   NIS 295B portable logarithmic scintillation dose rate meter monitor. 
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Detector Type: 
This monitor has a disk-shaped organic scintillator detector, diameter 44mm, 
height 15mm with a photomultiplier and mu-metal anti magnetic screen.   
 
Gamma radiation: 
Energy range: 28keV to 7MeV (within angular range of 600). 
 
This H*(10) model monitor is designed for photon (gamma and X-radiation) 
measurements.   
 
Scaling:  
3 different dose rate ranges:  
1) 0.01 to 15 Sv/h; 2) 0.01 to 15mSv/h; 3) 0.01 to 15Sv/h 
 
Measuring accuracy: 20% for dose rates 10 Sv/h 
    30% for dose rates <10 Sv/h 
 Fig. 6.4  Scintomat 6134A/H dose rate meter monitor. 
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6.2.2 Method of data acquisition 
 
The syringe was placed horizontally on the edge of a supporting block of Perspex 
or temex sheets (see Fig. 6.5 and Fig. 6.6). The geometric centre of syringe 
activity was placed in line with the central field axis of each of the dose rate 
meters. For the 10ml and 1ml syringes containing 90Y and 32P, readings were 
taken at distances of 30cm and 50cm from the syringe wall. Since the specific 
activity available for the 1ml syringe measurements was limited, the dose rates at 
30cm and 50cm were very low for certain shields and difficult to estimate 
accurately due to meter fluctuations.  (The NIS monitor was not available for the 
series of measurements involving the 1ml 90Y syringe due to a fault). Dose rate 
data is also presented for a 5ml syringe containing 32P to compare with published 
data (no measurements were made for a 5ml syringe containing 90Y). An 
additional measurement for each monitor touching the shield was recorded as at 
0cm.  
 
The syringe, together with the blind hub, was always withdrawn into the shield so 
that the true effect of the shield could be established. This was to exclude any 
possibility of a small remnant of activity within the blind-hub giving a dose rate 
value which would mask the effect of the syringe shield. Although this would 
occur in practice with day-to-day use, it was thought important that the true effect 
of the syringe shield for dose rate reduction was estimated.  
 
In addition to measurements made when the syringe was shielded in turn by 
each of the three types of 10ml or 1ml shields, a further measurement was 
undertaken using an unshielded syringe.    
  
For the two monitors with removable covers for the detection of beta radiation, 
readings were recorded with the cover (denoted by WC) and without the cover 
(denoted by WOC) to assess the effect of its removal.  
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A background value was also taken for each dose rate meter and used to correct 
the readings obtained. In practice this background reading was difficult to 
estimate accurately, particularly for the Smartion since the dose rate meter 
reading fluctuated considerably. Readings were also decay corrected and 
expressed as Sv/h/GBq. 
 
 
  
 
In order to better compare the responses, the ratios of the measured dose rates 
were also calculated. These are presented separately as ratios of the dose rate 
Fig. 6.5 
Shielded syringe placed on temex to 
centralise the activity in the centre 
of axis of Smartion.   
Fig. 6.6 
Measurement taken from the 
edge of the syringe to 
assess true effect of shield.   
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monitors and as ratios of the syringe shields.  The ratios of the dose rate 
monitors give an indication of the variation in response between the monitors.  
 
Error analysis 
 
Two primary sources of uncertainty contribute to the precision of the dose rate 
monitor ratio. The first factor is the accuracy of the dose rate monitors over the 
entire energy range and the second factor is the variation in recorded repeat 
measurements. 
 
 1. Accuracy of the dose rate monitors: 
The accuracy over the entire energy range for all dose rate monitors investigated 
is quoted as 20%, with the exception of the Scintomat.  The accuracy for the 
Scintomat is quoted as 20% for dose rates 10 Sv/h but for dose rates 
<10 Sv/h is quoted as 30%. 
 
2. The error associated with repeated dose rate measurements:  
A 90Y source was placed at two fixed distances to give dose rates of 7.5 Sv/h 
and 22 Sv/h respectively. Twenty repeat readings were made at each dose rate.  
The mean and standard deviation were calculated. This percentage error ( 2SD 
as a percentage of the mean) was calculated to be = 5.6%.  
 
Derivation of uncertainty (error)  
 
In general terms if X, Y, Z are quantities with independent standard deviations x, 
y, z 
 
Then, any function F (X,Y, Z) has a standard deviation of  
( F) = 2
2
2
2
2
2
z
Z
F
y
Y
F
x
X
F
    (6.1) 
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Applying this general principle to this research: 
If the dose ratio monitor ratio is calculated  x = 
b
a  
 
Where: 
x= ratio result between two monitors 
a and b = the dose rate monitors readings for the two monitors normalized to 
1GBq. 
Each dose rate reading will have a standard deviation a and b respectively 
 
 
a
x
= 
b
1
                    and 
b
x
= -
2b
a
                (6.2) 
 
 x = 
b
a
2
2
2
2
b
b
a
a
       (6.4) 
 
 
x
x
= 
22
b
b
a
a
                 (6.5) 
 
Uncertainty in the ratio for all dose rates 10 Sv/h  
 
The accuracy of the dose rate monitor ( 20%) and the variation in recorded 
repeat measurements ( 5.6%) for each monitor needs to be taken into account 
i.e. the standard deviations are 0.1 and 0.028 respectively. 
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x
x
= 
2222
*028.0*1.0*028.0*1.0
b
b
b
b
a
a
a
a
 = 0.147    (6.6) 
 
 The error ( 2SD) in all ratio results for dose rates 10 Sv/h will be 29%. 
 
Assuming the dose rate monitors should give the same response, within the 
errors outlined above; the ratio of their readings for the same source should be 
within 29%. Therefore all ratio values outside 0.71-1.29 are highlighted in yellow 
in these tables.   
  
In addition, the ratios of the dose rates for the different syringe shields are also 
calculated. These should give an indication of their relative merits of shielding 
and helps choose the optimum shield.  
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Results are presented as follows – 
 
10ml 90Y syringe 
Dose rate values are shown in Tables 6.1, 6.4 and 6.7.    
Ratio values for the dose rate monitors are shown in Tables 6.2 and 6.5. 
Ratio values for the syringe shields are shown in Tables 6.3 and 6.6. 
1ml 90Y syringe 
Dose rate values are shown in Tables 6.8, 6.11 and 6.14.    
Ratio values for the dose rate monitors are shown in Tables 6.9 and 6.12. 
Ratio values for the syringe shields are shown in Tables 6.10 and 6.13. 
10ml 32P syringe 
Dose rate values are shown in Tables 6.15, 6.18 and 6.21.    
Ratio values for the dose rate monitors are shown in Tables 6.16 and 6.19. 
Ratio values for the syringe shields are shown in Tables 6.17 and 6.20. 
1ml 32P syringe 
Dose rate values are shown in Tables 6.22, 6.25 and 6.28.    
Ratio values for the dose rate monitors are shown in Tables 6.23 and 6.26. 
Ratio values for the syringe shields are shown in Tables 6.24 and 6.27. 
5ml 32P syringe 
Dose rate values are shown in Tables 6.29, 6.32 and 6.33.    
Ratio values for the dose rate monitors are shown in Tables 6.30. 
Ratio values for the syringe shields are shown in Tables 6.31. 
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6.3  Results for 90Y 
 
6.3.1  Dose rate data for 90Y in a 10ml syringe, unshielded and with syringe 
shields 
 
1140MBq 90Y Zevalin in 7mls of solution was withdrawn into a 10ml syringe.  
 
Table 6.1 Dose rate measurements for three monitors at a distance of 
30cm from an unshielded and shielded syringe (90Y in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
12 WC                   72 
WOC          17100 
WC                   12 
WOC              440 
Perspex 
12 WC                   11 
WOC                25 
WC                   11 
WOC                13 
Tungsten 
4.0 WC                  3.7 
WOC                22 
   WC                  3.5 
WOC               3.6 
Zevalin 
4.0 WC                  3.2 
WOC                25 
WC                  2.7 
WOC               3.3 
 
 
Table 6.1 clearly shows extremely high dose rates from an unshielded syringe at 
30cm due to the betas. It also highlights the large variation in beta dose rate 
response (WOC) between the Smartion and the NIS monitors. 
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However, the bremsstrahlung dose rates are consistent across the three 
monitors for the shielded syringe measurements with the beta shield in place 
(WC). The higher dose rates without the beta shield (WOC) for the Smartion are 
thought to be due to the detection of the very low energy bremsstrahlung. 
 
 
Table 6.2 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.1. 
 
 
Ratio  Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 6.0 
 
1.0 
 
6.0 
 
Perspex 0.92 
 
0.92 
 
1.0 
 
Tungsten 0.92 
 
 
0.88 
 
1.1 
 
Zevalin 0.8 
 
0.68 
 
1.2 
 
 
 
All ratios <0.71 and >1.29 are highlighted. The increased values for the 
Smartion when there is no shield on the syringe are considered due to the beta 
shield being not totally effective.  Otherwise all monitor values are essentially 
consistent to ±29%. 
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Table 6.3 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.1.   
 
 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 3.0 3.0 
 
3.1 
 
Perspex : Zevalin 3.0 3.4 
 
4.1 
 
Tungsten : Zevalin 1.0 1.2 
 
1.3 
 
 
 
Table 6.3 shows the Zevalin shield provides marginally better dose reduction 
than the tungsten shield.  Both shields show an approximate factor x3 reduction 
in dose rate compared with the Perspex shield. The pattern is consistent for all 
three monitors. 
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Table 6.4 Dose rate measurements for three monitors at a distance of 
50cm from an unshielded and shielded syringe (90Y in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
4.0 WC                    26 
WOC             5500 
WC                   5.1 
WOC               160 
Perspex 
3.3 WC                   4.4 
WOC                 10 
WC                   4.7 
WOC                5.4 
Tungsten 
1.8 WC                   1.4 
WOC                 10 
WC                   1.5 
WOC                1.6 
Zevalin 
1.8 WC                   1.1 
WOC                 12 
WC                   1.3 
WOC                1.5 
 
The extremely high dose rates from an unshielded syringe are still apparent at 
50cm with noticeably different responses to the betas for the Smartion and NIS 
monitors. 
 107 
 
 
Table 6.5 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.4. 
 
 
Ratio Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 6.5 
 
1.3 
 
5.1 
 
Perspex 1.3 
 
1.4 
 
0.94 
 
Tungsten 0.78 
 
0.83 
 
0.93 
 
Zevalin 0.61 
 
0.72 
 
0.85 
 
 
 
All ratios <0.71 and >1.29 are highlighted  
 
The fluctuation in the dose rate readings with some of the monitors at distance 
becomes more significant.  This is reflected in the number of ratios in this table 
which now fall outside the range of <0.71 and >1.29 compared with Table 6.2. 
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Table 6.6 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.4.   
 
 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 1.8 3.1 
 
3.1 
Perspex : Zevalin 1.8 4.0 
 
3.6 
 
Tungsten : Zevalin 1.0 1.3 
 
1.2 
 
 
 
 
Table 6.6 is similar to that for 30cm and shows the Zevalin shield provides 
marginally better dose reduction than the tungsten shield.  Both shields show a 
factor of x2 →x4 reduction in dose rate compared with the Perspex shield. 
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Table 6.7 Dose rate measurements for three monitors at a distance of 
0cm from an unshielded and shielded syringe (90Y in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
Off-scale WC                2700 
  WOC       off scale 
WC                   350                 
WOC       off-scale 
Perspex 
360 WC                  190 
WOC             1100 
WC                   230 
WOC                390 
Tungsten 
270 WC                    83 
WOC               150 
WC                  110 
WOC                170 
Zevalin 
150 WC                    68 
WOC               150 
WC                    77 
WOC                120 
 
 
Table 6.7 has been included to give an indication only of the extremely high dose 
rates that hands will be exposed to when in close proximity with either unshielded 
or shielded syringes. In particular the beta doses from unshielded syringes are 
off-scale. The response of the monitors will be affected by the geometry of each 
detector’s volume relative to the syringe and the impact of this will have a 
substantial effect on the readings.  
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6.3.2 Dose rate data for 90Y in a 1ml syringe, unshielded and with syringe 
shields 
 
A maximum of 120MBq 90Y in 0.2ml or 0.4ml of solution was withdrawn into a 
1ml syringe. (Measurements were performed on two occasions).  
 
Table 6.8 Dose rate measurements for two monitors at a distance of 
30cm from an unshielded and shielded syringe (90Y in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover in situ  
WOC  -   refers to measurements without the beta cover; 
Monitor 
 
Series 1000 Smartion 
Sv/h/GBq 
No shield 
33 WC                   250 
WOC            47000 
Perspex 
7.5 WC                     11                
WOC                  37  
Tungsten 
9.7 WC                    8.0  
WOC                  29  
Zevalin 
7.0 WC                   2.8 
WOC                 7.0 
 
Table 6.8 clearly shows even higher dose rates for an unshielded 1ml syringe 
containing 90Y at 30cm than for the unshielded 10ml syringe (Table 6.1). This is 
due to the betas and is as expected with the smaller diameter of the syringe 
providing less self attenuation. 
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However, the bremsstrahlung dose rates for the shielded syringe measurements 
are essentially consistent for the two monitors investigated with the exception of 
the Zevalin shield. 
 
 
Table 6.9 Dose rate ratios for the two dose rate monitors; for 
measurements made at 30cm with the Smartion beta shield in place (WC) 
shown in Table 6.8. 
 
 
Ratio Smartion / Series 1000 
No shield 7.6 
 
Perspex 1.5 
 
Tungsten 0.82 
 
Zevalin 0.40 
 
 
All ratios <0.71 and >1.29 are highlighted  
 
The different response of the Smartion and Series 1000 monitor highlighted in 
Table 6.9 may reflect dose rate fluctuations.  The high ratio for the unshielded 
syringe is probably due to beta penetration of the Smartion beta shield. 
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Table 6.10 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 30cm with the Smartion beta shield in place (WC) 
shown in Table 6.8.   
 
 
Monitor Series 1000 Smartion 
Ratio 
 
  
Perspex : Tungsten 0.77 1.4 
 
Perspex : Zevalin 1.1 3.9 
 
Tungsten : Zevalin 1.4 2.9 
 
 
 
 
Table 6.10 shows the Zevalin shield provides the best dose reduction.  The 
results are inconclusive for the more superior shield in terms of dose reduction 
between the tungsten and Perspex shield. 
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Table 6.11 Dose rate measurements for two monitors at a distance of 
50cm from an unshielded and shielded syringe (90Y in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover in situ  
WOC  -   refers to measurements without the beta cover; 
Monitor 
 
Series 1000 Smartion 
Sv/h/GBq 
No shield 
20  WC                    84 
WOC            19000 
Perspex 
0 WC                   3.8                                 
WOC                  12 
Tungsten 
5.5  WC                   2.1 
WOC                    8  
 
 
 
Zevalin 
0 WC                      0 
WOC                 1.4 
 
 
The extremely high dose rates from an unshielded syringe are still apparent at 
50cm with the results as presented in the Table 6.11 above.  
The shielded syringe bremsstrahlung dose rates are reassuringly low. However, 
the low activity available led to large dose rate fluctuations with some zero values 
recorded (i.e. same as background). 
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Table 6.12 Dose rate ratios for the two dose rate monitors; for 
measurements made at 50cm with the Smartion beta shield in place (WC) 
shown in Table 6.11. 
 
N/A     - not applicable (i.e. dose rate reading of zero); 
Ratio Smartion / Series 1000 
No shield 4.2 
Perspex N/A 
Tungsten 0.38 
 
Zevalin N/A 
 
 
 
All ratios are <0.71 and >1.29 or undetermined. This reflects the low dose rate 
fluctuations. 
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Table 6.13 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 50cm with the Smartion beta shield in place (WC) 
shown in Table 6.11.   
 
 N/A     - not applicable (i.e. dose rate reading of zero); 
Monitor Series 1000 Smartion 
Ratio 
 
  
Perspex : Tungsten N/A 1.8 
 
Perspex : Zevalin N/A N/A 
 
Tungsten : Zevalin N/A N/A 
 
 
 
It is impossible to draw any conclusions from Table 6.13 due to the low dose rate 
measurements recorded. 
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Table 6.14  Dose rate measurements for two monitors at a distance of 0cm 
from an unshielded and shielded syringe (90Y in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover in situ  
WOC  -   refers to measurements without the beta cover; 
Monitor 
 
Series 1000 Smartion 
Sv/h/GBq 
No shield 
1200 WC                2700 
WOC       1200000 
Perspex 
410 WC                  210                                
  WOC             1500   
12.2 
Tungsten 
590 WC                  210 
WOC               460 
 
 
 
Zevalin 
170 WC                    68                     
WOC                 82                 
 
 
As for the 10ml syringe containing 90Y, Table 6.14 has been included to give an 
indication only of the extremely high dose rates that hands will be exposed to 
when in close proximity with either unshielded or shielded syringes. The 
response of the monitors will be affected by the geometry of each detector’s 
volume relative to the syringe and the impact of this will have a substantial effect 
on the readings.  
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6.4 Results for 32P 
 
6.4.1  Dose rate data for 32P in a 10ml syringe, unshielded and with syringe 
shields 
 
83MBq 32P in 5.5ml solution was withdrawn into a 10ml syringe.  
 
Table 6.15 Dose rate measurements for three monitors at a distance of 
30cm from an unshielded and shielded syringe (32P in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
15   WC                   8.4 
 WOC             7900 
 WC                    9.4 
 WOC                120 
Perspex 
7.2   WC                   8.4 
WOC                 12 
  WC                    8.4 
WOC                 9.4 
Tungsten 
4.8  WC                   1.2 
  WOC                 16 
  WC                    2.6 
  WOC                 2.6 
 Zevalin 
4.5   WC                   4.8 
  WOC                7.2 
WC                    2.6 
  WOC                 2.6 
 
 
Table 6.15 clearly shows extremely high dose rates from an unshielded syringe 
at 30cm due to the betas. As for the 10ml syringe containing 90Y, a 10ml syringe 
containing 32P also demonstrates a large variation in beta dose rate response 
(WOC) between the Smartion and the NIS monitors. 
 118 
 
 
However, the bremsstrahlung dose rates are largely consistent across the three 
monitors for the shielded syringe measurements with the beta shield in place 
(WC). The higher dose rates without the beta shield (WOC) for the Smartion are 
thought to be due to the detection of very low energy bremsstrahlung. 
 
 
Table 6.16 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.15. 
 
 
Ratio Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 0.56 
 
0.63 
 
0.89 
 
Perspex 1.2 
 
1.2 
 
1.0 
 
Tungsten 0.25 
 
0.54 
 
0.46 
 
Zevalin 1.1 
 
0.58 
 
1.85 
 
 
 
 
All ratios <0.71 and >1.29 are highlighted. The spread in ratio values is likely 
due to the lower activity available leading to lower dose rate readings giving 
greater errors. 
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Table 6.17 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.15.   
 
 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 1.5 7.0 
 
3.2 
 
Perspex : Zevalin 1.6 1.8 
 
3.2 
 
Tungsten : Zevalin 1.1 0.25 
 
1.0 
 
 
 
Table 6.17 shows the tungsten and Zevalin shield provide equivalent dose 
reduction.  The Perspex shield results in the least reduction of dose rate. 
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Table 6.18 Dose rate measurements for three monitors at a distance of 
50cm from an unshielded and shielded syringe (32P in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
7.2   WC                   3.6 
WOC             2000 
   WC                  5.2 
WOC                37 
Perspex 
3.6    WC                  3.6 
   WOC               3.6 
 
  WC                 4.2  
WOC               5.2 
Tungsten 
3.0    WC                     0 
   WOC               6.0 
   WC                 2.1 
   WOC              2.1 
 Zevalin 
3.6    WC                  2.4 
  WOC               3.6 
WC                 1.0 
   WOC              2.1 
 
 
The extremely high dose rates from an unshielded syringe are still apparent at 
50cm but with noticeably different responses to the betas for the Smartion and 
NIS monitors. 
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Table 6.19 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.18. 
 
N/A – not applicable (i.e. dose rate reading of zero); 
Ratio Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 0.5 
 
0.72 
 
0.69 
 
Perspex 1.0 
 
1.2 
 
0.86 
 
Tungsten N/A 
 
0.70 
 
N/A 
 
Zevalin 0.67 
 
0.28 
 
2.4 
 
 
 
 
All ratios <0.72 and >1.28 are highlighted. Again the ratio spread is due to dose 
rate fluctuations.  
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Table 6.20 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.18.   
 
N/A     - not applicable (i.e. dose rate reading of zero); 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 1.2 N/A 
 
2.0 
 
Perspex : Zevalin 1.0 1.5 4.2 
 
Tungsten : Zevalin 0.83 N/A 
 
2.1 
 
 
The relative merits of each shield in terms of dose reduction are less conclusive 
from the results of Table 6.20.  Overall the Perspex shield would appear to be the 
least effective.  
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Table 6.21 Dose rate measurements for three monitors at a distance of 
0cm from an unshielded and shielded syringe (32P in 10ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
360   WC                  210           
  WOC         270000 
WC                  260 
WOC           10000 
Perspex 
180   WC                  100 
 WOC               280 
WC                  170 
WOC               300 
Tungsten 
84   WC                   28 
WOC               280 
 WC                   37 
WOC                 57 
Zevalin 
60   WC                   28 
WOC                59 
  WC                   31 
WOC                 47 
 
 
As for the 10ml syringe containing 90Y, Table 6.21 has been included to give an 
indication only of the extremely high dose rates that hands will be exposed to 
when in close proximity with either unshielded or shielded syringes. The 
response of the monitors will be affected by the geometry of each detector’s 
volume relative to the syringe and the impact of this will have a substantial effect 
on the readings.  
The results for 32P are lower than for 90Y (Table 6.7) as expected from the lower 
beta energy. 
 124 
 
 
 6.4.2  Dose rate data for 32P in a 1ml syringe, unshielded and with syringe 
shields 
 
93MBq 32P in 0.3ml of solution was withdrawn into a 1ml syringe. 
 
Table 6.22 Dose rate measurements for three monitors at a distance of 
30cm from an unshielded and shielded syringe (32P in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
33   WC                    15 
  WOC           34000 
WC                   11                  
WOC              500        
Perspex 
11   WC                   7.5 
 WOC                 11 
 WC                 8.5 
WOC                11 
Tungsten 
3.2   WC                   2.1 
WOC                6.4 
  WC                 3.8 
WOC               3.8 
Zevalin 
3.2   WC                   1.1 
WOC                1.6 
  WC                 2.4 
WOC               3.8 
 
 
Table 6.22 clearly shows even higher dose rates for an unshielded 1ml syringe 
containing 32P at 30cm than the 10ml syringe containing 32P (Table 6.15). This is 
due to the betas and is as expected with the smaller diameter of the syringe 
providing less self attenuation. 
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However, the bremsstrahlung dose rates for the shielded syringe measurements 
are essentially consistent for the range of monitors investigated. 
 
 
Table 6.23 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.22. 
 
 
Ratio Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 0.45 
 
0.33 
 
1.4 
 
Perspex 0.68 
 
0.77 
 
0.88 
 
Tungsten 0.66 
 
1.2 
 
0.55 
 
Zevalin 0.34 
 
0.75 
 
0.46 
 
 
 
All ratios <0.71 and >1.29 are highlighted.  Low available activity again 
contributed to the dose rate fluctuations creating the spread in ratio values. 
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Table 6.24 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.22.   
 
 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 3.4 3.6 
 
2.2 
 
Perspex : Zevalin 3.4 6.8 
 
3.5 
 
Tungsten : Zevalin 1.0 1.9 
 
1.6 
 
 
The results of Table 6.24 show that the Zevalin shield is the optimum shield to 
use in terms of dose reduction.  However, both the tungsten and the Zevalin 
shield offer a factor of approximately x3 dose reduction over the Perspex shield. 
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Table 6.25 Dose rate measurements for three monitors at a distance of 
50cm from an unshielded and shielded syringe (32P in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
15   WC                   6.6   
  WOC            11000 
 WC                  4.8                 
WOC              150        
Perspex 
1.6   WC                   5.4 
 WOC                 6.4 
 WC                  4.2 
WOC                5.2 
Tungsten 
1.6   WC                   0.0 
WOC               0.54 
  WC                  1.9 
WOC                1.9 
Zevalin 
1.6   WC                   0.0 
WOC               0.54 
  WC                  1.9 
WOC                2.4 
 
The extremely high dose rates from an unshielded syringe are still apparent at 
50cm with noticeably different responses to the betas for the Smartion and NIS 
monitors. 
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Table 6.26 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.25. 
 
N/A     - not applicable (i.e. dose rate reading of zero); 
Ratio Smartion / Series 1000 NIS / Series1000 Smartion / NIS 
No shield 0.44 
 
0.32 
 
1.4 
 
Perspex 3.3 
 
2.6 
 
1.3 
 
Tungsten N/A 
 
1.2 
 
N/A 
 
Zevalin N/A 
 
1.2 
 
 
N/A 
 
 
 
All ratios <0.71 and >1.29 are highlighted  
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Table 6.27 Dose rate ratios for all combinations of syringe shields; for 
measurements made at 50cm with the beta shield in place (WC) shown in 
Table 6.25.   
 
N/A     - not applicable (i.e. dose rate reading of zero); 
Monitor Series 1000 Smartion NIS 
Ratio 
 
   
Perspex : Tungsten 1.0 N/A 
 
2.2 
 
 Perspex : Zevalin 1.0 N/A 
 
2.2 
Tungsten : Zevalin 1.0 N/A 
 
1.0 
 
 
 
Table 6.27 appears to show the shielding properties of tungsten and Zevalin to 
be equivalent and Perspex to be the least effective shielding material. However, 
dose rate fluctuations make interpretation difficult. 
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Table 6.28 Dose rate measurements for three monitors at a distance of 
0cm from an unshielded and shielded syringe (32P in 1ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion NIS 
Sv/h/GBq 
No shield 
550   WC                 240   
  WOC      off scale          
.9 
WC                  290                 
WOC           43000        
Perspex 
210   WC                 130 
 WOC              220 
 WC                  180 
WOC               360 
Tungsten 
240   WC                   68 
WOC              120 
  WC                    90 
WOC               150 
Zevalin 
69   WC                   29 
WOC                44 
  WC                   36 
WOC                 57 
 
As for the 10ml syringe containing 32P, Table 6.28 has been included to give an 
indication only of the extremely high dose rates that hands will be exposed to 
when in close proximity with either unshielded or shielded syringes.  
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6.4.3  Dose rate data for 32P in a 5ml syringe, unshielded and with syringe 
shields 
 
An additional set of measurements was made for a 5ml syringe containing 
161MBq 32P in 2ml of solution (Table 6.29). These were performed because a 
5ml Perspex shield and a 5ml lead shield became available. The Perspex shield 
had a thinner wall thickness being 5.4mm at the thickest wall edge and 2.0mm on 
the tapered edge.  The 5ml lead shield wall thickness was 2.1mm.  The 10ml 
Zevalin shield was used to shield the 5ml syringe. In addition a Scintomat dose 
rate monitor was also available for use (the NIS monitor was out of service). 
 
In order to better compare the responses, the ratios of the above dose rates were 
also calculated for the various combinations of dose rate monitors (Table 6.30) 
and also for the various combinations of shields (Table 6.31).  The latter results 
are presented for 30cm measurements only. Table 6.32 shows the dose rate 
data for 50cm. Time constraints meant that not all readings could be obtained for 
all dose rate monitors. Also fluctuations in this data were large; therefore ratio 
tables have not been calculated. 
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Table 6.29 Dose rate measurements for three monitors at a distance of 
30cm from an unshielded and shielded syringe (32P in 5ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion Scintomat 
Sv/h/GBq 
No shield 
8.7   WC                   12 
  WOC          14000 
 WC                   10                
WOC              870         
Perspex 
7.5   WC                  7.8 
 WOC                16 
 WC                  8.1 
WOC                10 
Lead 
3.7   WC                  5.3 
 WOC                31   
  WC                  2.2 
WOC               2.8 
Zevalin 
2.5  WC                0.31 
WOC                12 
  WC                  2.2 
WOC               2.2 
 
 
Table 6.29 clearly shows extremely high dose rates for an unshielded 5ml 
syringe containing 32P at 30cm.  The results for the Smartion are consistent with 
the values expected i.e. higher dose rate/GBq than the 10ml syringe but less 
than the 1ml syringe.  The Scintomat (which is not a recognized monitor for the 
detection of betas) has a higher value for WOC than would have been expected 
if the NIS was used. 
However, the bremsstrahlung dose rates for the shielded syringe measurements 
are essentially consistent for the range of monitors investigated. 
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Table 6.30 Dose rate ratios for all combinations of dose rate monitors; for 
measurements made at 30cm with the beta shield in place (WC) shown in 
Table 6.29. 
 
 
Ratio Smartion / Series 1000 Scintomat / Series 1000 Smartion / Scintomat 
No shield 1.4 
 
1.1 
 
1.2 
 
Perspex 1.0 
 
1.0 
 
0.96 
 
Lead 1.4 
 
0.59 
 
2.4 
 
Zevalin 0.12 
 
0.88 
 
 
0.14 
 
 
 
 
All ratios <0.71 and >1.29 are highlighted.  The lower dose rates observed with 
the lead and Zevalin shields leads to the fluctuations in the ratios as shown. 
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Table 6.31 Ratios of the dose rate measurements at 30cm shown in Table 
6.29 for all combinations of shields with the beta shield in place (WC). 
 
 
Monitor Series 1000 Smartion Scintomat 
Ratio 
 
   
Perspex : Lead 2.0 1.5 
 
3.7 
 
Perspex : Zevalin 3.0 25 
 
3.6 
 
Lead : Zevalin 1.5 17 
 
1.0 
 
 
These results confirm that the Zevalin shield is the preferred choice in terms of 
dose reduction. However, this was a 10ml Zevalin shield used for comparative 
purposes only, and this would not be practical to use for routine work. The 
Perspex shield is the least effective. High ratio values for Perspex and lead to 
Zevalin are observed with the Smartion.  These are due to a very low dose rate 
for the Zevalin shield observed with the Smartion.  It is thought this is anomalous 
and due to low dose rate fluctuation. 
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Table 6.32 Dose rate measurements for three monitors at a distance of 
50cm from an unshielded and shielded syringe (32P in 5ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion Scintomat 
Sv/h/GBq 
No shield 
 
4.1 
  WC                    7.8 
  WOC              4600 
 WC                   4.1                 
WOC               250        
Perspex 
Not measured 
 
  WC                  0.93 
 WOC                 7.8 
 WC                   3.1 
WOC                3.7 
Lead 
Not measured 
 
  WC                  0.93 
 WOC                 7.2   
116.9 
  WC                 0.93 
WOC              0.93 
Zevalin 
Not measured 
 
 WC  Not measured 
WOC Not measured 
  WC                 0.93 
WOC              0.93 
 
The extremely high dose rates from an unshielded syringe are still apparent at 
50cm with noticeably different responses to the betas for the Smartion and 
Scintomat monitors. 
 
 
 
 136 
 
 
Table 6.33 Dose rate measurements for three monitors at a distance of 
0cm from an unshielded and shielded syringe (32P in 5ml syringe).   
 
WC     -   refers to measurements with the beta cover/cap in situ  
WOC  -   refers to measurements without the beta cover/cap; 
Monitor 
 
Series 1000 Smartion Scintomat 
Sv/h/GBq 
No shield 
 
340 
  WC                  250 
 
 WC                  930                 
WOC           81000 
       Perspex 
 
310 
  WC                  250 
 WOC               340 
 WC                  530 
WOC               930 
Lead 
 
130 
  WC                    60 
 WOC               380   
116.9 
  WC                 190 
WOC               230 
Zevalin 
 
62 
 WC                   36 
 WOC                 50 
  WC                   93 
WOC              140 
 
 
As for the 10ml syringe and 1ml syringe containing 32P, Table 6.33 has been 
included to give an indication only of the extremely high dose rates that hands 
will be exposed to when in close proximity with either unshielded or shielded 
syringes.  
 
 Dose rate measurements were also made from a P5 glass vial containing 
193.5MBq of 32P in 2ml of solution (Table 6.34).  The experimental set-up to 
obtain these values was exactly the same as that detailed for the syringe 
measurements. (The overall dimensions of a P5 vial are similar to a 10ml P6 vial 
or a 10ml Schott vial). 
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Table 6.34 Dose rate measurements at 0cm and 30cm from a P5 vial 
containing 2ml of 32P. 
 
WC     -  refers to measurements with the beta cover/cap in situ  
WOC  -  refers to measurements without the beta cover/cap; 
Distance from  
the vial 
(cm) 
Series 1000 Smartion NIS 
Sv/h/GBq 
0 
340   WC                220 
WOC    Off scale   
 WC                 190                 
WOC            2700 
175.5        
30 
5.9   WC                 9.8 
 WOC           2900 
 WC                 6.5 
WOC               37 
 
The WOC results at 30cm (for the monitors with the beta cover/cap removed) are 
lower than for the syringe measurements but are still high.  This is due to the 
walls of the glass vial attenuating the betas to a greater extent than the plastic 
syringe. 
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6.5 Discussion   
The effect of different shielding on whole body dose measurements 
obtained during the course of this research reviewed in relation to results 
available in the literature. 
 
Many authors, Rimpler et al. [5, 13], Delacroix et al. [27], The Society for 
Radiological Protection [33] and the Nuclear Community website [34] refer to 
dose rates at various distances from point sources of beta emitting radionuclides. 
In addition, Delacroix et al. [27] quotes dose rates from infinite plane sources. 
Although not directly comparable, the results of this research for dose rates at 
distances of 30cm and greater will be most closely equivalent to the point source 
values quoted. 
 
6.5.1 Unshielded 90Y source:  
 
Summary of published data. 
For a 1GBq point source of 90Y, beta dose rates at a distance of 30cm from the 
source range from 98mSv/h/GBq [34] through 108mSv/h/GBq [27] to 
120mSv/h/GBq [5,13]. The beta dose rate quoted by [34] decreases to 
8.5mSv/h/GBq at 100cm from the point source of 90Y. [The Society for 
Radiological Protection [33] value of 100Sv/h/GBq has been ignored as the value 
quoted has been assumed to be a typographical error in units]. 
 
Some publications simply refer to an activity of the beta emitting radionuclide but 
do not state the container type or volume involved for the dose rate results cited.   
These results range from a dose rate of 838mSv/h/GBq at 10cm from unshielded 
90Y to 81Sv/h/GBq for the same source at 1cm [11]. An exposure rate constant of 
103Sv/h/GBq at the mouth of an open vial of 90Y is quoted by MDS Nordion [23] 
and Delacroix et al. [27] reports 0.071mSv/h/GBq at 100cm from a 10ml glass 
vial. 
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Unshielded 10ml and 1ml 90Y syringe:  
 
Results of this research. 
It must be noted that the 90Y sources used in this research were not point 
sources.  As the aim of this work was to establish the most effective shield for a 
source type that would be encountered in routine clinical practice a volume of 
7ml was used in the 10ml syringe. The 1ml syringe contained 0.2ml or 0.4ml of 
solution (measurements were made on two occasions). Table 6.35 summarises 
the beta dose rate results (corrected for activity) for the unshielded 10ml and 1ml 
syringe when the cover was removed from the Smartion and NIS monitors 
(WOC). 
 
Table 6.35 Dose rate measurements at 30cm and 50cm from an 
unshielded 10ml and 1ml syringe containing 90Y. 
 
N/A - Not available; 
 MONITOR (all readings WOC) 
 Smartion NIS Smartion NIS 
SYRINGE 
SIZE 
Dose rate at 30cm from 
syringe 
Dose rate at 50cm from 
syringe 
 mSv/h/GBq 
10ml 17 0.44 5.5 0.16 
1ml 47 N/A 19 N/A 
 
 
It is to be expected that the results obtained for the source used in this research 
are lower than those quoted in the literature for the point source, due to the 
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increased volumes in both syringe sizes. This will result in self attenuation of the 
beta emissions. The smaller volume in the 1ml syringe gives a higher dose rate 
as a result of less self attenuation of the beta radiation.   
 
The vastly different dose rates from the betas compared to the bremsstrahlung 
radiation is highlighted with the large difference in results obtained with the 
Smartion and the NIS dose rate meters both with and without their covers in 
place for the unshielded syringe.  
 
The Smartion dose rates for unshielded syringes are higher than those for the 
NIS when their beta covers were in place.  This was probably due to remnant 
high energy betas getting through the Smartion cover, since this is quoted as 
only effective for up to 1MeV betas and demonstrates the care needed in 
interpreting dose rates from beta emitters. 
 
Nevertheless the dose rates from unshielded syringes at 30cm and 50cm are 
extremely high and are dominated by the beta dose.  Depending on the type of 
dose meter used, this aspect may be underestimated or even undetected.  These 
high dose rates for unshielded syringes can have implications for skin dose to the 
operators’ hands even when careful handling keeps syringes at a distance. 
 
 
6.5.2 The shielded 90Y syringe:  
 
Comparative analysis of published data with this research. 
Jodal [31] calculated bremsstrahlung yields for 90Y shielded by different materials 
which included lead, Perspex and aluminium.  For this theoretical calculation 
information was taken from a Windows software Radiological Toolbox v.2.0.0. 
The calculated bremsstrahlung yields from shielded 90Y indicated a ratio for lead 
relative to Perspex of 18.2. The results are summarised with the statement that 
90Y should not be shielded by lead but by 10mm Perspex (or 5mm aluminium).   
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If the bremsstrahlung dose rate results are relied upon as derived using the 
Nuclear Community website calculator [34] it can be seen why many people still 
believe Perspex is the optimum material for shielding 90Y – see Table 6.36.   
 
Table 6.36 Calculated bremsstrahlung dose rate values for a point source 
of 90Y shielded by various shielding materials [34] 
 
 Bremsstrahlung dose rates 
               Sv/h/GBq 
SHIELD 30cm 50cm 
10.8mm Perspex  
(equivalent to 10ml Perspex shield) 
6.8 2.5 
2.8mm tungsten 
(equivalent to 10ml tungsten shield) 
65 23 
1.9mm tungsten 
(equivalent to 1ml tungsten shield) 
74 27 
 
 
The calculated bremsstrahlung dose rate for the Perspex shielded point source is 
almost a factor of 10 lower than the calculated result 2.8mm tungsten (i.e. as 
used to shield the 10ml syringe) or 1.9mm tungsten (i.e. as used to shield the 
1ml syringe).  
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Results obtained from this research. 
 
This research reports the measured bremsstrahlung dose rates for the syringes 
shielded with the materials as described in Table 6.36 with additionally the 
results for the hybrid Zevalin shield. 7ml of solution was contained in the 10ml 
syringe; 0.2ml or 0.4ml in the 1ml syringe (measurements were performed on two 
occasions). These volumes are representative of what would be used in routine 
clinical practice. 
 
6.5.2.1 10ml shielded 90Y syringe: 
The results at 30cm are summarised in Table 6.1 and at 50cm in Table 6.4. 
The measured bremsstrahlung is approximately a factor of 2 higher for the 
Perspex shield than that predicted using a point source (Table 6.36).  This is 
consistent over the range of monitors investigated. However, the tungsten shield 
provides a measured bremsstrahlung rate which is a factor of approximately 16 
less than predicted by the calculator (Table 6.36) for a point source. 
 
6.5.2.2      1ml shielded 90Y syringe: 
The results for the 1ml shielded syringe at 30cm are summarised in Table 6.8 
and at 50cm in Table 6.11. 
The measured bremsstrahlung is approximately a factor of 1.3 higher for the 
Perspex shield than that predicted for a point source (Table 6.36) at 30cm. 
However, the tungsten shield provides a measured bremsstrahlung rate which is 
a factor of 8 less than predicted by the calculator (Table 6.36) for a point source. 
 
 
6.5.3 Overall observations for the 90Y dose rate data obtained during the 
course of this research 
There are some significant differences in measured dose rates observed 
between the three monitors. This particularly applies to the Smartion and also to 
the NIS monitors without their beta shields. However with their beta shields fitted, 
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results for the dose rates at 30cm and 50cm for 90Y in the 10ml Perspex, 
tungsten and Zevalin shields were consistent for the three monitors and also with 
the inverse square law.  All results are background corrected. 
For 30cm, the average dose rates [ Sv/h/GBq] for Perspex were 11, for tungsten 
3.7 and for Zevalin 3.3. Applying the inverse square law calculation to the 30cm 
results gives a 50cm value of 4.0 for Perspex (c.f. 4.1 measured), 1.3 for 
tungsten (c.f. 1.6 measured) and 1.2 for Zevalin (c.f. 1.4 measured).  
 
These results imply that the Perspex shield gives approximately 3 times the 
external dose rate than the tungsten shield and 3.3 times that of the Zevalin 
shield. The tungsten shield gives approximately 15% more than the external 
dose rate of the Zevalin shield.  
 
Due to the lower activity for the 1ml measurements dose rate and background 
fluctuations are going to be far more significant.  For 30cm, average dose rates 
[ Sv/h/GBq] for Perspex were 9.3, for tungsten 8.9 and for Zevalin 4.9. Applying 
the inverse square law calculation to the 30cm results gives 50cm values 
[ Sv/h/GBq] of 3.3 for Perspex (c.f. 1.9 measured), 3.2 for tungsten (c.f. 3.8 
measured) and 1.8 for Zevalin (c.f. 0 measured). However, these discrepancies 
are probably due to errors in the low dose rate values.  For example, the range 
for the measured Perspex values at 50cm was 0 – 3.8 Sv/h/GBq. 
 
The 30cm results for the 1ml shielded syringe imply that the external dose rate 
for the Perspex shield is approximately 4% more than that for the tungsten shield 
and 90% more than that for the Zevalin shield. The external dose rate for the 
tungsten shield is approximately 82% more than that for the Zevalin shield.  
 
The pattern for the 1ml 90Y results was less conclusive due to the low dose rate 
for the Zevalin shield at 50cm.    
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For the 10ml shielded syringe results, a difference in response is noted between 
the Smartion and the NIS when their covers are removed.  When the NIS beta 
cover is removed the results are essentially similar to those obtained when the 
cover is in place. However, the Smartion shows a significant increase in dose 
rate response when the beta cover is removed compared to the values obtained 
when the cover is in situ; a factor of 6 to 7 for both tungsten and Zevalin, but a 
factor of approximately 2 for the Perspex shield. Since the shield dimensions 
should be sufficient to completely stop all beta particles penetrating the wall 
thickness, the large change in response must be due to increased low energy 
bremsstrahlung detection with the beta cover removed. These increases may 
relate to low energy bremsstrahlung emissions at 22keV or lower being 
attenuated by the beta shield when in place, since the energy range changes 
from 22keV to 10keV with and without the shield.  Also, the monitor response 
curve from the manual drops by approximately 20% below 140keV with the cover 
in place.  
 
These increases are substantially greater than observed with the NIS monitor.  
The NIS has a low energy gamma cut-off of 45keV which is much higher than the 
Smartion, so any low energy bremsstrahlung effect might not be noticed.   
 
To investigate the effect of the response of the Smartion to low energy x-ray 
emissions with and without its cover in place, an 125I seed (14.94MBq) was 
placed in a plastic vial at 0 and 30cm from the axis of the monitor.  The 
emissions of 125I (which decays via electron capture) are  = 35.5keV, x-rays = 
27keV and 31keV). The results are presented in Table 6.37. 
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Table 6.37 Results of the dose rate measurements using the Smartion 
dose rate monitor at 0cm and 30cm from the vial containing an 125I seed.  
 
WC     -  refers to measurements with the beta cover in situ  
WOC  -  refers to measurements without the beta cover; 
Monitor type At 0cm At 30cm 
Sv/h/GBq 
Smartion  WC             9200 
 WOC        14300 
WC            380  
WOC         590 
 
 
Measurements in Table 6.37 above indicate a 55% increase in response (with 
and without the cover) at energies of 27-31keV. Bremsstrahlung energies will 
extend lower than 27keV.  An explanation for the increased dose rates observed 
with the Smartion when the cover was removed may therefore relate to a change 
in response at very low bremsstrahlung energies (<22keV).   
 
With no shield in place on the syringe and the cover removed, the Smartion is 
very sensitive to betas. There is a much greater dose rate observed with the 
Smartion than for the NIS meter without its beta shield. The very high readings 
obtained with unshielded syringes have significant implications for skin doses 
when hands and fingers may be in close proximity to the syringe during activity 
measurements. As expected, the series 1000 has no effective sensitivity to 
betas. This demonstrates that using a dose rate meter to estimate doses close to 
unshielded beta sources may not necessarily give an accurate estimate, 
depending on the beta response of the dose rate meter. Care has to be taken to 
select an appropriate dose rate monitor. 
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In summary:  
 For the 10ml syringe, tungsten and Zevalin give lower dose readings for 
all 3 meters (WC). The Perspex shielded syringe results in the highest 
dose rate reading. The dose reduction for the Zevalin shielded syringe is 
marginally better than tungsten. 
 
 For the 1ml syringe, Zevalin is again the most effective shield to use.  
There is no conclusive difference between the Perspex and tungsten 
shields, with both being equally effective. 
 
If 50cm is taken as a typical body dose distance, then values were reassuringly 
low both for 10ml and 1ml syringe results.  Using the 10ml tungsten or Zevalin 
shield, doses of 1.6 Sv/h and 1.4 Sv/h respectively for 1GBq in the syringe were 
recorded. Perspex gave approximately 4.1 Sv/h which though a higher dose 
rate, still affords useful shielding.  However, the values recorded for all shielded 
10ml syringes increase when the cover is removed on the Smartion possibly 
reflecting this dose meter’s sensitivity to low energy bremsstrahlung. 
 
The measured shielded dose rates are significantly different from those predicted 
by the Nuclear Community website Radiation Calculator [34].  The most likely 
explanation is that the Radiation Calculator does not take into account 
attenuation of the bremsstrahlung radiation produced within the solution or 
shielding material. This may be seen from the fact that the calculated dose rates 
for 1.9mm tungsten and 2.8 mm tungsten shields are very similar.  Such 
attenuation has a significant effect on the measured dose rates. 
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6.5.4 Unshielded 32P source + 32P vial: 
 
Summary of published data. 
Several authors have proposed dose rates at various distances from point source 
of 32P.  These results have been summarized in Table 6.38. 
 
Table 6.38 Dose rate results published in the literature at various 
distances for a 1GBq point source of 32P. 
 
 Dose rate at distance from 1GBq point source of 32P 
mSv/h 
 1cm 15cm 30cm  100cm 305cm 
Reference     
Delacroix et al. [27]   118   
Kent State University 
[29] + Michigan State 
University [30] 
94000 403   0.405 
The Society for 
Radiological Protection 
[33] 
  100000*   
Nuclear Community 
website calculator [34] 
  105.3 9.16  
 
* Assumed to be a typographical units error – appears to be a factor of 1000 too 
high. 
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The published results presented in Table 6.38 are mapped onto an inverse 
square plot as illustrated in Fig. 6.7 and fit extremely well with a gradient of -2.12. 
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Fig. 6.7  Inverse square plot for published dose rate data presented in 
Table 6.38; for a 1GBq point source of 32P at various distances. 
 
 
Delacroix et al. [27] also quotes a value (which does not include bremsstrahlung 
radiation) at 10cm from an infinite plane source of 140mSv/h (beta dose). This 
decreases to 48mSv/h (beta dose) for 1GBq 32P at 1m. The Canadian Nuclear 
Safety Commission [20] reports a dose rate of 9.17mSv/h/GBq at 1m but gives 
no dimensions of the source. A dose rate at 10cm from an unshielded 32P source 
(no specific details documented) is quoted as 729mSv/h/GBq, which increases to 
a dose rate of 73Gy/h/GBq at 1cm from the same source, Stanford University 
[12].    There are also various reports for dose rates on surfaces of 32P in 1ml 
ranging from 21.1Gy/h/GBq as quoted by Michigan State University [30] to 
211Gy/h/GBq as quoted by Kent State University [29]. The latter two authors also 
report dose rates at the mouth of an open vial containing 32P in 1ml liquid of 
7.03Gy/h/GBq.   Delacroix et al. [27] reports 1.3 Sv/h/GBq at 100cm from a 10ml 
glass vial.  The Society for Radiological Protection [33] quotes a bremsstrahlung 
dose rate of 0.27 Sv/h/GBq at 100cm from a glass vial containing 32P.  
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It is worth highlighting at this point that in using the Nuclear Community website 
calculator [34] the beta emitting dose rate from a point source at 30cm for 32P is 
higher than that obtained for 90Y, despite the lower beta energy.   
 
 
Unshielded 1ml, 5ml and 10ml syringe containing 32P:  
 
Results of this research. 
It should be noted that the 32P sources used in this research were not point 
sources.  The aim of the research was to establish the most effective shield for a 
source type that would be encountered in routine clinical practice.  Volumes 
appropriate to the syringe size were dispensed. The dose rates at 30cm for the 
unshielded 1, 5 and 10ml syringe are summarised in Table 6.39.   
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Table 6.39 Summary of the dose rate measurements at 30cm for the 
unshielded 1, 5 and 10ml syringes containing 32P. 
  
N/A - not available; 
 
Volume of syringe 
 
1ml  
(0.3ml  
solution) 
5ml  
(2ml  
solution) 
10ml 
(5.5ml 
 solution) 
Dose rate Monitor 
( Sv/h/GBq) 
   
Series 1000                     33 8.7  15 
Smartion        (with cover) 15 
34000 
12 
14000 
8.4 
7900                   (without cover) 
NIS                   (with cap)   11 
500 
N/A 
N/A 
9.4 
120                     (without cap) 
Scintomat        (with cap)                       N/A
N/A 
10 
870 
N/A 
N/A                     (without cap) 
 
The vastly different responses of the Smartion and NIS dose rate monitors (with 
their caps removed) to betas, noted for 90Y, were also observed for 32P. The 
Smartion response is approximately a factor of 66 greater than the NIS monitor. 
It is to be expected that the results obtained for the source used in this research 
are lower than those quoted in the literature for the point source due to the 
volume in the unshielded syringe. As expected, the smaller volume in the 1ml 
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syringe gives a higher dose rate as it more closely resembles a point source and 
this will result in less self attenuation of the betas.  The dose rate values for the 
1ml syringe monitored using the Smartion with its cover removed most closely 
equate to the published literature results.   
 
However, the large difference in response between the Smartion and the NIS 
monitors with the cover in place, noted for the unshielded 90Y sources is not 
replicated for 32P.  This is most probably due to the lower beta energy of 32P. 
Hence, very few remnant high energy betas get through the Smartion cover.  
 
  
Unshielded P5 glass vial:  
 
Results of this research. 
Again it is extremely difficult to correlate this research to published data as no 
specific dimensions or volumes within the vials or bottles are quoted for Delacroix 
et al. [27] and The Society for Radiological Protection [33]. From the diagram 
associated with the glass vial in [27] it could be assumed that the vial contained 
10ml of solution. Equally the thickness of the glass vial is not specified in either 
reference.  
 
The measurements made during the course of this research were at 30cm (Table 
6.34).  To assess the beta dose rate the cover/cap was removed (WOC).  The 
marked difference in response to betas and low energy bremsstrahlung became 
very pronounced as already commented on for the 10ml and 1ml 32P syringe.  To 
compare the values to those published in the literature the dose rate data has 
been extrapolated to 100cm using the inverse square law.  However if, as stated 
by Martin and Sutton [17], that beta particles do not obey the inverse square law,  
extrapolating the results of this research to 100cm is likely to overestimate the 
calculated dose rate. The NIS (WOC) gave 3.3 Sv/h/GBq and the Smartion 
(WOC) gave 261 Sv/h/GBq at 100cm, a factor of 79 increase.  
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If the bremsstrahlung results (with cap/cover) in Table 6.34 are extrapolated to 
100cm. the results varied between 0.53 Sv/h/GBq (Series 1000) through 
0.59 Sv/h/GBq (NIS) to 0.89 Sv/h/GBq (Smartion) – the latter two monitors 
having their cover/cap in situ.  These results are mid-way between the values 
quoted by Delacroix et al. [27] and Society for Radiological Protection [33] 
(1.3 Sv/h/GBq and 0.27 Sv/h/GBq respectively). 
 
 
6.5.5 The shielded 32P syringe: 
 
Comparative analysis of published data with this research. 
If the bremsstrahlung dose rate results are relied upon as derived by the Nuclear 
Community website calculator [34] it can be seen why many people still believe 
Perspex is the optimum material for shielding 32P – see Table 6.40.  
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Table 6.40 Calculated bremsstrahlung dose rate values for a point source 
of 32P shielded by various shielding materials [34] 
 
 Bremsstrahlung dose rates 
               Sv/h/GBq 
SHIELD 30cm 50cm 
10.8mm Perspex  
(equivalent to 10ml Perspex shield) 
3.1 
 
1.1 
2.8mm tungsten 
(equivalent to 10ml tungsten shield) 
34 12 
1.9mm tungsten 
(equivalent to 1ml tungsten shield) 
31 11 
 
 
The calculated bremsstrahlung dose rate for Perspex is approximately a factor of 
10 lower than the calculated dose rate for 2.8mm tungsten (i.e. as used to shield 
the 10ml syringe). If a slightly thinner thickness (1.9mm) of tungsten is used in 
the calculation to mimic the thickness of the 1ml syringe shield, the 
bremsstrahlung dose rate values decreases only slightly compared to the 2.8mm 
calculation. This is contrary to the situation involving dose rate calculations for 
90Y and the thinner tungsten shield - Table 6.36.  32P has a much lower maximum 
and average energy compared with 90Y; as a consequence less bremsstrahlung 
radiation will be produced when the beta particles interact with the shielding 
material. However, one might still expect the 1ml tungsten shielded syringe dose 
rate reading to be higher than the 10ml shielded dose rate as there will be; a) 
less self attenuation of the bremsstrahlung radiation by the solution itself and b) 
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less shielding in the thinner wall to attenuate any bremsstrahlung radiation 
produced.   
 
Overall, using the Nuclear Community website calculator [34], the 
bremsstrahlung dose rates at 30cm (and 50cm) for a point source of 32P shielded 
with Perspex or tungsten are a factor of 2 less than those predicted using the 
same calculator for 90Y.  
 
 
Results obtained during this research. 
This research reports the measured bremsstrahlung dose rates for the syringes 
shielded with the materials as described in Table 6.40 with additionally the 
results for the hybrid Zevalin shield. 5.5ml of solution was contained in the 10ml 
syringe; 0.3ml in the 1ml syringe. These volumes are representative of what 
would be used in routine clinical practice. However, as noted for 90Y, the results 
of this research for 32P are not strictly point sources so direct comparison of 
measured and calculated dose rates is unlikely to be accurate.   
 
 
6.5.5.1 10ml shielded 32P syringe: 
The results at 30cm are summarised in Table 6.15 and at 50cm in Table 6.18. 
The measured bremsstrahlung is approximately a factor of 3 higher for the 
Perspex shield than that predicted using a point source [34].  This is consistent 
over the range of monitors investigated. However, the tungsten shield provides a 
measured bremsstrahlung rate which is a factor of 7 11 less than predicted by 
the Nuclear Community website calculator [34] for a point source. 
 
 
6.5.5.2 1ml shielded 32P syringe: 
The results for the 1ml shielded syringe at 30cm are summarised in Table 6.22 
and at 50cm in Table 6.25. 
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The measured bremsstrahlung is approximately a factor of 3 higher for the 
Perspex shield than that predicted for a point source (Table 6.40). This is 
consistent over the range of monitors investigated. However, the tungsten shield 
provides a measured bremsstrahlung rate which is a factor of approximately of 
9.5 less than predicted by the calculator (Table 6.40) for a point source. 
 
 
6.5.6 Overall observations for the 32P dose rate data obtained during the 
course of this research 
The results for 32P show significant differences in measured dose rates between 
the dose rate monitors as was seen for 90Y. This particularly applies to the 
measurement of beta dose rates from unshielded syringes recorded with the 
Smartion, NIS and Scintomat monitors without their caps or covers. For the 
shielded 32P syringes, the Smartion dose rate values without its cover were all 
higher than the values with the cover in situ.  However this increase is not as 
significant as that seen for the shielded 90Y syringe.  With their caps or covers 
fitted, results for the dose rates at 30cm and 50cm for 32P in the 10ml Perspex, 
tungsten and Zevalin shields were consistent for the three monitors and also with 
inverse square law.  
 
The average dose rate results [ Sv/h/GBq] for the 10ml, 5ml and 1ml syringe at 
30cm are summarized in Table 6.41. 
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Table 6.41 Average dose rate measured at 30cm for 32P in a variety of 
syringes and shields 
            
Volume of syringe Perspex 
 
Tungsten 
 
Zevalin 
 
Average dose rate 
Sv/h/GBq 
10ml 8.0  2.9  4.0  
5ml 7.8  3.7  
(in a lead shield) 
1.7  
(in the 10ml Zevalin 
shield) 
1ml 9.0  3.0  2.2  
 
 
The average dose rate results [ Sv/h/GBq] for the 10ml, 5ml and 1ml syringe at 
50cm are summarized in Table 6.42. 
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Table 6.42 Average dose rate measured at 50cm for 32P in a variety of 
syringes and shields 
 
Volume of syringe Perspex Tungsten Zevalin 
Average dose rate 
Sv/h/GBq 
10ml 3.8  1.7  2.3  
5ml 2.0  0.93  
(in a lead shield) 
0.93  
(in the10ml Zevalin 
shield) 
1ml 3.7  1.2  1.2  
 
 
For the 10ml syringe: Applying the inverse square law to the 30cm results gives 
a 50cm value of 2.9 for Perspex (c.f. 3.8 measured), 1.0 for tungsten (c.f. 1.7 
measured) and 1.4 for Zevalin (c.f. 2.3 measured).  
These results imply that the 10ml Perspex shield gives approximately 2.2 times 
the external dose rate of the 10ml tungsten shield and 1.7 times that of the 10ml 
Zevalin shield. The 10ml tungsten shield gives approximately 0.7 times the 
external dose rate of the 10ml Zevalin shield.  
 
For the 5ml syringe: Applying the inverse square law to the 30cm results gives 
a 50cm value of 2.8 for Perspex (c.f. 2.0 measured), 1.3 for lead (c.f. 0.93 
measured) and 0.6 for Zevalin (c.f. 0.93 measured).  
These results imply that the 5ml Perspex shield gives approximately 2.1 times 
the external dose rate of the 5ml lead shield and 4.7 times that of the 10ml 
Zevalin shield. The 5ml lead shield gives approximately 2.2 times the external 
dose rate of the 10ml Zevalin shield.  
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For the 1ml syringe: Due to the low dose rates from the low activity for the 1ml 
measurements, dose rate and background fluctuations are going to be very 
significant. 
Applying inverse square law calculation to the 30cm results gives a 50cm value 
of 3.2 for Perspex (c.f. 3.7 measured), 1.1 for tungsten (c.f. 1.2 measured) and 
0.8 for Zevalin (c.f. 1.2 measured).  
These results imply that the 1ml Perspex shield gives approximately 3 times the 
external dose rate of the 1ml tungsten and 1ml Zevalin shields. The 1ml tungsten 
shield gives the same external dose rate of the 1ml Zevalin shield.  
 
As observed for 90Y, the Smartion dose rate results for 32P shielded syringes 
when the cover was removed are all higher than when the cover was in situ. This 
most probably relates to the change in low energy bremsstrahlung response as 
previously discussed for 90Y.   The results of the Scintomat further point to the 
effect being due to low energy bremsstrahlung as this monitor is only designed to 
measure photons (gamma and X-radiation) and has an energy cut-off of 28keV.    
Both the NIS and Scintomat with their caps removed gave only a minimal 
increase in response and neither show the increase exhibited by the Smartion. 
 
Considering all three shields, Perspex always resulted in the highest dose rate 
readings for all three meters with their cover/cap in place. The Zevalin shield was 
marginally better than tungsten. 
 
If 50cm distance is taken as body dose then values are reassuringly low. Using 
the Perspex, tungsten or Zevalin 10ml shield, the dose rate range is 1.0 Sv/h 
4.2 Sv/h for 1GBq handled. However the value for the Smartion is higher 
when the cover is removed, in particular for the tungsten and Zevalin shields. 
This would reflect a higher dose to skin (Hp(0.07)). 
 
As for 90Y, the most likely explanation for the difference between the measured 
shielded dose rates and those predicted by the Nuclear Community website 
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Radiation Calculator [34], is attributed to the attenuation of the bremsstrahlung 
radiation produced within the shield itself not being taken into account.  
 
With no shield, (WOC), the Smartion is very sensitive to betas. As concluded for 
90Y, the high dose rate readings seen have implications for hand and finger dose 
when unshielded sources of 32P need to be manipulated (e.g. during activity 
measurements, or fitting syringe shields). The unshielded dose rates appear to 
be significantly underestimated with the NIS meter, emphasizing the importance 
of appropriate dose rate meter selection for betas.   
 
 
6.5.7. Published generalised dose rate formulas for beta emitting 
radionuclides 
Various authors have made generalised statements regarding beta radiation 
dose rates for a beta emitting source at a range of distances. The Radiation 
Protection Service, Glasgow University [16] states that the radiation doses 
received from beta radiation do not depend on the energy of the beta particle.   
The dose rate D, in Sv/h produced by a point source of beta radiation of Activity 
M MBq at a distance of 10cm = 1000M Sv/h.        (6.7)  
Therefore, using Equation 6.7, 1GBq would give a dose rate of 1Sv/h at 10cm, 
which extrapolated gives 111mSv/h at 30cm. This extrapolation, however, does 
not take into account any attenuation in air [17] and in reality the dose rate might 
be expected to be less than 111mSv/h at 30cm. This result concurs with 
published data presented by various authors in the literature for a point source of 
90Y and 32P [5, 11, 13, 27 and 34].  For this research the unshielded 1ml syringe 
most closely resembled a point source. The measured dose rates at 30cm (with 
the cover removed on the Smartion) were 47mSv/h/GBq for 90Y and 
34mSv/h/GBq for 32P.  The lower values are due to self attenuation of the betas 
within the syringe. 
As stated above Martin and Sutton [17] states the inverse square law is not 
applicable for betas which are attenuated considerably by air.  Use of the inverse 
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square law will therefore overestimate the dose rate from betas. The degree of 
variance from the inverse square law will depend on the energy of the beta 
particles and the air distances involved. The dose rate at 1cm from a beta source 
(no dimensions recorded) is quoted as about 80Gy/h/GBq [17]. This is consistent 
with the results quoted by Stanford University [11-12] and Michigan State 
University [30] who both cite point sources as the source dimension.  
 
Haslam, University of Leeds [19] states that for beta emitting radionuclides 
having energies >0.3MeV: 
  dose rate (mSv/min) at 1cm = 1.3A         (6.8) 
Where A=activity in MBq (assumed a point source).  
This is described as the hand accessible extremity dose rate. Equation 6.8 
results in a hand accessible dose rate of 78Sv/h/GBq for 32P. This is almost 
identical to the value above for Martin and Sutton [17].  
 
Haslam, University of Leeds [19] also stated: 
 dose rate at 30cm = 1.5x10-3A mSv/min.                (6.9) 
Where A= activity in MBq. 
 
This generalised formula (Equation 6.9) gives a whole body dose rate of 
1.5mSv/min for 1GBq, or 90mSv/h/GBq.  
 
The Society for Radiological Protection [33] reports that for a point source of 
radiation (neglecting self and air absorption) of known activity in GBq, the dose 
rate at 30cm = 100Sv/h/GBq.  This is a factor of 1000 higher than the reported 
results by 90Y Rimpler et al. [5] and Delacroix et al. [27], where the range was 
108 to 120mSv/h/GBq, and 118mSv/h/GBq for 32P Delacroix et al. [27].  The 
most likely explanation is therefore a typographical error in the units, i.e. Sv 
should be mSv. 
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Relating the distances at which the measurements were made, both during this 
research and as quoted in the literature, to tasks carried out in clinical practice it 
would not be unreasonable to make the following comparisons:- 
 For dispensing and injections, the measurements at 0cm to 1cm could be 
considered an estimate of general finger dose.  
 For dispensing, the measurements performed at 30cm could be 
considered an estimate of skin dose to the uncovered hand/wrist and 
arms.   
 The 50cm results can be considered to represent whole body dose whilst 
performing radiopharmaceutical administrations or measurements. 
 
The Radiation Protection Service, Glasgow University [16] and Martin and Sutton 
[17] highlight the issue of bremsstrahlung production.  They use a generalised 
approximation formula to calculate the fraction of beta energy which is converted 
to bremsstrahlung. The Radiation Protection Service, Glasgow University [16] 
states this fraction: 
 
                                    (f) = 3.3x10-4ZE                                                          (6.10) 
Where Z is the atomic number; E  is the maximum beta energy in MeV.  
 
Applying Equation 6.10 for 90Y shielded with Perspex would result in 0.4% of beta 
energy being converted into bremsstrahlung radiation, and shielded with 
tungsten would result in 5.6% being converted into bremsstrahlung radiation.  
(Martin and Sutton [17], however, states this fraction (f) is = 3 x10-3ZE  , a factor 
of 10 higher which is likely to be a misprint). Both references use this 
approximation to explain why beta shields are normally constructed of materials 
with low atomic mass number (e.g. Perspex). The Radiation Protection Service, 
Glasgow University [16] is a very similar approximation to that quoted by Van 
Pelt and Drzyzga [35] where fraction 
                                  (f) = 3.5x10-4ZE .     (6.11) 
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However, the latter Van Pelt and Drzyzga [35] question the conventional wisdom 
suggesting Perspex is the ideal material to use.  Van Pelt and Drzyzga [35] 
propose that one might expect about 12.6 times more photon radiation for a 32P 
source shielded with a tungsten shield than a Perspex shield. This is based on 
Equation 6.11. Applying this to 32P gives a f value of 0.04403 for tungsten (Z=74), 
0.0035 for Perspex (Z=5.9) and 0.049 for Lead (Z=82). The ratio of 
0.04403/0.0035 = 12.6, the value as quoted by Van Pelt and Drzyzga [35].  
If the same calculation is applied to 90Y: f = 0.05957 for tungsten (Z=74), 0.0047 
for Perspex (Z=5.9) and 0.06601 for Lead (Z=82).  This implies 12.7 more 
photons for 90Y shielded with tungsten rather than Perspex. 
Van Pelt and Drzyzga [35] used an automated database called ESTAR (NIST 
2006) to calculate the ratio of radiation yield for electrons up to 2MeV.  From this 
work it was suggested that 32P might produce about 20 times more photon 
radiation from a lead than a plastic absorber. (The thickness of lead or plastic 
used was always greater than the beta particle range). As a consequence it 
might be expected that there would be an advantage factor of 13 to 20 when 
using plastic versus lead for shielding 32P. However, from their measured results 
it was determined that the advantage of placing the plastic first is about 10% to 
40% versus placing the lead first (i.e. less significant than suggested by the 
bremsstrahlung production theory and implied by standard textbooks). This is a 
further example of a predicted value not being borne out direct measurements. 
However, the order of the shielding, given the choice of lead and Perspex, is in 
agreement with the results of this research in that ideally the Perspex should be 
placed adjacent to the beta emitting source and the lead wrapped around the 
Perspex, resulting in the lead being the furthest from the beta emitting 
radionuclide.  This is demonstrated later with the spectral results in Table 7.10. 
 
Additionally Martin and Sutton [17] quotes the average energy (Eav) of 
bremsstrahlung produced by beta particles with a maximum energy E  keV, when 
interacting with a material of atomic number Z, will be approximately:  
                                  Eav= 1.4 x 10
-7ZE 2keV    (6.12) 
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(Z for Perspex =5.9; Z for tungsten = 74).  
 
For 90Y shielded with Perspex the average bremsstrahlung energy calculated 
with Equation 6.12 is 4.3keV and shielded with tungsten is 53.8keV. These 
values highlight the fact that the bremsstrahlung spectra are highly skewed to low 
energies as observed in our spectra. This may help explain the higher values 
seen by the Smartion detector without the beta shield, thought to be due to low 
energy bremsstrahlung detection. 
 
The equation for the total bremsstrahlung dose rate from a point source of beta 
radiation is stated by Martin and Sutton [17] and McLintock [36] as: 
Kair = 6AE
2/d2[(Zeff+I) en/ ] Gyh
-1                    (6.13) 
Where A = activity in MBq; E = maximum energy of the beta spectrum; d= 
distance travelled through the medium; Z = effective atomic number; I = Internal 
Bremsstrahlung; en/  = mass energy absorption coefficient. [For 
32P: I=5.4; 
Perspex Zeff = 5.9].  
Hence the dose rate can be calculated at any distance depending on the value 
entered for d into the equation.  
 
Amato and Lizio [56] compared the attenuation properties and bremsstrahlung 
radiation yield of different types of plastic materials used for beta radioactive 
sources and found significant differences. Research was carried out using Monte 
Carlo simulation in Geant4. 
 
The Nuclear Community website calculator [34] also attempts to show the effect 
of shielding with different materials on beta emitting radionuclides. The predicted 
beta and bremsstrahlung dose rates for shielding with Perspex or tungsten have 
been referred to earlier in this section.  The calculator also permits combinations 
of materials to be assessed for the impact on dose rates. Of concern, however, is 
the large discrepancy between the measured dose rates and the predicted dose 
rate using this type of software.  The calculator does not appear to account for 
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any of the self attenuation of the bremsstrahlung that would occur within the 
shielding and source. This is clearly a critical factor to include in any assessment. 
 
 
6.5.8 Summary of Dose Rate results and Recommendation for the most 
appropriate dose rate monitor 
 
The dose rate results at 30cm & 50cm provide the following order of preference 
regarding the effectiveness of dose reduction for each shield:  
 
10ml 90Y syringe: 1st Zevalin marginally better than 2nd tungsten; 3rd Perspex. 
1ml 90Y syringe: 1st Zevalin; 2nd Perspex & tungsten equivalent. 
10ml 32P syringe: 1st Zevalin & tungsten equivalent; 3rd Perspex. 
1ml 32P syringe: 1st Zevalin; 2nd tungsten; 3rd Perspex. 
 
The importance of selecting the most appropriate monitor, particularly for the 
detection of the beta particles is critical.  Of the monitors investigated during the 
course of this research the Smartion would be the recommendation of the 
monitor of choice to use.  It has the widest energy range for the detection of the 
beta particles and this is reflected in the increased response presented in the 
results.  All of the monitors investigated gave a similar response if only the 
bremsstrahlung dose rate was being measured. 
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CHAPTER 7     COMPARISON OF THE DOSES FROM SHIELDED SOURCES 
OF 90Y AND 32P USING BREMSSTRAHLUNG SPECTRA 
MEASURED WITH A GERMANIUM DETECTOR  
 
7.1 Introduction 
Due to the difficulties associated with the dose rate measurements, an approach 
based on the measured spectra, acquired with a calibrated hyperpure co-axial 
germanium detector, was considered. (The calibration of channel number in 
terms of keV was obtained using a combination of five different radionuclides 
including 99mTc (140keV), 57Co (122 & 136keV), 60Co (1.17MeV & 1.33MeV), 
22Na (511keV) and 133Ba (81, 276, 302, 356keV)). If the bremsstrahlung energy 
spectrum is obtained for each radionuclide/shield combination then this may 
allow a comparison of the relative shielding properties of each shield. Therefore 
this may provide an independent (and possibly more accurate) representation of 
the relative merits of each shield as opposed to the dose-meter readings. This 
became particularly important when it was established how different the monitors 
were in their response to each radionuclide and its associated shield during 
measurements.  An equally important factor affecting the accuracy of the dose 
rate monitor results was the low quantity of activity that was generally available to 
perform some of the measurements.  Spectral measurements only require 
relatively small levels of activity when using a germanium detector. 
 
The calibrated energy response of the germanium detector allowed the spectra 
to be converted to a value representing the total energy content of the spectrum. 
This was used as an independent check on the efficiencies of the syringe shields 
for bremsstrahlung dose rate reduction. 
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7.2 Materials and Methods 
 
7.2.1 Technical specification of the Germanium detector 
 
 
Fig. 7.1  The hyperpure Germanium detector at City Hospital, Birmingham 
used to acquire bremsstrahlung spectra.  
 
The hyperpure germanium detector is a co-axial system with Model number 
GMX-10200-S. The detector diameter=45.7mm; detector length=35.1mm.    
This detector has a 0.5mm thick Beryllium window which only affects energies 
below 10keV.  Above 10keV there is a ‘dip’ (a Germanium characteristic) in the 
efficiency which returns to 100% at about 30keV. The thickness of the crystal 
starts to affect the counting efficiency above 100keV.  Therefore, a specific 
correction has been developed for counts above this energy. 
 
N.B. A germanium detector used at Birmingham University for one set of spectral 
analysis is approximately twice as sensitive at the City Hospital detector at all 
gamma ray energies.  
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7.2.2. Corrections to acquired spectra 
 
The conversion of the spectral data into a value representing the total energy 
content of the spectrum was carried out as follows:- 
The acquired spectra give counts in each channel. There are two corrections 
which need to be made: (i) a background correction and (ii) a correction for 
detector efficiency. The latter correction has to be made because the efficiency of 
the germanium detector reduces for energies above 100keV.  As a consequence 
all counts per channel above this energy will be underestimated. The germanium 
detectors used had been previously calibrated to obtain an energy efficiency 
equation for energies above 100keV. These correction factors are shown in 
Equations 7.1-7.4. 
 
For the germanium detector at City Hospital:  
The efficiency correction factor for energies>100keV is:  
 
                                            = 
291.6
0442.0
rgyChannelene
 
-1.1274
               (7.1) 
 
 
Where: 
Channelenergy = energy of each respective channel (keV) 
      
 
For the germanium detector at Birmingham University: 
The efficiency correction factor for energies>1500keV is:  
 
 
                                            =  1/[e(7.05-1.3*ln(channelenergy) ]                          (7.2) 
 
 
Efficiency 
correction factor 
Efficiency 
correction factor 
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The efficiency correction factor for energies>600keV and <1500keV is:   
   
 
                                            = 1/[0.276-(0.00013* Channelenergy)]                 (7.3) 
 
 
The efficiency correction factor for energies>100keV and < 600keV is:  
 
                                            = 1/[1.16-(0.0016* Channelenergy)]                     (7.4) 
 
 
Where: 
Channelenergy = energy of each respective channel (keV) 
 
Therefore,  
       =  (spectrum  
                             = (count / channel – background) * efficiency correction     (7.5) 
in each channel 
 
It is then assumed the total emitted energy (proportional to dose) relates to the 
sum over the spectrum of (corrected count / channel) * (channel keV). 
(i.e. 10 photons of 100keV give the same dose as 1 photon of 1MeV)  [57-58]. 
 
To obtain the representative total dose of the spectrum we use the following 
summation to give a spectral parameter related to dose: 
 
All channels   
[(Corrected counts / channel) * (channel number energy)]                  (7.6) 
 
The analysis of all the spectra acquired was carried out using a spreadsheet 
created in Microsoft  Office Excel 2003 to give ratios of Perspex/tungsten, 
Perspex/Zevalin and tungsten/Zevalin. 
Corrected  
counts / channel 
Efficiency
correction factor 
Efficiency 
correction factor 
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7.2.3. Method of spectra acquisitions 
 
A calibrated germanium detector at City Hospital, Birmingham (Fig. 7.1) was 
used to acquire the spectra for the results presented in Fig. 7.2 – Fig. 7.14 and 
Fig. 7.21- Fig. 7.37. However, during the course of this research the detector at 
City Hospital was decommissioned. Following the later purchase of a 1ml Zevalin 
shield, a repeat set of 1ml 90Y spectral measurements was performed at 
Birmingham University.  This utilized a similar hyperpure germanium detector for 
which an energy efficiency correction curve was also available. However, the 
University detector had almost twice the energy efficiency at higher energies than 
the City Hospital model.  The University detector was surrounded by a lead 
shield and so the lead K  x-ray fluorescent peak is present in the 1ml 90Y 
shielded spectra acquired, Fig. 7.15 – Fig. 7.20.   
 
Approximately 20MBq of 90Y in a 10ml and 1ml syringe was used for the spectral 
analysis measurements made at City Hospital.   Both syringe sizes were shielded 
with various syringe shields and placed on a jig at a distance of 25cm, measured 
from the detector to the syringe wall.  A blind hub, placed on both the 10ml and 
the 1ml syringe, ensured the syringe could always be totally retracted into the 
shield.  Hence, the syringe contents were always fully shielded. Acquisition time 
for data collection for the 10ml and 1ml shielded 90Y syringe was 100 seconds. 
The spectral results for the 10ml shielded syringe are displayed in Fig. 7.2 to Fig. 
7.9; those for the 1ml shielded syringe are displayed in Fig. 7.10 to Fig. 7.14. 
 
A marginally lower activity of 15.7MBq 90Y in the 1ml syringe was used for the 
Birmingham University data acquisition (Fig. 7.15 – Fig. 7.20) and the acquisition 
time was increased to 600 seconds in order to increase the counts at higher 
energies.  
 
An additional set of spectra were acquired at 25cm from the detector for ~20MBq 
of 90Y in a 10ml syringe to establish the effect of combining different materials.  
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The syringe was shielded with the standard 10ml Perspex shield (Fig. 4.1) and 
with the Zevalin shield (Fig. 4.3) for comparative purposes.  The first series of 
acquisitions involved wrapping the syringe in increasing layers of lead sheet.  
The second series of measurements were made using a combination of different 
thicknesses of lead and Perspex sheets.  All data was acquired for 100 seconds. 
Four of the acquired spectra are illustrated in Fig. 7.21 to Fig. 7.24.  
 
All spectral acquisitions for 32P were acquired over 300 seconds. The shielded 
10ml and 1ml syringe contained approximately 16MBq 32P and 17MBq 32P 
respectively.  As for the 90Y measurements the syringe contents were totally 
shielded at all times. The 10ml syringe measurements were made at 25cm (Fig. 
7.27 to Fig.  7.33); the 1ml measurements were made at 10cm to counteract low 
available activity (Fig. 7.34 to Fig. 7.37). 
 
Two gain selections were used to acquire spectra to cover the full range of 
energies of bremsstrahlung produced. Background spectra with these gains were 
also acquired.  Although theoretically the bremsstrahlung production should have 
energies up to the maximum beta energy (2.28MeV for 90Y), in practice the 
detected counts above 1MeV were very small for the germanium detector at City 
Hospital. This energy range (up to 1MeV) was therefore used for the spectral 
display relating to this detector.  
 
The germanium detector at Birmingham University, however, was found to be 
more efficient at the higher energies.  For the spectra relating to this detector the 
energy range (up to 1.5MeV) was used. 
 
For each shield the raw data (before background subtraction and efficiency 
correction) will be displayed (Fig. 7.2 - Fig. 7.7; Fig. 7.10 - Fig. 7.24; Fig. 7.28 - 
Fig. 7.37).  The analysis of the impact of the shields will be performed on the 
values derived using Equation 7.6.   
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7.3 Results for 90Y 
 
7.3.1 Spectral analysis for 90Y syringe in 10ml syringe shields 
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Fig. 7.2   Uncorrected spectrum for 90Y in 10ml Perspex syringe shield 
with the thickest wall facing the detector.  
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Fig. 7.3   Uncorrected spectrum for 90Y in 10ml Perspex syringe shield 
with the tapered wall facing the detector. 
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Fig. 7.4   Uncorrected spectrum for 90Y in 10ml Tungsten syringe shield 
with the tungsten wall facing the detector. 
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Fig. 7.5   Uncorrected spectrum for 90Y in 10ml Tungsten syringe shield 
with the lead glass wall facing the detector. 
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Fig. 7.6   Uncorrected spectrum for 90Y in a 10ml syringe in the Zevalin 
syringe shield with main wall thickness facing detector. 
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Fig. 7.7   Uncorrected spectrum for 90Y in the 10ml Zevalin shield with 
the Perspex window facing detector. 
 
 
 
Fig. 7.8 illustrates of the effect of applying the background and efficiency 
correction to the data presented for the Zevalin shield with the Perspex 
window facing the detector as shown in Fig. 7.7. 
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Fig. 7.8    Spectrum corrected for background and detector efficiency for 
90Y in the 10ml Zevalin shield with the Perspex window facing detector. 
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Fig. 7.9    Spectrum for corrected counts multiplied by channel number 
energy for 90Y in the 10ml Zevalin shield with the Perspex window facing 
detector. 
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Fig. 7.9 illustrates the effect of multiplying the corrected counts / channel by the 
corresponding channel number energy for the data presented in Fig. 7.8. (To 
reduce the noise fluctuation, spectrum in Fig. 7.9 was further summed over 3 
channel intervals; Y axis counts have been scaled down by a factor of 1000 for 
display). 
 
 
Brief comments on Fig. 7.2 to Fig. 7.9: 
As expected, the tapered wall section of the Perspex shield (Fig. 7.3) shows a 
higher peak count than the thick wall (Fig. 7.2). The reduction in low-energy 
bremsstrahlung from the tungsten shield is reflected in the low peak count (Fig. 
7.4) compared to the Perspex shield (Fig. 7.2). However, the lead glass wall of 
the tungsten shield (Fig. 7.5) does show a slight increase over tungsten (Fig. 
7.4). The Perspex window of the Zevalin shield shows a lower value than that 
seen with the Perspex shield (Fig. 7.2). This reflects the thickness of the Perspex 
window of the Zevalin shield being greater than the thickness of the Perspex 
shield (18mm vs 10.8mm). 
 
The effect of applying background and efficiency correction to the Zevalin 
spectrum is shown in Fig. 7.8. This causes a weighting of data points at higher 
energies. 
 
To compare relative dose values the corrected counts / channel were multiplied 
by the channel number energy (keV). This is illustrated in Fig 7.9 for the 
spectrum in Fig. 7.8. All data comparisons use the summation calculation of 
Equation 7.6 i.e. the sum of all the data values in Fig. 7.9.  
 
With limited counting time available and the lower efficiency of the City Hospital 
germanium detector at high energies the counts per channel were very low 
above 1MeV.  Applying the detector efficiency correction and multiplying by the 
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channel energy amplifies these low count values causing the higher statistical 
fluctuations seen in Fig. 7.9.  
 
For each 10ml syringe shield, the values obtained using Equation 7.6 are shown 
in Table 7.1. The wall projection facing the detector is listed alongside the shield 
used. 
 
Table 7.1  10ml 90Y shield results for the Germanium detector at City 
Hospital (summation over 23keV - 1MeV) 
 
 
Shield type  
(Efficiency corrected 
 counts *keV)/1000 
Perspex – wall  29533 
Perspex – tapered wall  31143 
Tungsten – wall  18686 
Tungsten – lead glass 20029 
Zevalin – wall 15637 
Zevalin – Perspex window 25298 
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Table 7.2  Ratio of spectral results for 10ml 90Y shields as shown in Table 
7.1 for shield main wall results. 
 
 
Shield type ratio 
 
 
Ratio 
Perspex : Tungsten  1.58 
Perspex : Zevalin  1.89 
Tungsten  : Zevalin  1.20 
Zevalin (Perspex window) : Zevalin 
(main wall) 1.62 
 
A point to note from this table is the higher value obtained through the Perspex 
window of the Zevalin shield compared to that obtained through the Zevalin main 
wall.  This increase (62%) may be an important issue for the operator to consider 
when handling the shield. 
 
The results presented in Table 7.2 concur with the findings of the TLD and dose 
rate measurements i.e. the Perspex shield is the least effective in terms of dose 
reduction.  The Zevalin shield is marginally more effective than the tungsten 
shield. 
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Table 7.3  Spectral ratio results for shielded 10ml 90Y syringe as shown in 
Table 7.1 compared with dose rate ratios from radiation monitors. 
 
 
Shield type ratio 
 
Ratio 
 
Dose rate ratios @ 30cm  
(with cap/cover in situ) 
 
  
Series 1000 Smartion NIS 
Perspex : Tungsten  1.58 3.0 3.0 3.1 
Perspex : Zevalin  1.89 3.0 3.4 4.1 
Tungsten : Zevalin  1.20 1.0 1.2 1.3 
 
The spectral ratio for tungsten:Zevalin correlates very well with the corresponding 
dose rate ratios across the range of monitors investigated during the course of 
this research (taking into account the errors of dose rate measurements). 
 
However, the spectral ratios for the other shield combinations compared with the 
dose rate ratios are lower than the dose rate ratios.  No obvious reasons for this 
variation could be determined. It may relate to the lower energy cut-off values of 
the dose rate monitors compared to the germanium detectors.  
 
 
7.3.2 Spectral analysis for 90Y syringe in 1ml syringe shields 
 
A similar presentation of spectra and data analysis is given for 90Y in 1 ml syringe 
shields.  Initial spectra were obtained using the City Hospital germanium 
detector.  Following a later acquisition of a 1ml Zevalin shield, spectra and data 
analysis are presented for the Birmingham University detector.  
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Fig. 7.10    Uncorrected spectrum for 90Y in 1ml Perspex syringe shield 
with the thickest wall facing the detector. 
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Fig. 7.11    Uncorrected spectrum for 90Y in 1ml Perspex syringe shield with 
the tapered wall facing the detector. 
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Fig. 7.12    Uncorrected spectrum for 90Y in 1ml Tungsten syringe shield 
with the tungsten wall facing the detector. 
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Fig. 7.13    Uncorrected spectrum for 90Y in 1ml Tungsten syringe shield 
with the lead glass window facing the detector. 
  Highlights  
the 59keV  
K  x-ray 
fluorescent 
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tungsten  
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An additional spectrum acquisition was performed with the 1ml syringe placed 
inside the 10ml Zevalin shield.  (This was performed for spectral comparison 
only since a 1ml Zevalin shield was not available at this time). 
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       Fig. 7.14    Uncorrected spectrum for 90Y in a 1ml syringe shielded with 
the 10ml Zevalin shield with the main wall edge facing the detector. 
 
Similar comments on the observed peak counts of the spectra as observed for 
the 10ml data also apply to the 1ml spectra.  Also, since the activities were 
similar for the 1ml and 10ml syringes, the higher peak counts from the tungsten 
shield for 1ml (Fig. 7.12) compared to the 10ml shield (Fig. 7.4) can be seen. 
This reflects the thinner tungsten wall of the 1ml shield compared with the 10ml 
shield. 
 
The following 5 spectra (Fig. 7.15 to Fig. 7.20) present the data acquired at 
Birmingham University for a 1ml syringe containing 90Y, and incorporate the 1ml 
Zevalin shield data. 
  Highlights  
the 74keV  
K  x-ray 
fluorescent 
peak of lead  
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Fig. 7.15    Uncorrected spectrum for 90Y in 1ml Perspex syringe shield with 
the thickest wall facing the detector. 
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Fig. 7.16    Uncorrected spectrum for 90Y in 1ml Perspex syringe shield with 
the tapered wall facing the detector. 
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Fig. 7.17    Uncorrected spectrum for 90Y in 1ml Tungsten syringe shield 
with the tungsten wall facing the detector. 
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Fig. 7.18    Uncorrected spectrum for 90Y in 1ml Tungsten syringe shield 
with the lead glass window facing the detector. 
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Fig. 7.19    Uncorrected spectrum for 90Y in 1ml Zevalin syringe shield with 
the main wall facing the detector. 
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Fig. 7.20    Uncorrected spectrum for 90Y in 1ml Zevalin syringe shield with 
the Perspex window facing the detector. 
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For each 1ml syringe shield, the values obtained using Equation 7.6 are shown in 
Table 7.4.  The wall projection facing the detector is listed alongside the shield 
used. 
 
Table 7.4 1ml 90Y shield results for the City Hospital detector.  Data 
analysed between 23keV - 1MeV.  
 
 
Shield type  
(Efficiency corrected 
counts *keV)/1000 
 Perspex –wall 32453 
 Perspex – tapered wall 34930 
 Tungsten – wall 39786 
 Tungsten – lead glass 41299 
1ml syringe in 10 ml 
Zevalin shield 
15335 
 
NB The Zevalin shield is a 10ml shield with a 1ml syringe placed inside. 
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Table 7.5    Ratio of spectral results for 1ml 90Y shields as shown in Table 
7.4 for shield main wall results.   
 
 
Shield type ratio 
 
Ratio 
Perspex : Tungsten  0.82 
Perspex : Zevalin 2.12 
Tungsten  : Zevalin  2.59 
NB The Zevalin shield is a 10ml shield with a 1ml syringe placed inside. 
Analysis of this table shows that the Zevalin is the best shield in terms of dose 
reduction by a factor of more than 2. (However, this dose reduction factor is only 
an estimate for the Zevalin shield since a 10ml shield was used).  The Perspex 
shield is marginally more effective in terms of dose reduction than tungsten.  This 
correlates with the findings of the TLD results and the dose rate ratio 
measurements as obtained with the Series 1000 dose rate monitor.  
 
The Birmingham University detector was more sensitive than the City Hospital 
detector and spectra were acquired for longer times. Therefore some spectral 
counts above 1MeV were observed for the Birmingham University detector.  In 
order to compare the results for the two detectors the Birmingham University 
spectra were analysed using two energy bands 4keV  2.3MeV and 4keV  
1MeV.  
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Table 7.6 1ml 90Y shield results for the Birmingham University detector.  
Data analysed between 4keV - 2.3MeV and also 4keV - 1MeV.  
 
Shield type 
(Efficiency corrected 
Counts *keV) /1000 
4keV - 2.3MeV 4keV - 1MeV 
Perspex – wall 149739 133696 
Perspex –  tapered wall 155525 137528 
Tungsten – wall 199823 177276 
Tungsten – lead glass 186377 163446 
Zevalin - wall  87173  71063 
 
Zevalin - Perspex window  129168  114402 
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Table 7.7   Ratio of spectral results for 1ml 90Y shields as shown in Table 
7.6 for shield main wall results.  
 
 
Shield type ratio  
 
Ratio 
 
Ratio 
 4keV -  2.3MeV 4keV - 1MeV 
Perspex : Tungsten  0.75 0.75 
Perspex : Zevalin 1.72 1.88 
Tungsten : Zevalin 2.29 2.49 
Zevalin (Perspex 
window) : Zevalin 
(main wall edge) 
 
1.48 
 
1.61 
 
The results in Table 7.7 show that the counts from energies >1MeV do not 
appear to significantly change the ratio for the shielded syringe spectral counts.  
This could not be determined for the City Hospital detector due to poorer 
efficiency at the higher energies compared with the detector sited at the 
University. Also longer acquisition times were used for the Birmingham University 
spectra. The results summarized in Table 7.5 and Table 7.7 for energies up to 
1MeV also indicate that the calculated ratios are comparable for the two detector 
systems used.  This helps verify that the data obtained for the 10ml 90Y shields 
using the City Hospital detector are acceptable.  
Although comparable, the ratio values for Perspex or tungsten against Zevalin 
are lower in Table 7.7 compared to Table 7.5 (for energies up to 1MeV). This is 
due to the fact that a 10ml Zevalin shield was used for the measurements 
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obtained in Table 7.5 whereas a dedicated 1ml Zevalin shield was used for the 
results in Table 7.7.  
An additional point to note from this table is the higher ratio for the Perspex 
window of the Zevalin shield compared to the main wall. As noted for the 10ml 
situation this increase (48%) is an important issue for the operator to consider 
when handling the shield. 
 
Table 7.8  Spectral ratio results for shielded 1ml 90Y syringe as shown in 
Table 7.7 compared with dose rate ratios from radiation monitors for data 
analysed between 4keV - 2.3MeV.   
 
 
Shield type ratio 
 
Ratio 
Dose rate ratios @ 30cm 
 (with cap/cover in situ) 
 
 
4keV - 2.3MeV Series 1000 Smartion 
Perspex : Tungsten  0.75 0.77 1.4 
Perspex : Zevalin  1.72 1.1 3.9  
Tungsten : Zevalin  2.29 1.4 2.9 
 
The results in Table 7.8 do show some variation in the ratio values compared to 
the ratio values for the two monitors. However, even the two monitors show very 
different ratio values from each other.  Nevertheless, the conclusions are similar 
regarding the relative order of the three shield types, with the Zevalin shield 
providing the best shielding.  Perspex is slightly better than tungsten for the 
spectra and Series 1000 monitor results, but is worse than tungsten with the 
Smartion.
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7.3.3 Spectral analysis for different thickness lead/Perspex combinations 
shielding 90Y in a 10ml syringe 
 
As has been highlighted for the results presented in Table 7.5 and Table 7.7 
there is an insignificant contribution to the counts for energies >1MeV for the City 
Hospital germanium detector.  Therefore, this energy range (up to 1MeV) was 
used to display the spectra in Fig. 7.21 to Fig 7.24. Only a few representative 
spectra are shown. 
  
The first series of acquisitions involved wrapping the syringe in increasing layers 
of lead sheet ranging from 0.15mm to 1.6mm.  The second series of 
measurements were made using a combination of different thicknesses of lead 
sheets (0.15mm – 0.9mm) adjacent to the syringe surrounded with a second 
layer of Perspex sheets (3mm – 9mm). The third series of measurements 
mimicked a Perspex/lead/Perspex shield with varying thicknesses of each 
material used. The syringe was also shielded with the standard 10ml Perspex 
shield (Fig. 4.1) and with the Zevalin shield (Fig. 4.3) to provide comparison 
values. 
 
The impact of the shielding materials using the spectral parameter derived with 
Equation 7.6 is shown in Tables 7.9, 7.10, 7.11 and Fig. 7.25, 7.26.  
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Fig. 7.21    Uncorrected spectrum for 10ml 90Y syringe inside a 10ml 
Perspex syringe shield with the thickest wall facing the detector. 
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Fig. 7.22    Uncorrected spectrum for 10ml 90Y syringe shielded by 1mm 
of lead. 
  Highlights  
the 74keV  
K  x-ray 
fluorescent 
peak of lead  
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Fig. 7.23    Uncorrected spectrum for 10ml 90Y syringe inside a 10ml 
Zevalin shield. 
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Fig. 7.24    Uncorrected spectrum for 10ml 90Y syringe shielded by 6mm 
Perspex then 1.6mm lead and then an additional 3mm Perspex. 
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Table 7.9  Spectral analysis results to assess the effect of different 
thicknesses of lead shielding a 10ml 90Y syringe.  Data analysed between 
24keV - 1MeV. 10ml Perspex shield included for comparison. 
 
 
 
Shielding used  
(Efficiency corrected 
Counts *keV)/1000  1SD 
10ml Perspex shield– 10.8mm thick (for 
comparison) 
32720  1.6% 
 
0.15mm lead 111205  0.75% 
0.3mm lead 51760  1.2% 
0.45mm lead 43346  1.3% 
0.6mm lead 39414  1.4% 
0.75mm lead 37007  1.5% 
0.9mm lead  36625  1.5% 
1mm lead 32009  1.7% 
1.15mm lead 31008  1.8% 
1.6mm lead 28377  1.9% 
  
[N.B. The standard deviation in all the corrected counts shown in Table 7.9 can 
be seen to be very small and so are not shown on the corresponding plot in Fig. 
7.25.  Derivation of the standard deviation is described in the Discussion section 
7.5 under Error Analysis].  
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Fig. 7.25    Plot of the data in Table 7.9 showing the variation in the spectral 
parameter of (Efficiency corrected counts *keV)/1000 with thickness of 
lead shielding around a 10ml 90Y syringe. 
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Table 7.10 Spectral analysis results (24keV - 1MeV) to assess the effect of 
combinations of different thicknesses of lead coupled with a backing of 
different thicknesses of Perspex on a 10ml 90Y syringe. 
 
 (Efficiency corrected counts *keV)/1000 
 
Perspex thickness 
 (mm) 
Pb thickness 
 (mm) 
 
3 
 
6 9 
0.15 ( Not done ) 47458 47103 
0.45 ( Not done ) 43757 42980 
0.6 40952 40460 39650 
0.9 35608 35068 35165 
 
Fig. 7.26    Plot of the variation in the parameter of  (Efficiency corrected 
counts *keV)/1000 with thickness of Perspex backing (0-9mm, Tables 7.9 
and 7.10) for three thicknesses of lead around a 10ml 90Y syringe. 
 197 
 
 
Table 7.11 Spectral analysis results (24keV - 1MeV) to assess the effect 
on a 10ml 90Y syringe of shields combining Perspex plus lead plus Perspex, 
mimicking the construction of the Zevalin configuration. The Zevalin shield 
is included for comparison.  
 
 
 
Shielding used  
(Efficiency corrected 
Counts *keV)/1000 
Zevalin shield 17958 
3mm Perspex plus 0.9mm lead 
plus 3mm Perspex 23706 
6mm Perspex plus 0.9mm lead 
plus 3mm Perspex 23078 
6mm Perspex plus 1.6mm lead 
plus 3mm Perspex 21154 
 
 
As demonstrated in Table 7.9, the standard deviation of the corrected counts in 
Tables 7.10 and 7.11 are similarly very low and can be ignored. From Table 7.9 it 
can be seen that 1mm lead has an almost equivalent shielding effect on the 10ml 
90Y syringe contents as the 10.8mm wall thickness of the Perspex shield. This is 
not what is expected if the Nuclear Community website dose calculator in [34] is 
used.  Using this, the prediction is a factor of approximately 15 times higher 
bremsstrahlung dose rate for the 1mm lead shielded syringe versus the 10.8mm 
Perspex shielded syringe. However,  Van Pelt and Drzyzga [35] presents results 
for 32P which show that calculated values of bremsstrahlung for lead or tungsten 
shielding are not borne out by practical measurements. This will be discussed 
later in Section 7.5.3.  
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Fig. 7.25 shows that there is only a slow reduction in the derived spectra 
parameter with thickness of lead shielding above 0.45mm. 0.9mm lead only 
provides a 15% dose reduction over 0.45mm, and 1.6mm lead only provides a 
35% dose reduction over 0.45mm.  
 
Fig. 7.26 shows that for thicknesses of lead greater than 0.45mm the effect of 
any backing thickness of Perspex is essentially negligible. This result has 
implications for the Zevalin shield design and for the optimum design of syringe 
shield. Table 7.11 shows that having an inner liner of Perspex will significantly 
reduce the spectral parameter value. For example, the spectral parameter for the 
combination 0.9mm lead\3mm Perspex is 35608 (Table 7.10). Incorporating a 
3mm Perspex liner gives 23706 (combination 3mm Perspex\0.9mm lead\3mm 
Perspex in Table 7.11). The addition of a 3mm Perspex liner therefore reduces 
the spectral parameter value by 33%. The value for the combination 6mm 
Perspex\0.9mm lead\3mm Perspex in Table 7.11 (spectral parameter = 23078) 
shows that an increase in the inner Perspex liner from 3mm to 6mm gives only a 
2.5% reduction. The optimum order of materials for shielding a beta emitting 
radionuclide is therefore for Perspex to precede lead if a combination of the two 
materials is to be used. This agrees with the conclusions reached by Kent State 
University [29], Michigan State University [30], Jodal [31] and Van Pelt and 
Drzyzga [35].  However these results indicate that the Perspex inner wall only 
needs to be 3mm thick. 
 
The combination of shielding 6mmPerspex\1.6mm lead\3mm Perspex was to 
mimic as closely as possible the thickness of material in the commercially 
available Zevalin shield. The combination shielding comprised of flat sheets 
placed between the syringe and the detector.  This will have a less efficient 
geometry than a close fitting curved syringe shield, and explains the lower 
parameter values obtained for the Zevalin shield compared to the above 
combination. 
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The combination of 3mm Perspex and 0.9mm lead would appear to provide an 
optimum choice of dose reduction and practical design. However, to encompass 
the maximum range of the beta particle in lead, a combination of 3mm Perspex 
and 1.6mm lead would advisable.  There appears to be little advantage in having 
a further Perspex layer as in the Zevalin design. This would result in a much 
thinner shield which would be more easily handled by the operator.  
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7.4 Results for 32P 
 
7.4.1 Spectral analysis for 32P syringe in 10ml syringe shields 
 
Similar spectra results and analysis are presented for 32P using 10ml syringe 
shields. These were collected with the City Hospital germanium detector.  Some 
minor residual 83Rb contamination was present and can be seen as small peaks 
on the spectra presented Fig. 7.28 to Fig. 7.33. These peaks are removed with 
background correction, and for reference a background spectrum is shown in Fig. 
7.27 demonstrating these peaks. 
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Fig. 7.27    Background acquisition for 300 seconds with coarse gain of 50.  
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Fig. 7.28    Uncorrected Spectra for 32P in 10ml Perspex syringe shield with 
the thickest wall facing the detector. 
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Fig. 7.29   Uncorrected spectrum for 32P in 10ml Perspex syringe shield with 
the tapered wall facing the detector. 
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Fig. 7.30    Uncorrected spectrum for 32P in 10ml Tungsten syringe shield 
with the tungsten wall facing the detector.  
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Fig. 7.31   Uncorrected spectrum for 32P in 10ml Tungsten syringe shield 
with the lead glass facing the detector.  
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Fig. 7.32   Uncorrected spectrum for 32P in 10ml Zevalin syringe shield with 
wall facing the detector.  
 
0
500
1000
1500
2000
2500
3000
0 200 400 600 800 1000
keV
C
o
u
n
ts
 
Fig. 7.33   Uncorrected spectrum for 32P in 10ml Zevalin syringe shield with 
Perspex window facing the detector.  
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As seen with 90Y, the tapered wall of the Perspex shield (Fig. 7.29) shows a 
higher peak count than the thick wall (Fig. 7.28). The low-energy bremsstrahlung 
from the tungsten shield is reflected in the low peak count (Fig. 7.30) compared 
to the Perspex shield (Fig. 7.28). However, as for 90Y, the lead glass wall of the 
tungsten shield (Fig. 7.31) shows an increase in counts over tungsten. The 
spectral analysis of the 10ml 32P syringe shielded with the Zevalin shield (Fig. 
7.32) shows higher peak counts than the tungsten shielded syringe. The Perspex 
window of the Zevalin shield again shows a substantially higher peak (Fig. 7.33). 
As has been previously noted the thickness of the Perspex window of the Zevalin 
shield is greater than the thickness of the Perspex shield (18mm vs. 10.8mm). 
 
 
Table 7.12 10ml 32P shield results for the City Hospital detector.  Data 
analysed between 24keV - 1MeV.  
 
 
 
 
Shield type  
(Efficiency 
corrected counts 
*keV)/1000 
Perspex  –  wall 27467 
Perspex  – tapered wall 27081 
Tungsten – wall  4186 
Tungsten  – lead glass 11023 
Zevalin – wall  6344 
Zevalin – Perspex window 17949 
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Table 7.13   Ratio of spectral results for 10ml 32P shields as shown in Table 
7.12 for shield main wall results.    
 
 
Shield type ratio 
 
Ratio 
 
Perspex : Tungsten  6.56 
Perspex : Zevalin  4.33 
Tungsten : Zevalin  0.66 
Zevalin (Perspex window): Zevalin 
(main wall) 
2.83 
 
Table 7.13 also highlights the increased counts (factor of 2.8) through the Zevalin 
Perspex window compared to those through the Zevalin shield wall. Again this is 
an important point for the operator to note when handling the shield.  This table 
does, however, show the tungsten shield to be the most effective in terms of 
dose reduction. The Perspex shield is the least effective. 
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Table 7.14  Spectral ratio results for shielded 10ml 32P syringe as shown 
in Table 7.13 compared with dose rate ratios from radiation monitors.   
 
 
 
Shield type ratio 
 
Ratio 
          Dose rate ratios @ 30cm 
            (with cap/cover in situ) 
  Series 1000 Smartion NIS 
Perspex : Tungsten   6.56 1.5 7.0 3.2 
Perspex : Zevalin  4.33 1.6 1.8 3.2 
Tungsten : Zevalin  0.66 1.1 0.25 1.0 
 
The main issue with the data in Table 7.14 is that the ratios for the three monitors 
are at variance. This relates to the errors in dose rate measurements with all 
three monitors.  Therefore, the spectral results are difficult to correlate with the 
dose rate ratio results.  However, the spectral results and the monitors do all 
demonstrate that Perspex provides least dose reduction.  They differ on the most 
effective shielding material.  The spectral results and the Smartion indicate 
tungsten to be the optimum choice whereas the dose rate ratios for the Series 
1000 and NIS monitors would imply that the Zevalin shield and the tungsten 
shield are similar. 
 
 
7.4.2 Spectral analysis for 32P syringe in 1ml syringe shields 
 
A similar presentation of spectra and data analysis is given for 32P in 1 ml syringe 
shields.   
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Fig. 7.34    Uncorrected spectrum for 32P in 1ml Perspex syringe shield with 
thickest wall facing the detector. 
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Fig. 7.35    Uncorrected spectrum for 32P in 1ml Perspex syringe shield with 
tapered wall facing the detector.  
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Fig. 7.36    Uncorrected spectrum for 32P in 1ml Tungsten syringe shield 
with tungsten wall facing the detector.  
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Fig. 7.37    Uncorrected spectrum for 32P in 1ml Tungsten syringe shield 
with lead glass window facing the detector. 
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The relative observed peak counts of the 1ml spectra are similar to those 
observed for the 10ml data, i.e. the counts are much lower for the tungsten 
shielded syringe than for the Perspex shield.   
 
Table 7.15  1ml 32P shield results for the City Hospital detector.  Data 
analysed between 24keV - 1MeV.  
 
 
 
Shield type  
(Efficiency corrected 
 Counts *keV)/1000 
Perspex  - wall 161971 
Perspex  - tapered wall 163101 
Tungsten  - wall  110686 
Tungsten - lead glass 133557 
 
 
Table 7.16    Spectral ratio results for shielded 1ml 32P syringe as shown in 
Table 7.15 compared with dose rate ratios from radiation monitors.   
 
 
Shield type ratio Ratio           Dose rate ratios @ 30cm 
            (with cap/cover in situ) 
  Series 1000 Smartion NIS 
Perspex : Tungsten  1.46 3.4 3.6 2.2 
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Again there is a difference in the calculated ratio of the spectral data to the ratio 
obtained from dose rates. However, all results show tungsten to be a preferred 
choice of shield in terms of dose reduction.  The spectral ratio is lower than 
observed for the 10ml shields (Table 7.14). This may reflect the thinner tungsten 
wall used in the 1ml shield.  
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7.5 Discussion 
 
Error analysis 
 
The calculations used to compare the different syringe shields relied on the total 
spectrum counts over the energy range 4keV -1MeV, 4keV-2.3MeV or 24keV-
1MeV.   
 
Normally the total counts over such energy ranges are high leading to low values 
of standard deviation. For example, the spectrum for the 10ml 90Y Zevalin shield 
gave the following total counts and error – 
 
Background total counts   = 15660 
90Y Zevalin shield total counts  = 34553 
Background corrected counts   = 18893 
 
Standard deviation    = 3455315660  
       = 224.0826 
 
Standard deviation as a percentage = 1.19% 
 
However, corrections to the individual channel counts were necessary prior to the 
calculation of the ratios for the different shields.  The first involved multiplying 
each background corrected channel count value by a factor which corrected for 
the energy efficiency of the detector (Equation 7.5).  The second correction factor 
was to multiply by the energy of each channel (Equation 7.6). 
The consequence of these corrections was to enhance the higher energy 
channel values. Since these had low initial counts/channel, the effect of such 
corrections on the error of the total derived values needed to be investigated. 
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To calculate the error associated with the spectral ratios the following steps were 
taken. First consideration is given to the standard deviation of the corrected total 
counts. 
 
If Ci are the counts per channel 
F = 
N
i
iC
1
 if N channel spectrum 
   
So the standard deviation of F, total counts, is 
 
 
since 
i
C
F
1
= 1;  
i
C
F
2
=1; 
i
C
F
3
=1 etc  
 
i.e. f = F as expected 
 
However, if F = 
N
i
iiCk
1
 i.e. each channel count is modified by a value ki 
 
 
Since 
1C
F
 = k1;  
i
C
F
2
=k2; 
i
C
F
3
=k3 etc;  
 
Equation 7.7 was used to calculate the standard deviation of the corrected total 
spectrum counts, as illustrated in Table 7.9. 
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Returning to the 10ml 90Y Zevalin spectrum as an example: 
 
Standard deviation of the total value of the energy corrected spectrum for the 
Zevalin shield   =    3.01% 
 
The Zevalin shield gave the lowest total spectrum counts and therefore 
represents a worse case scenario.  Although the standard deviation has doubled 
in value with the corrections applied, it is still very low. 
 
The standard deviation of the ratio values used to compare the shields can then 
be calculated using Equation 6.5 (derived in the error analysis section of Chapter 
6). 
 
For 10ml 90Y results, the ratio for tungsten to Zevalin gave the greatest value of 
standard deviation of 4%, a very low value. 
 
For 1ml 90Y results, the ratio for Perspex to Zevalin gave the greatest value of 
standard deviation of 1.1%, again a very low value. 
 
For 1ml 32P results, the ratio for Perspex to tungsten had a standard deviation of 
only 1.1%. However, due to the low available activity and lower spectra counts 
the standard deviation of the ratio for 10ml 32P for Perspex to tungsten was 20%. 
However, this higher value of standard deviation would not affect the overall 
conclusion of the most effective shield from the ratio values.   
 
Therefore counting statistical error even of the corrected spectra can be ignored 
as a factor when considering the ratio values. 
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7.5.1 Spectral analysis for shielded 90Y and 32P syringes using a 
Germanium detector 
 
There does not appear to be any published data from any other group attempting 
spectral analysis of the effect of shielding on beta emitting radionuclides using a 
germanium detector.  The only paper publishing a measured spectrum for 
shielding a beta emitter with 10mm Perspex was Jodal [31] and this used a 
gamma camera. They publish no data specific to this spectrum to permit 
correlation with the data obtained in this research.  However, the authors do point 
out some of the limitations of using the camera and that the spectrum will only 
give an approximation of what might be the true picture between 70 300keV.  
They record the fact that low and high energy data will be missing.  This research 
confirms the importance of acquiring data with the highest efficiency detector 
over the complete bremsstrahlung energy range of the beta emitting radionuclide 
to obtain the true picture.  
 
 
7.5.2 Effect of acquired energy range and different detector efficiencies on 
the spectral results for 90Y in a 1ml syringe 
 
Spectral results for the 90Y shielded syringes were acquired using the germanium 
detectors at City Hospital, Birmingham and at Birmingham University.   In 
carrying out analysis of the acquired data at City Hospital, it was established that 
the counts at energies >1MeV were very small.   Spectral analysis of the data 
was therefore performed over the energy range 24keV to 1MeV. However, the 
University germanium detector was more efficient than the City Hospital detector 
at energies >1MeV and also the spectra were acquired for longer times. This 
resulted in bremsstrahlung counts being detected up to the maximum energy of 
the beta particle.  The effect of this increased energy range is amplified when the 
spectral parameter of Equation 7.6 is calculated. This not only increases the 
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counts to account for the low detector efficiency but also weights the corrected 
count with the energy value.  
 
However, if the data from both germanium detectors is analysed over the energy 
range up to 1MeV then the calculated ratios for the different shields are 
reassuringly comparable.  Also, when the higher energy bremsstrahlung counts 
from the University detector are included and corrected for efficiency and energy, 
the ratios of the shields relative to each other do not change significantly.  
 
Limited times were available for the acquisitions which gave low counts per 
channel for the higher energies (>1MeV). Although these low counts are 
enhanced during the calculations, the overall statistical errors for the total counts 
in the corrected spectra are very low. 
 
Another factor affecting the spectral analysis method is the low detector 
efficiency at higher energies.  This means that a significant proportion of the high 
energy bremsstrahlung simply scatter in the detector giving a false low energy 
event. This means that the detector efficiency correction still does not necessarily 
produce the true spectrum at higher energies.  
 
 
7.5.3 Spectral analysis of different shielding materials relative to each 
other for a 10ml 90Y syringe  
 
If the spectra acquired for the different shielding materials are superimposed it 
becomes apparent why either a tungsten or Zevalin shield is usually a more 
effective shield than Perspex (Fig. 7.38 and Fig. 7.39).  These are uncorrected 
for background and detector efficiency. It can be seen that the main 
bremsstrahlung emissions occur at the low energy part of the spectrum. There is 
a significant reduction in counts of the lower energy component (< 300keV) seen 
for the tungsten and Zevalin shields as compared to the Perspex shield.  This 
 216 
 
 
reflects the much greater self absorption at these energies within the tungsten 
and Zevalin shields.  
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Fig. 7.38 Superimposed bremsstrahlung spectra of the Perspex and 
Tungsten shielded 10ml 90Y syringe. 
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Fig. 7.39 Superimposed bremsstrahlung spectra of the Perspex and Zevalin 
shielded 10ml 90Y syringe. 
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The effect of applying background subtraction, efficiency correction and channel 
number energy on the spectra are clearly seen when the same shield 
combinations are displayed with these corrections applied (Fig. 7.40 and Fig. 
7.41).   These are the corrections which should relate to dose. The weighting to 
efficiency and then energy causes the higher energy components of both spectra 
to increase significantly. The reduced values below 300keV for Zevalin and 
tungsten can be seen, reflecting the much lower spectral counts observed in Fig. 
7.38 and Fig. 7.39. (N.B. To reduce the noise fluctuation, spectra in Fig. 7.40 and 
Fig. 7.41 were further summed over 3 channel intervals). 
 
0
100
200
300
400
500
0 200 400 600 800 1000
keV
 (
E
ff
. 
C
o
rr
. 
c
o
u
n
ts
*c
h
a
n
n
e
l 
n
u
m
b
e
r 
e
n
e
rg
y
)/
1
0
0
0
 
 Fig. 7.40   Superimposed efficiency and energy corrected bremsstrahlung 
spectra of the Perspex and Tungsten shielded 10ml 90Y syringe. 
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Fig. 7.41    Superimposed efficiency and energy corrected bremsstrahlung 
spectra of the Perspex and Zevalin shielded 10 ml 90Y syringe. 
 
The spectral analysis also highlighted another important point to consider.  The 
counts were shown to be higher (62%) through the Perspex window of the 
Zevalin shield compared to the Zevalin main wall.  The thickness of this window 
is greater than the wall thickness of the Perspex shield.  As a consequence the 
Zevalin shield still gives a reduced count (and hence dose) in comparison to the 
Perspex shield. In contrast the values for the lead glass window of the tungsten 
shield are only approximately 7% greater than the tungsten wall.  This is an 
additional shielding aspect which favours the tungsten shield. 
 
As was discussed following the spectral analysis using various Perspex/lead 
combinations (Tables 7.9, 7.10, 7.11), the results of this research concurred with 
published literature.  If this combination of materials is to be used the Perspex 
should be placed adjacent to the beta emitting source and the lead placed 
furthest from the source. The spectral analysis also showed that increasing 
thicknesses of material are only beneficial in reducing dose up to a certain point. 
The inner Perspex only needs to be 3mm thick (Table 7.11).  Of particular note is 
 Perspex 
 Zevalin 
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the combination of 3mm Perspex followed by 0.9mm lead followed by 3mm 
Perspex. This is as effective as the 6mm Perspex sandwiching 0.9mm lead with 
3mm Perspex. In addition, the results of Fig. 7.26 indicate that having a further 
outer layer of Perspex does not lead to any significant reduction in dose. 
Therefore the combination of 3mm Perspex followed by 0.9mm lead may be as 
effective and has a wall thickness of only 3.9mm. If this were implemented it 
would result in a much thinner shield which would be more easily handled by the 
operator but be as effective as the Zevalin shield. Also the diameter of the lead 
component would be less so reducing the shield weight (by at least 22% for a 
10ml shield and 49% for a 1ml shield). 
 
Although not directly comparable to the germanium detector spectra, Van Pelt 
and Drzyzga [35] describes the results of measurements of relative 
bremsstrahlung radiation produced when lead is placed directly adjacent to the 
beta source of 32P versus when plastic is placed first. The author used a sodium 
iodide 1x 1 inch scintillation detector for the bremsstrahlung measurements. Van 
Pelt and Drzyzga [35] concludes that 0.16mm lead gave the same shielding as 
12mm Perspex for 32P. During the course of this research, no comparative 
measurements were performed using 32P with lead of this thickness. The 
thickness of lead quoted to be equivalent is certainly thinner than the results from 
this research would suggest being necessary for 90Y, but that is not unexpected 
given the higher energy of the 90Y bremsstrahlung. Extrapolating the graphical 
data supplied in this paper for 32P to the situation encountered in this research, 
3mm lead appears to give a 73% reduction compared to 12mm of Perspex. 
 
From this research for 32P spectra: 
 
10ml syringe: Using the Perspex and tungsten 10ml values for 32P, we see that 
2.8mm tungsten gives an 85% reduction compared to 10.8mm Perspex.  This is 
similar to that extrapolated above from publication by Van Pelt and Drzyzga [35] 
i.e. 73% reduction.   
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1ml syringe: Extrapolating the data supplied by Van Pelt and Drzyzga [35] to the 
situation encountered in this research, it can be seen that 2mm lead gives 
approximately a 60% reduction compared to 12mm of Perspex. From the 32P 
spectra data we saw that 1.9mm tungsten gives a 32% reduction compared to 
10mm Perspex.  It is to be expected that there will be discrepancies in this 
comparison as Van Pelt and Drzyzga [35] only uses uncorrected cpm from a NaI 
(Tl) detector.    
The other factor to take into account is the geometry of the source involved.   The 
10ml syringe contained 5.5ml of 32P; the 1ml syringe contained 0.3ml for this 
research.  The source used by Van Pelt and Drzyzga [35] was 0.05ml in a V 
shaped bottle. The author also placed this bottle in a lead cylinder to try and limit 
bremsstrahlung reaching the detector from extraneous nearby object; it is unclear 
if any significant secondary bremsstrahlung was produced in the lead shield.   
 
Again, not directly comparable to the germanium detector but a gamma camera 
(with a 3/8” NaI(Tl) crystal) was used by Jodal [31] to acquire a spectrum from a 
90Y source surrounded by 10mm Perspex.  It was noted that some of the higher 
energy bremsstrahlung may pass straight through the crystal so the true 
spectrum effect may not be accurate. The camera only looks at energies > 70keV 
and this will be particularly significant for the Perspex shield where much of the 
contribution is from the low energy bremsstrahlung; (10% of total efficiency 
corrected counts*energy for 10ml 90Y syringe acquired using the germanium 
detector in this research).  The author placed the shielded source at a 200 angle 
to the gamma camera (collimator removed) and stated that about 60% of 300keV 
photons would be detected because the effective crystal thickness had been 
increased three fold. A spectrum for the same source shielded with an additional 
1mm lead was calculated. To determine this spectrum the measured 
bremsstrahlung spectrum was multiplied by energy-dependent attenuation for 
1mm lead.  The measured and calculated spectra produced by Jodal [31] are 
comparable to the results obtained with measured spectra from the germanium 
detector attained during this research; i.e. the higher atomic number materials 
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have a profound effect on self-attenuating the lower bremsstrahlung produced 
within the shield and the source.  The authors did not report having measured the 
spectrum of the 90Y sample in lead using the gamma camera to correlate their 
findings with calculated values.   
 
A further observation from the spectral analysis results is compliance with the 
inverse square law.  Several of the measurements were performed at both 10cm 
and 25cm from the germanium detector. 
 
One specific situation is examined as an example:-  
 
1. 1ml tungsten shielded syringe with 32P at 10cm: 
110686 (efficiency corrected*energy/1000) 
Applying inverse square law :  
17710 at 25cm cf 17025 measured. 
   1ml tungsten shield results are consistent with inverse square law. 
 
7.5.4  Summary of Spectral Analysis results and Recommendation for use 
of a Germanium detector for spectral analysis 
 
Spectral analysis of the external bremsstrahlung radiation indicates the following 
order of preference for the syringe shields- 
 
10ml 90Y syringe: 1st Zevalin; 2nd tungsten; 3rd Perspex. 
1ml 90Y syringe: 1st Zevalin; 2nd Perspex; 3rd tungsten. 
10ml 32P syringe: 1st tungsten; 2nd Zevalin; 3rd Perspex. 
1ml 32P syringe: 1st tungsten; 2nd Perspex (N.B. Zevalin shield not available for 
1ml 32P spectral measurements). 
 
The ideal germanium detector to use would be one with the highest efficiency 
over the widest energy range.  This would ensure the most accurate detection of 
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the highest and lowest energy bremsstrahlung during shorter counting intervals. 
Of the two germanium detectors investigated, the detector at the University had 
the highest efficiency.  However, due it’s location (close to other high energy 
radiopharmaceutical preparation); this detector had the disadvantage of having to 
be surrounded by a lead shield. This created undesired K  x-ray fluorescent 
peaks on all spectra from the interaction of the bremsstrahlung emissions with 
the lead shield. Correction factors are applied to the channel counts of the 
spectra which enhance the contribution from the higher energy channels 
containing low count values.  However, these corrections do not increase the 
standard deviation of the total corrected counts to a significant level.  
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CHAPTER 8   FURTHER POINTS OF DISCUSSION 
 
With the increasing use of beta-emitting radionuclides for therapeutic purposes, it 
is vital to establish the most effective shielding to minimise the high finger doses 
to staff being reported by authors (as previously referred to in the introduction). 
Some authors are also reporting significant dose rate readings at distance from 
the beta emitting source, particularly for unshielded sources.   This will contribute 
to whole body doses recorded by staff. The effect of the shielding in terms of 
dose reduction was, therefore, not limited to close proximity work but was 
extended to include measurements at distance. 
 
As has already been highlighted in the discussions relating to the TLD, dose rate 
and spectral analysis results in Chapter 5, Chapter 6 and Chapter 7 respectively, 
there is very little data available in the literature for measured finger and whole 
body dose rates to operators.  This relates particularly to situations where various 
types of shielding have been directly compared for effectiveness in dose 
reduction to the operator. Much of the available data are calculated estimates of 
dose which have been derived via various computer modelling programmes. 
 
In addition to the detailed discussion sections; namely 5.6 relating to the TLD 
results; 6.5 relating to the dose rate monitor results and 7.5 for the spectral 
analysis results two further areas of discussion are required.   The first highlights 
issues which were encountered during the course of this research. The second 
proposes future developmental work. 
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8.1 Issues encountered during the course of this research: 
In the process of carrying out this research several problem areas were 
identified.  These are discussed in detail in the following sections: 
8.1.1 Large discrepancy between TLD results 
8.1.2  Gravitational settling of the 90Y citrate colloid 
8.1.3 Large variance in the response of dose rate monitors used 
8.1.4 Effect of volume on the TLD and dose rate monitor results 
8.1.5 Determining the bremsstrahlung spectra for different shield 
conditions. 
 
 
8.1.1 Large discrepancy between TLD results 
In the field of radiological protection, the critical tissue when dealing with dose to 
the skin is considered to be the basal cell layer of the epidermis.  The dose 
equivalent at a depth of 0.07mm, Hp(0.07) averaged over an area of 1cm
2 is 
required to be assessed to satisfy Regulation 11 of the Ionising Radiations 
Regulations 1999 [38]. Similarly ICRP 60 [59] and the European Commission 
[60] state that finger doses are assessed by averaging over 1cm2.    Christensen 
et al. [61], Rimpler and Barth [62], Dutt et al. [63], Brasik et al. [64], Oilveira and 
Caldas [65] however, highlight the problem of accurate monitoring of beta and 
low energy photons due to energy threshold problems if the filter and/or detector 
are too thick or too large.  These authors point out that, if the thickness of the 
detector and or overlying material is too thick a beta ray threshold of about 
500keV or greater may be imposed. 
 
Christensen et al. [61] states that ideally TLDs should be capable of measuring 
beta rays of energies down to 60keV, since beta rays of this energy are able to 
penetrate to a depth of 7mg.cm-2.   Ideally a tissue equivalent detector of 
5mg.cm-2 filtered by 5mg.cm-2 would provide an appropriate dosemeter for the 
measurement of Hp(0.07). Near-tissue equivalent TLDs, however, are usually 
thicker. For near-tissue equivalent TLDs LiF is often used.  Thus if e.g. a 240 
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mg.cm-2 thick LiF chip is covered by 7mg.cm-2   tissue equivalent material, this 
will underestimate Hp(0.07) for exposures to 0.5MeV beta rays by a factor of 6.5 
for normal radiation incidence and a factor of 9 for 600 incidence [61].  This 
aspect may help explain why the measured TLD results for the surface dose on 
unshielded syringes were a factor of 2 to 10 lower than calculated values. 
However, Christensen et al. [61] does note that the sensitivity is lowered with the 
thinner detector due to the smaller detector mass.   
 
There is also the issue of the calibration of the dosemeters suitable for high 
energy betas. Ideally operators should use specific TLDs for working with beta 
emitting radionuclides with an appropriate calibration factor applied.    
 
An additional issue to address is deciding where the TLD should be worn to most 
accurately record the dose received by the extremity. As stated above current 
legislation requires that finger doses are assessed by averaging over 1cm2.   
Previously, legislation required that this dose averaging was over 100cm2.  As a 
consequence of this change an IPEM meeting [66] stated that dose assessments 
would have to be undertaken using finger stall devices rather than ring monitors. 
Nevertheless some radiation protection services still routinely issue ring monitors 
rather than finger stall TLDs.  
 
There are also reports regarding the large differences in results depending on the 
position on the finger where TLDs are worn: up to a factor of between 1 and 6 for 
gamma emitting radionuclides [21, 50-53].  Liepe et al. [14] reports beta radiation 
doses are substantially underestimated by a factor of <100, when comparing a 
ring dosimeter (Harshaw BTKD 2001) worn at the base of the ring finger 
compared with LiF TLD (MCP-NS-type) placed at the fingertip.  The author states 
that this ring TLD is unable to measure beta radiation. Mention is made of a 
‘special’ finger ring TLD which is suitable for beta radiation but no further details 
were given. Rimpler et al. [13, 62] also highlight the position of the TLD as being 
critical for an accurate dose to be recorded, especially for beta emitters. Rimpler 
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and Barth [62] reports that a correction factor of 3 (with a range of 1.1 9.8) is 
required for staff wearing a ring TLD appropriate for beta radiation (TK 70 or 
TLD-200) in order to arrive at a better estimate of the accurate skin dose to be 
measured. This factor is applicable for situations where appropriate high 
protection standards have been used; stated to be >5mm Perspex shielding.  
 
The effect on the dose recorded when wearing a ring TLD at the base of the 
finger compared to that recorded by a TLD worn on the fingertip was made on 
one occasion during the course of this research. This comparison was made by 
an operator connecting up an infusion of 90Y Zevalin.  Concern had been raised 
by the author of this research about the accuracy of the MeasuRing TLD strips 
from experience of using them in routine clinical practice. It was decided to wear 
these TLDs at the fingertip alongside some TLD-100 strips supplied by 
Birmingham.  Concurrently two ring TLDs were worn at the base of two of the 
fingertips being monitored.   
 
The ring TLD results were found to be lower compared to the TLD-100 strips 
(Birmingham) by a factor of 1.7 6 depending on the digit monitored. If the 
MeasuRing TLD results worn as a strip were compared to those worn as a ring 
TLD a surprising result was obtained.  The dose recorded by the TLD worn as a 
ring was higher by a factor of 1.1 to 1.2 than that worn at the fingertip.  
 
Ideally for beta emitting radionuclides, the need is for a TLD suitably calibrated 
over a broad range of beta ray energies as well as bremsstrahlung. Prokic [67] 
indicates the dosemeter should have low transparency with near tissue 
equivalence and high sensitivity. The same author also states that for estimation 
of beta radiation dose to the skin from low energy beta rays, an extremely thin 
effective detector thickness is required.  The graphite mixed dosemeters 
developed by Prokic [67] changed the dosemeter’s transparency and this 
resulted in a low energy dependence of the response to beta rays.  Some of the 
available TLDs have a thick plastic layer over the detector area as reported by 
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Rimpler et al. [13].  As a consequence the beta skin dose may be 
underestimated.  
The TLD-100 chips in this research were contained within a stall which had a 
0.2mm thick plastic front cover. The majority of the TLD-100 results for 90Y from 
this research reflect the opinion of Rimpler et al. [13] i.e. TLD-100 chips resulted 
in lower reported dose values than the LiF-7 powder type TLDs. The effect was 
less conclusive for the 32P results. This difference in response may cause 
problems for many Nuclear Medicine departments where most wearers of the 
TLDs are doing so for their work with diagnostic radiopharmaceuticals, hence the 
TLD response is optimum for gamma emitting sources. If work is being carried 
out with beta emitting radionuclides these may give an underestimate of finger 
dose. 
 
Not only was there is a very large disparity between TLD results of the different 
types used in this research, this disparity was even observed within results when 
the same type of TLD was used for repeat measurements.   
 
There were particular technical difficulties reported by the Radiation Protection 
Service in processing the TLD-100 chips. Any small scratches, loss of mass or 
foreign deposits affect the light emission. It appears they are difficult to 
manipulate (ideally vacuum tweezers should be used – not mechanical tweezers 
or fingers) and many results had to be discarded due to uncertainty over which 
chip a particular TLD result related to when the processing of the chips was 
carried out.   
 
 
8.1.2 Gravitational settling of the 90Y citrate colloid 
Although some increase in TLD reading might have been expected due to 
backscatter (as reported by [40-45] for the unshielded beta source), the 
extremely large increases in backscattered values reported for some results 
obtained during this research would not have been predicted. The significance of 
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this is seen in the TLD results for both the 10ml and 1ml syringes containing 90Y 
citrate colloid when the syringe was placed horizontally. Fig. 5.17 shows that 
there is gravitational settling of the 90Y citrate colloid. A large hurdle was how to 
best negate this settling effect as effectively as possible, in order to establish the 
most effective shielding.  The decision was taken to support the syringe (within 
each appropriate shield) vertically.  Any effect of settling should make the same 
contribution to the dose recorded by both TLDs (i.e. one with and one without the 
backscatter Perspex block) if they were placed directly opposite each other.  
However this meant that it was important to try to position all TLDs in the same 
position relative to the syringe contents when the syringe was placed within 
different shields.  
 
The results for the 10ml and 1ml syringe containing 90Y citrate positioned 
horizontally are also presented, as these more accurately reflect the dose 
operators will receive to their fingers; e.g. when retrieving syringes from transport 
boxes or during injection. It should also be noted that when placed vertically, 
there will be an activity gradient in the syringe. Therefore the TLD readings 
expressed as mSv/h per GBq activity will have an inherent error due to the non-
uniformity of the activity. This made it even more important to try and standardise 
the TLD positions relative to the syringe contents. 
 
 
8.1.3 Large variance in the response of the dose rate monitors used 
Of the monitors available for use during this research, the Smartion showed the 
most significant variation in dose rates compared to the other monitors 
investigated.  This was particularly apparent when the beta cover was removed 
but was also noted when the cover was in place.    Reasons for this effect have 
already been discussed (Section 6.5).  
 
A similar effect was noted for the NIS monitor pre and post removal of its cap, 
although the increase in response was much smaller than that seen with the 
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Smartion. The ratio of the change in response for these two monitors when 
removing the cap or cover is not affected significantly by distance for each of the 
shield types studied for 90Y or 32P. The main difference between the monitor 
responses is that the low energy photon response for the Smartion is much lower 
than the NIS (10keV compared to 45keV). 
 
The Scintomat was only used to obtain one set of dose rate readings (it was not 
available at the outset of this research but was used as a replacement for the 
NIS monitor). This also showed an increased response when removing its cap, 
but like the NIS the change in response was much smaller than the Smartion.  
 
Perhaps unsurprisingly the largest impact in removing the cover or cap for any of 
the three monitors mentioned above was seen for unshielded syringes.  For the 
Smartion and NIS the beta particles will be dominating the readings recorded.   
 
It should be noted that for the Smartion the measurements with the shield in situ 
give values equivalent to Hp(10). Whereas the measurements with the shield 
removed are equivalent to Hp(0.07).  An additional fact to highlight is that the 
monitor manual documents the statistical fluctuation for dose rates up to 
2.5µSv/h being as high as 33%.  These dose rate fluctuations introduced 
significant variations in the measurements made at distance, especially when 
combined with situations of low activity. 
 
To highlight the difficulty in selecting the most appropriate monitor to use, the 
clinical situation of measuring the dose rate around patients following a 
therapeutic administration of 90Y Zevalin is considered.  Data is quite sparse in 
the literature but a range of monitors have been utilized by various authors.  
These include: a high pressure ionization chamber, Victoreen 450P used by 
Cremonesi et al. [2]; ion chamber of unknown type used by Wiseman et al. [68]; 
and a proportional counter FH-40G used by Geworski et al. [69]. Their results are 
generally a factor of 2 higher than those obtained with the Series 1000 monitor 
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used in this research; see Table 8.1. However, the variation in results between 
the reported values of these authors is also a factor of 2.  Some variations would 
be expected and explained due to the physical size of the patient and on the 
range of administered activities. 
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Table 8.1 Dose rate from patient monitored immediately post infusion with the Mini-Rad Series 1000R dose rate 
monitor. 
 
 Dose rate at distance (cm) from the patient  
( Sv/h) 
Patient Administered 
activity  
MBq 
20cm  30cm 50cm  100cm  Directly 
over  
Anterior 
chest 
Directly 
over 
Anterior  
abdomen 
Directly 
over  
Anterior   
Knees 
Directly 
over  
Anterior 
Feet 
1 807 2 1.7 0.8 0.7 13 9 4 2 
2 1188 1.5 1.25 0.75 0.5 8 4 2 1.5 
3 1112 5 2.25 - 0.75 13 9 4 2 
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However, the results of Rimpler et al. [5, 13] are startlingly different.  Rimpler et 
al. [5, 13] reports using a BD-01 (STEP) end-window ionization chamber monitor 
and a TOL-F (Berthold) Proportional counter monitor. The BD-01 (STEP) website 
details the energy response range of betas as 80keV to 3MeV, and for photon 
radiation between 5-10keV and 3MeV.  The TOL-F monitor is designed to 
measure low-energy photon radiation, but also indicates high-energy betas 
efficiently with a relative dose response of ~0.8 for 90Y.  Rimpler et al. [5, 13] 
state that often inappropriate area dosemeters with insufficient response to beta 
radiation are used for such patient dose rate measurement purposes.  
 
One of the aims of Rimpler et al. [13] was to investigate the widely assumed view 
that the beta particles from 90Y are absorbed within the patient, and that the 
exposure to staff, family etc is only due to bremsstrahlung, which is very low. The 
author concluded that this was not the case and the exposure of family members 
is dominated by primary beta radiation instead of bremsstrahlung. The results are 
a factor of 10 43 higher than other published data using the BD-01 monitor, and 
a factor of 16 70 higher using the TOL-F monitor.  It may be possible that the 
results are a consequence of detecting the abundant low energy bremsstrahlung 
since the lower energy cut-off of the monitor is so low. This would mirror the 
increased response observed during this research using the Smartion with the 
cover removed. 
 
Herbaut et al. [70] reports that survey monitors designed for detection of photons 
generally have quite significant sensitive volumes. These monitors will give 
information representative of the average dose in the sensitive volume. Although 
such monitors often have a thin window which allows betas to be detected, they 
will generally underestimate the real absorbed dose, especially in the case of low 
energy betas. Added to which the influence of angular response of the instrument 
needs to be considered, because the absorption of radiation of low range in the 
window or in the wall is dependent on the angle of incidence of the radiation.  If, 
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as was carried out during this research an estimate of dose in contact with the 
source or very near the source is performed, the sensitive volume is not 
uniformly irradiated.  This will result in an underestimate of the real absorbed 
dose. 
 
 
8.1.4 Effect of volume on the TLD and dose rate monitor results  
The volume of solution and geometry undoubtedly does have an impact on the 
dose recorded.  
 
In practice it has proved difficult to compare results from this research to 
published values since the latter often relate to point sources or infinite plane 
sources, or do not quote source geometries for distributed sources.  
 
The effect of volume will be greatest for unshielded syringes due to attenuation of 
the beta component. Larger volume syringes will have a much greater self 
shielding effect on the betas.  This can be seen from the unshielded 32P TLD 
results which show the surface dose rate on the 1ml syringe to be a factor of 10 
higher than that for the 10ml syringe. It should be noted that some of this 
difference will also be attributable to the average distance the beta emitting 
source is from the TLD (the smaller distance being for the 1ml syringe). 
 
However, it is difficult from this research to draw any conclusions as to the effect 
of any volume contribution to the TLD readings for 90Y.  This is partly due to the 
differing response of the TLDs used and partly due to the different 
radiopharmaceuticals used.  The settling observed with 90Y citrate masks any 
volume effect.   
 
The effect of volume on bremsstrahlung dose is lower due to much less self 
attenuation effect in the volume of the syringe. This can be seen from the 
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Smartion dose rates at 30cm (Table 6.1 and Table 6.8) for 90Y in Perspex 
shields. The dose rates for the 1ml and 10ml syringes are essentially the same. 
 
 
8.1.5 Determining the bremsstrahlung spectra for different shield 
conditions  
This has already been outlined in Chapter 7– section 7.5.2 and the difficulties 
discussed. Inherently the bremsstrahlung energy spectrum from shielded 
sources should allow doses to be calculated using low activity sources.  
However, corrections are needed to the spectra for the fall in energy efficiency of 
the detector at higher energies.  There will be a significant number of photons 
which will Compton scatter and so the observed spectra are not identical to the 
bremsstrahlung emissions.  Nevertheless the relative shielding effect of the 
different shields seemed to be practical to determine by spectral analysis. 
 
 
8.2 Future developmental work: 
Further work needs to be performed to try to resolve the disparity between the 
different types of TLDs and their responses to betas and bremsstrahlung.  An 
appropriately calibrated TLD for use with beta emitting radionuclides is essential 
to measure skin dose results accurately.  It is critical the finger dose results are 
dependable and reproducible, given the high dose rates when handling some of 
the newer therapy agents. The finger dose recorded may restrict the number of 
procedures an individual can participate in during any 12 month period to 
maintain a non-classified worker status. However, as discussed above this task 
is not straight forward.  
 
There are already some computer based programs e.g. VARSKIN Mod 2 to  
allow the operator to calculate dose to the skin from beta and gamma 
contamination either directly on the skin or on a material in contact with the skin 
over 1cm2  as reported by Durham [71].  The skin dose from a point, infinitely thin 
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disk (area) and a three dimensional source can be calculated. Durham [71] 
states that for point or area sources of contamination on the skin, backscatter 
accounts for up to 40% of the dose. (This backscatter correction factor is not 
applied to three-dimensional sources or to irradiation areas other than 1cm2). 
However, this is a DOS based program written when standard computers were 
much slower and had smaller memory capacities than today’s personal 
computers.  This program has since been upgraded to VARSKIN 3 [72] to correct 
some known errors and to calculate doses over 10cm2 (a US regulatory 
requirement). VARSKIN 3 is capable of calculating the dose at any depth in the 
skin or in a volume of skin from a point, disk, cylindrical, spherical or rectangular 
source. It does still, however, have the ability to calculate the dose to 1cm2.  
 
Monte Carlo, however, now appears to be the way forward to model events.  This 
will help to clarify which are spurious readings versus true events. Blunck et al. 
[73] highlights the issue of inhomogeneous radiation fields when handling beta 
radiation sources, which make it difficult to determine absorbed doses reliably. 
The authors point out that routine monitoring with dosemeters does not 
guarantee accurate determination of local skin dose. In general, correction 
factors are used to correct for the measured dose and the maximum absorbed 
dose received. One of the main concerns raised in the paper was the reliability of 
dose measurements for beta emitting radiation. The Monte Carlo code, MCNPX 
was used for their simulations. Their conclusion is that simulations can be used 
to better calculate the maximum possible exposure by removing the variability on 
where an individual may choose to wear a TLD. Simulations may also help 
pinpoint the steps in the handling procedure which result in the highest absorbed 
doses.  
 
Monte Carlo modeling could also help with the design of an optimum shield.  As 
shown with the spectral data, there may be potential to substantially reduce the 
wall thickness and weight for a hybrid shield. 
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CHAPTER 9   CONCLUSIONS 
 
Table 9.1  Summary of Results 
 
Option of choice 90Y 32P 
TLD LiF-7 LiF-7 
Dose Rate monitor Smartion (without its 
cover for betas) 
Smartion (without its 
cover for betas) 
Shield: 
Dose reduction for  
10ml syringe  
1. Zevalin 
2. Tungsten* 
3. Perspex 
Shield: 
Dose reduction for 
1ml syringe  
1. Zevalin 
2. Perspex or 
tungsten* 
1. Zevalin 
2. Tungsten* 
3. Perspex 
* ergonomically, tungsten would be first choice 
 
Each of the shields investigated serve the purpose they were designed for in 
reducing whole body doses and extremity finger doses to the operator whilst 
handling beta emitting radionuclides. 
   
For the 10ml syringe containing 90Y or 32P 
The hybrid Zevalin shield is the most effective at reducing the finger and whole 
doses to the operator.  This is illustrated with dose rate measurements, extremity 
TLD monitoring and spectral analysis using the germanium detector.  However, 
the operators find this very cumbersome to use due to its large diameter.  
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Ergonomically the tungsten shield is preferred by operators. Even though it is 
heavier, it is more easily handled due to its reduced bulk.  More importantly the 
doses recorded with the tungsten shield are significantly lower than the Perspex 
shield, which is still widely regarded by many as being optimum for beta emitting 
radionuclides. In addition the Perspex shield also has a large diameter and can 
be cumbersome in use.  The Perspex shields used in this work had a tapered 
wall to improve venous access.  However, this gives increased dose values and 
operators need to try to avoid placing their fingers over this area.  
 
The additional reduction in dose when using the Zevalin shield compared to the 
tungsten therefore appears to be outweighed by the difficulties experienced by 
operators in manipulating the Zevalin shield.  These difficulties result in longer 
handling times for the operator. In addition, the Zevalin shield has a significant 
cost whereas most departments will have tungsten shields available. Tungsten is 
therefore the recommended shield for 10ml syringes. 
 
For the 1ml syringe containing 90Y or 32P 
Again the Zevalin shield proves to be the optimum shield of choice as far as 
finger dose and whole body dose reduction is concerned. However, the external 
dimensions of the 1ml Zevalin shield are identical to the 10ml version.  As a 
consequence it suffers from the same problem of not being easy to use by 
operators.  
 
The dose evidence is not as conclusive as for the 10ml situation as to the most 
effective alternative between tungsten and Perspex for the 1ml shield for 90Y. 
However, the Perspex shield is cumbersome in use.  It has a tapered wall to help 
with injections, but care must be taken to avoid holding the shield at that point.  If 
that situation is likely then a tungsten shield might be the better alternative to the 
Zevalin shield.  However the dose reduction offered by the Zevalin shield is much 
more significant for the 1ml situation. If a significant workload with 90Y in 1ml 
syringes is likely then the purchase of the 1ml Zevalin shield should be 
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considered, although ergonomics of its use will also need to be taken into 
account.   
 
Additional findings: 
1. Most Nuclear Medicine departments will already have tungsten shields 
available for routine clinical work.  This avoids the extra cost of the 
expensive Zevalin shield which only gives a substantial reduction of 
dose compared to tungsten for the 1ml shield.  
2. The design of the Zevalin syringe shield with its plastic/lead/plastic 
combination does seem ideal, but this shield is too thick. An alternative 
hybrid design may be possible.  As reported in Chapter 7 Section 
7.3.3, if a thinner inner Perspex layer is used and the outer Perspex 
layer is discarded, then a more manageable shield would result but 
with a similar dose reduction. Care also needs to be exercised 
regarding the Perspex window of the Zevalin shield which gives less 
dose reduction than the main body of the shield. 
3. Care is needed to ensure that TLDs worn by operators are 
appropriately positioned to measure the fingertip dose. Also there is a 
need to ensure that the TLDs are optimal for beta measurement and 
are calibrated for the beta emitter used. 
4. Dose rate meter readings need to be carefully considered in relation to 
their energy response to photons and also for betas. 
5. Settling of 90Y citrate can cause problems in dose assessment and 
also may lead to higher finger doses than expected if sources are held 
with the fingers on the lower wall of the shield. 
6. As can be seen from the TLD results, very significant finger doses can 
be accumulated in very short time periods if unshielded sources are 
handled e.g. during activity measurements. Such significant finger 
doses could lead to a designation of Classified worker for operators 
who regularly perform manipulations with high activity beta emitting 
syringes. If syringes are handled directly over the active area finger 
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doses can exceed dose limits in a very short time period.  This is a 
significant training issue for all staff handling beta emitters. 
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